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This thesis concerns a 15 year follow-up study of a cohort of people with clinically 
isolated syndromes (CIS) suggestive of multiple sclerosis (MS). I investigate (1) how 
MRI can be used to improve the diagnosis of MS around the time of CIS; (2) early 
MRI predictors of long-term disease course in people with CIS; and (3) mechanisms 
responsible for long-term disability and disease progression in relapse-onset MS. 
 
There has been significant evolution of the diagnostic criteria for MS in recent years. 
I examined the influence of changing diagnostic criteria for MS by retrospectively 
applying the McDonald criteria in the CIS cohort. I found that MS can be diagnosed 
significantly earlier in CIS patients using the McDonald criteria. I investigated two 
possible modifications to dissemination in space (DIS) criteria: firstly whether lesions 
in the symptomatic region should be included in DIS; and secondly whether the 
number of periventricular lesions in DIS criteria should be increased from 1 to 3. 
Including lesions in the symptomatic region improved the performance of MRI criteria 
but increasing the number of periventricular lesions in DIS did not improve diagnostic 
accuracy or specificity. These findings will inform future revisions to the diagnostic 
criteria for MS. 
 
MS-related disability is frequently referable to the spinal cord. I investigated early 
brain and spinal cord MRI abnormalities in the CIS cohort and found that spinal cord 
measures explained more of the disability after 5 years than brain MRI measures. 
Asymptomatic spinal cord lesions at the time of presentation in patients with a non-
spinal CIS were the strongest early MRI predictor of disability after 5 years. These 
findings were then confirmed with long-term follow-up: spinal cord lesions at the time 
of presentation with CIS and new spinal cord lesions after 1 year and 3 years were 
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associated with both physical disability and secondary progressive disease course 
after 15 years. These findings suggest that spinal cord MRI may provide important 
prognostic information in people with CIS and early MS. Early spinal cord damage 
may be an important mechanism contributing to long-term disability and disease 
progression in relapse-onset MS. 
 
Disease course heterogeneity in MS remains poorly explained. I investigated the 
influence of HLA-DRB1*15:01 on disease course and MRI measures of inflammation 
and neurodegeneration in the CIS cohort. Carriage of the HLA-DRB1*15:01 allele 
was associated with a faster accrual of disability, greater inflammatory disease 
burden and a faster rate of brain atrophy over the 15 year follow-up period. The HLA-
DRB1*15:01 allele may not only influence the susceptibility to MS but also the disease 
phenotype and long-term clinical course. 
 
Neuroaxonal energy failure is thought to be central to disease progression in MS. I 
applied the novel metabolic imaging method sodium (23Na) MRI in patients followed 
up after 15 years to investigate the relationship of brain sodium accumulation in vivo 
with long-term disease course and disability. I found evidence of sodium accumulation 
in grey matter, in normal-appearing white matter and in lesions in people who 
developed MS. Cortical grey matter sodium concentration was associated with 
physical disability and cognitive performance at 15 years, even after adjusting for 
brain atrophy. 23Na-MRI should be investigated further as a possible outcome 
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Chapter 1   
Introduction to multiple sclerosis and the clinically isolated syndrome 
1.1 Introduction 
This thesis concerns a 15 year clinical, imaging and genetic study of people with 
clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS). This chapter 
provides background to MS, a common disabling neurological disorder affecting 
young adults. A CIS is the first clinical manifestation of relapse-onset MS. The clinical 
features of CIS are reviewed along with risk factors for the development of MS and 
long-term neurological disability in CIS patients. 
 
1.2 Multiple sclerosis  
MS is a chronic, immune-mediated disorder of the central nervous system (CNS) 
affecting over 2 million people worldwide. In 80-85% of people, the initial course is 
characterised by relapses and remissions (relapsing-remitting MS, RRMS). In the 
longer term many people with RRMS will develop neurologic disability either because 
of poor recovery from relapses or because of a change to a progressive disease 
course with a gradual increase in disability over time, with or without superimposed 
relapses (secondary progressive MS, SPMS). In 10-15% the initial course is 
progressive from the outset with an insidious onset of symptoms and a slow increase 
in disability over time (primary progressive MS, PPMS). 
  
In this section the epidemiology, aetiology, pathology, diagnosis, natural history and 




1.2.1  Epidemiology 
MS is a disorder of young adults (peak age at onset 20 – 40 years) and is more 
common in females than males (Weinshenker et al., 1989). For reasons that are not 
well understood, the sex ratio in MS is increasing, driven principally by an increase in 
the incidence of RRMS in young women (Orton et al., 2006). Although MS occurs 
throughout the world, there are striking geographical differences in prevalence, 
thought to be due to differences in genetic and environmental risk factors. 
Epidemiological studies from Europe, North America and Australasia have 
demonstrated a significant latitudinal gradient in the incidence of MS (more common 
at higher latitudes), with some notable exceptions such as Sardinia which is an area 
of unexpectedly high prevalence (Simpson et al., 2011).  
 
1.2.2 Aetiology 
The cause of MS is unknown. The current widely held view is that MS develops in 
genetically susceptible individuals after expose to one or more environmental triggers 
(Ascherio et al., 2012). Recently completed genome-wide association studies have 
found that the majority of genetic loci that influence susceptibility to MS are related to 
immune system function and there is significant genetic overlap with other 
autoimmune disorders (International Multiple Sclerosis Genetics Consortium et al., 
2011; International Multiple Sclerosis Genetics Consortium et al., 2013). These 
findings support the concept that MS is primarily an immune-mediated illness. 
 
Genetic Factors 
An association between MS and class II human leukocyte antigen (HLA) alleles was 
first identified more than 40 years ago (Sawcer et al., 2014). Modern genetic 
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techniques have established HLA-DRB1*1501 as the most important genetic risk 
factor for MS. In Northern European populations HLA-DRB1*1501 is associated with 
a three-fold increase in the risk of developing MS, with the risk increased in 
homozygotes (Moutsianas et al., 2015). A number of other HLA loci have been 
identified that influence susceptibility to MS; some increase the risk of MS and others 
exert a protective effect, for example, HLA-A*02:01 (Moutsianas et al., 2015). 
 
Outside the HLA system >100 genetic variants have been identified that also 
influence susceptibility to MS, although the individual effect sizes are small 
(International Multiple Sclerosis Genetics Consortium et al., 2013). Many of the loci 
identified to date are implicated in immune system processes, although how they 
contribute to the development of MS is poorly understood (Sawcer et al., 2014). 
Although genetic factors are important in the development of MS the contribution 
appears to be much smaller than that of environmental factors. 
 
Environmental factors 
The most compelling evidence for a role of environmental factors in the development 
of MS comes from migration studies (Ascherio et al., 2012). In a seminal study from 
South Africa the prevalence of MS was highest in European immigrants compared 
with South African English and Afrikaners (Dean, 1967). Europeans who immigrated 
to South Africa as adults had a similar risk of MS to their country of origin, whereas 
children moving to South Africa before the age of 15 year had a risk similar to those 
born in South Africa (Dean, 1967). The converse is true for people moving from an 
area of low-risk to an area of high-risk. For example, MS is uncommon in the West 
Indies and among immigrants to the United Kingdom from this region in the 1960s 
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the risk of MS was low. However, in their children the risk of MS was comparable to 
the general British population (Elian and Dean, 1987).  
 
Collectively these results suggest a role for environmental factors operating in 
childhood that subsequently lead to MS. A number of environmental risk factors have 
been proposed including vitamin D insufficiency, viral infections, cigarette smoking 
and obesity (Ascherio et al., 2012). 
 
Vitamin D insufficiency 
Vitamin D is a fat-soluble vitamin that has a range of biologic effects. Ultraviolet B 
radiation in sunlight converts vitamin D precursors in the skin into vitamin D3 
(cholecalciferol). In order to become biologically active vitamin D needs to undergo 
two hydroxylations, the first in the liver to form 25-hydroxyvitamin D3 and the second 
in the kidneys and other tissues to form 1, 25-hydroxyvitamin D (calcitriol). 1, 25-
hydroxyvitamin D3 binds to the vitamin D receptor and acts as a transcription factor 
for more than 500 genes with effects that extend beyond its well-known role in calcium 
and bone metabolism. Vitamin D has multiple immunomodulatory actions potentially 
relevant to the pathogenesis of MS, including down-regulation of antigen-presenting 
cells, an increase in the number of regulatory T cells, a shift in T helper cell responses 
away from Th1 / Th17 and decreased production of pro-inflammatory cytokines by 
activated monocytes (Koch et al., 2013). Vitamin D insufficiency is associated with a 
number of autoimmune conditions including type 1 diabetes, rheumatoid arthritis and 




In a longitudinal study in US military recruits in which serum samples were collected 
prior to disease onset, lower levels of vitamin D were associated with an increased 
risk of developing MS (Munger et al., 2006). A strong association between low levels 
of vitamin D and risk of MS was also confirmed in a Mendelian randomisation analysis 
that investigated three single nucleotide polymorphisms that influence serum vitamin 
D concentrations (Rhead et al., 2016).  
 
There is some evidence that vitamin D insufficiency may influence the course of MS 
(Ascherio et al., 2014). This is discussed in section 1.3.2. 
 
Epstein-Barr virus infection 
Epstein-Barr virus (EBV) is a herpes virus that commonly causes an asymptomatic 
infection in early childhood and infectious mononucleosis in older children and young 
adults. Following primary infection with EBV, the virus becomes latent in memory B 
cells and a complex system of immune surveillance keeps the number of infected B 
cells at a stable number (Lucas et al., 2011). A history of infectious mononucleosis 
(by self-report or hospital admission data) and serological evidence of EBV infection 
is more common in people with MS than in the general population (Goldacre et al., 
2004). In a longitudinal study of United States military personnel with serial stored 
serum samples, 5% of participants were EBV negative at baseline (Levin et al., 2010). 
During follow-up MS did not develop in any of the participants who remained EBV 
negative. Ten people who were EBV negative at baseline developed MS, all of whom 
seroconverted to EBV positive prior to onset of symptoms. These findings support a 
role for EBV in disease initiation. The mechanism by which EBV influences 





The risk of MS has been reported to be increased in current smokers, with the risk 
increasing based on the number pack years (Hernán et al., 2001). Passive smoking 
may also increase the risk of MS. In a case-control study from France parental 
smoking was a risk factor for paediatric-onset MS (Mikaeloff et al., 2007).  
 
Obesity 
Increased BMI (by self-report) in the teenage years is associated with a two-fold 
increase in the risk of MS (Munger et al., 2009). These findings have been confirmed 
in a prospective study of Danish school children aged 7–13 years with BMI 
measurements available. For every one unit increase in BMI z scores there was a 15-
20% increase in the risk of MS (Munger et al., 2013). 
 
1.2.3  Pathology  
MS is characterised pathologically by inflammation, demyelination, remyelination, 
astrogliosis and neuroaxonal loss (Popescu and Lucchinetti, 2012). The major 
pathological changes can be grouped anatomically into those affecting the white 
matter, grey matter, meninges and spinal cord. 
 
White matter pathology 
A plaque is the pathological description for the multifocal areas of inflammatory 
demyelination that occur throughout the white matter in people with MS, but with a 
predilection for the periventricular, juxtacortical and cerebellar white matter of the 
brain, the optic nerves and the spinal cord (Popescu and Lucchinetti, 2012). Plaques 
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evolve from acute active lesions to chronic lesions with variable degrees of 
remyelination. 
 
In the acute active plaque there is breakdown of the blood brain barrier resulting in 
trafficking of immune cells into the brain. The acute active plaque is hypercellular with 
infiltration of macrophages and T cells plus proliferation of astrocytes. Although 
pathologists use relative axonal preservation to help differentiate inflammatory 
demyelination and infarction (Popescu and Lucchinetti, 2012), considerable axonal 
transection occurs within acute MS lesions (Trapp et al., 1998). Permanent axonal 
injury and loss is thought to be the pathological basis for incomplete recovery 
following relapses in RRMS.   
 
Chronic plaques have a sharply demarcated border with demyelination, loss of axons 
and oligodendrocytes, a minor inflammatory cell infiltrate and areas of gliosis 
(Popescu and Lucchinetti, 2012). Half of chronic plaques remain active with a rim of 
activated microglia, sometimes referred to as slowly-expanding lesions. Ongoing 
axonal loss occurs within chronic lesions and may be one of the substrates for 
disability progression (Trapp et al., 1998).  
 
Widespread, diffuse changes occur in the brain within macroscopically normal-
appearing white matter (NAWM). These include glial cell proliferation (astrogliosis) 
and patchy inflammatory cell infiltrates, predominantly centred around small veins 




Evidence of axonal injury can be seen pathologically in NAWM (Trapp et al., 1998; 
Kutzelnigg et al., 2005) and this is thought to contribute to diffuse neuroaxonal loss. 
The mechanisms of axonal loss within the NAWM are unresolved. In part, it can be 
explained by the secondary effects of Wallerian degeneration due to axonal 
transection in remote focal lesions; however, activated microglia (which are increased 
in number in the NAWM) produce nitric oxide and other free radicals resulting in 
mitochondrial dysfunction, energy failure and axonal loss (Friese et al., 2014). 
 
Grey matter pathology 
In recent years there has been increasing recognition of the importance of grey matter 
pathology in MS including demyelination, neuronal and synaptic loss, and grey matter 
atrophy (Kutzelnigg et al., 2005; Lucchinetti et al., 2011; Popescu and Lucchinetti, 
2012).  
 
Within the cerebral cortex widespread demyelination occurs particularly within the 
cingulate gyrus, frontal and temporal lobes and cerebellum. Demyelination can be 
extensive, affecting up to two thirds of the cerebral cortex (Kutzelnigg et al., 2005). 
Three types of cortical demyelinating lesions can be categorised based on their 
location (Popescu and Lucchinetti, 2012). The most abundant are subpial lesions 
extending from the pial surface through the cortical layers, sometimes extending 
through the full thickness of the cerebral cortex and across multiple gyri. Intracortical 
lesions form around blood vessels and do not extend to the pial surface or grey-white 
junction. Finally, leukocortical lesions involve the deeper layers of the cerebral cortex 




While grey matter pathology is prominent pathologically in progressive forms of MS 
(Kutzelnigg et al., 2005), it has also been demonstrated in early RRMS. In a series of 
patients who underwent brain biopsy for tumefactive demyelination, more than a third 
were found to have cortical demyelinating lesions (Lucchinetti et al., 2011).  
 
Meningeal pathology 
Most patients with progressive MS have evidence of a low-grade meningeal 
inflammatory infiltrate, with or without discrete follicles containing B cells and 
plasmablasts that resemble secondary lymphoid organs (Magliozzi et al., 2007). 
Clinically the presence of meningeal lymphoid follicles is associated with an earlier 
age at disease onset and a more aggressive disease course (Magliozzi et al., 2007). 
Meningeal pathology has also been documented in early MS and is said to correlate 
with the extent of cortical demyelination (Lucchinetti et al., 2011).  
 
Spinal cord pathology 
Demyelinating plaques similar to those found in the brain also occur in the spinal cord 
in MS with the cervical cord affected more frequently than the thoracic or lumbar cord 
(Oppenheimer, 1978). Like in the brain, there is considerable neuroaxonal loss within 
lesions, NAWM and grey matter resulting in spinal cord atrophy (Ganter et al., 1999; 
Bot et al., 2004b). 
 
1.2.4 Immunopathogenesis 
Focal areas of demyelination and evidence of neurodegeneration are the major 
pathological hallmarks of MS (Popescu and Lucchinetti, 2012). Although there is 
debate as to whether MS is primarily an immune-mediated or neurodegenerative 
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disorder, inflammation appears to be important both in the development of focal 
demyelinating lesions and more diffuse neurodegeneration (Dendrou et al., 2015).  
 
T cells are the major immune cell present in the acute MS lesion. Autoreactive T cells 
cross the blood brain barrier using adhesion molecules such as vascular cell adhesion 
molecule-1 (VCAM-1) to traffic into the CNS. This interaction is targeted by the 
monoclonal antibody natalizumab which blocks very-late antigen-4 (VLA-4), the T cell 
ligand for VCAM-1 (Wingerchuk and Weinshenker, 2016). CD4+ T cells become 
activated by antigen presenting cells through interactions with MHC class II molecules 
with a predominant TH1 and TH17 phenotype. This leads to production of cytokines 
and chemokines that attract circulating monocytes, CD8+ T cells and B cells resulting 
in demyelination and injury to axons and oligodendrocytes (Dendrou et al., 2015). 
Because of the breakdown of myelin in acute MS lesions it is assumed that the 
antigenic target of T cells is a myelin antigen, but this is yet to be identified (Dendrou 
et al., 2015). 
 
There are differences in the immunophenotype of relapsing and progressive MS. This 
is reflected in their differing responses to the currently available immunomodulatory 
treatments (Wingerchuk and Weinshenker, 2016). Relapsing MS is thought to be 
mainly due to autoreactive peripheral immune cells crossing the blood brain barrier 
and causing inflammation in the brain and spinal cord, whereas progressive MS may 
be due to the effects of compartmentalized inflammation driven by immune cells 
already present in the CNS (Friese et al., 2014; Dendrou et al., 2015). Widespread 
microglial activation occurs resulting in chronic inflammation and production of 
inflammatory mediators such as reactive oxygen species that damage mitochondria 
(Campbell et al., 2011). The maladaptive reorganisation of ion channels to maintain 
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ionic homeostasis coupled with the effects of glutamate excitotoxicity leads to 
irreversible damage to axons and neurodegeneration (Friese et al., 2014). Peripheral 
plasma cells, B cells and T cells in the CNS can form tertiary lymphoid follicles within 
the meninges and produce soluble neurotoxic factors that promote cortical 
demyelination and neuroaxonal injury (Magliozzi et al., 2007; Howell et al., 2011). 
Rather than occurring in separate phases it is likely these processes occur in parallel, 
even from the earliest stages of the illness (Friese et al., 2014). Using positron 
emission tomography, increased binding of PK11195 (a microglial marker) has been 
reported in patients with CIS (Giannetti et al., 2015).  
 
1.2.5 Clinical features 
MS is classified based on the initial disease course as either relapsing or progressive 
onset. In RRMS the initial course is characterised by relapses, defined as episodes 
of neurological dysfunction that evolve subacutely over hours or days in the absence 
of fever or infection (Lublin et al., 2014). Relapses typically last for several weeks and 
by definition must last at least 24 hours. Relapses usually improve spontaneously 
with or without steroid treatment with a variable degree of recovery. Relapses 
commonly result in persistent symptoms and/or abnormal neurological signs (e.g. 
optic disc pallor, pathologically brisk reflexes). Relapses in RRMS are punctuated by 
periods of remission in which patients may have ongoing symptoms related to 
previous relapses or other chronic neurological symptoms (e.g. fatigue, Uhthoff’s 
phenomenon), but there is no progression of disability between attacks.  
 
The term CIS describes a first episode of neurological symptoms suggestive of MS 
without clinical or MRI findings sufficient to make a diagnosis (Polman et al., 2011; 
Lublin et al., 2014). CIS is discussed further in section 1.3. 
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After a variable latency (usually 10 – 15 years or more), some patients with RRMS 
have a change in disease course with a steady increase in disability over time, 
referred to as secondary progression (Scalfari et al., 2014). SPMS typically takes the 
form of a progressive myelopathy. SPMS is usually a retrospective diagnosis in the 
context of increasing disability not attributable to relapses over more than 12 months 
(Lublin et al., 2014). The transition between RRMS and SPMS is subtle and a 
significant period of diagnostic uncertainty is common (Katz Sand et al., 2014).  
 
In patients with PPMS the disease course is progressive from onset. Patients with 
PPMS are usually older than patients with RRMS (mean age at onset 40 years) and 
there is no gender bias (Miller and Leary, 2007). PPMS typically presents with a 
progressive asymmetric spastic paraparesis or less commonly progressive 
hemiparesis, cerebellar ataxia, visual failure or dementia (Miller and Leary, 2007). 
Once established the course of PPMS and SPMS is indistinguishable 
(Kremenchutzky et al., 2006). Superimposed relapses can occur in both forms of 
progressive MS, but less often in PPMS than SPMS (Paz Soldan et al., 2015).   
 
Disease course definitions for MS have been recently updated, including the addition 
of new disease modifiers to describe the clinical phenotype of MS (Lublin et al., 2014). 
Patients are classified as relapsing or progressive MS with an additional descriptor of 
whether the disease is active or not (Figure 1.1). Disease activity can be assessed 
clinically based on the presence of relapses or with MRI showing new T2-
hyperintense and/or gadolinium-enhancing lesions. Patients with progressive MS are 
further classified based on whether the disease is progressing or not progressing. 
Disease progression is defined as an objective increase in neurological disability, 




Figure 1.1   Multiple sclerosis clinical phenotypes  
MS is classified as being relapsing or progressive and patients are further classified 
as being active or non-active (based on the presence of relapses or MRI disease 
activity) and with or without progression (assessed clinically). 
 
1.2.6 Diagnosis and differential diagnosis 
The core feature of MS is the presence of lesions in the CNS that are disseminated 
in both time and space. There is no definitive clinical sign or diagnostic test for MS 
and care is needed to exclude other inflammatory and non-inflammatory CNS 
disorders.  
 
In the last 30 years MRI has emerged as the key investigation in making a diagnosis 
of MS. Conventional T2-weighted MRI sequences are highly sensitive to the detection 
of focal demyelinating lesions in the cerebral white matter. Abnormal brain MRI is 
seen in almost all patients with established MS and in up to 80% of CIS patients who 
develop MS (Fisniku et al., 2008a). MRI is also helpful in excluding other pathologies 
that might mimic MS (e.g. structural or vascular lesions), and identifying abnormalities 
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that suggest an alternative diagnosis (e.g. leptomeningeal contrast enhancement, 
longitudinally-extensive spinal cord lesions). 
 
Other tests that may be helpful in establishing a diagnosis of MS include lumbar 
puncture and evoked potentials. CSF findings in people with MS include a normal or 
mildly raised white cell count (<25 cells/cm3, predominantly lymphocytes), normal or 
mildly raised protein, raised IgG index and IgG oligoclonal bands (OCBs) not present 
in serum (Freedman et al., 2005). OCBs are found in up to 90% of people with 
established MS but can also occur in other disorders (Dobson et al., 2013). Evoked 
potential testing to look for evidence of demyelination in the anterior visual pathways 
(or less commonly the auditory or sensory pathways) may provide additional evidence 
for dissemination in space (DIS) in patients with suspected MS, but is less sensitive 
than MRI or CSF examination (Pelayo et al., 2010).  
 
Diagnostic criteria for MS 
The first widely accepted diagnostic criteria for MS were proposed by Schumacher in 
1965. The Schumacher criteria required objective evidence of two lesions involving 
different parts of the CNS and at least two or more attacks in a person aged 10 – 50 
years with no alternative explanation for the symptoms (Schumacher et al., 1965). 
Changes were recommended to the diagnostic criteria by an international panel in 
1983 (Poser et al., 1983). The Poser criteria introduced the concept of clinically-
definite MS (CDMS) requiring two attacks with evidence of two separate lesions. The 
Poser criteria recognised that para-clinical investigations could also provide 
alternative evidence for DIS and that the certainty of diagnosis could be increased if 
unmatched IgG OCBs were found in the CSF (laboratory-supported MS). The Poser 
criteria have been used widely in clinical settings, research studies and clinical trials. 
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They remain the gold-standard in evaluating new diagnostic criteria for MS (Swanton 
et al., 2006; Rovira et al., 2009). 
 
In the years following the publication of the Poser criteria MRI became a widely 
available tool for diagnosing MS. On this background changes to the diagnostic 
criteria for MS were proposed in 2001 (McDonald et al., 2001). The original McDonald 
criteria introduced MRI criteria for DIS and dissemination in time (DIT) that could be 
used as a substitute for relapses and objective examination findings, including in 
patients with a CIS. The McDonald 2001 criteria also set out diagnostic criteria for 
PPMS, which had not been given special consideration by the Poser criteria. 
 
The original McDonald criteria were revised in 2005 (Polman et al., 2005) and 2010 
(Polman et al., 2011) with modification of the requirements for DIS and DIT (Table 
1.1). In the McDonald 2010 criteria (Table 1.2) DIS requires one or more T2 lesions 
in at least two regions of the CNS commonly affected in MS – periventricular, 
juxtacortical, infratentorial regions and the spinal cord (Figure 1.2). If the symptomatic 
lesion is referable to the spinal cord or brainstem then lesions in this site are excluded 
from DIS. DIT requires the presence of simultaneous asymptomatic gadolinium 
enhancing and non-enhancing lesions on a single MRI scan or a new lesion on a 
follow up scan done at any time point (Figure 1.3). Using the McDonald 2010 criteria 
a diagnosis of MS can be made in patients at the time of first clinical event (i.e. a CIS) 
when there is MRI evidence of DIS and DIT. 
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Table 1.1  Comparison of MRI criteria for dissemination in space and time in McDonald 2001, 2005 and 2010 criteria 
 Dissemination in space Dissemination in time 
McDonald 2001 criteria 
(McDonald et al., 2001) 
Three of the following: 
- At least one GdE lesion or nine T2 lesions 
- At least one infratentorial lesion 
- At least one juxtacortical lesion 
- At least three periventricular lesions 
One spinal cord lesion can be substituted for one 
brain lesion 
One of the following: 
- A new GdE lesion on a scan done >3 months 
after the clinical event  
- A new T2 and/or GdE lesion at any time with 
reference to a scan done >3 months after the 
clinical event 
 
McDonald 2005 criteria 
(Polman et al., 2005) 
Three of the following: 
- At least one GdE lesion or nine T2 brain 
and/or spinal cord lesions  
- At least one infratentorial or spinal cord lesion 
- At least one juxtacortical lesion 
- At least three periventricular lesions 
One of the following: 
- A new GdE lesion > 3 months after the initial clinical 
event 
- A new T2 lesion compared with a reference scan 
done at least 30 days after the initial clinical event 
McDonald 2010 criteria 
(Polman et al., 2011) 
One or more T2 lesion in two of four sites typically 




- Spinal cord 
* Lesions in the symptomatic region excluded 
One of the following: 
- Asymptomatic GdE and nonenhancing lesions on a 
single MRI 
- A new T2 and/or gadolinium-enhancing lesion on 




Table 1.2  McDonald 2010 criteria (modified from Polman et al 2011) 
Presentation Additional data needed for diagnosis of MS 
≥2 attacks; objective 
clinical evidence of ≥2 
lesions or objective 
clinical evidence of 1 
lesion with reasonable 
historical evidence of a 
prior attack 
None 
≥2 attacks; objective 
clinical evidence of 1 
lesion 
Dissemination in space, demonstrated by either: 
- ≥1 T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS*  
- Further clinical attack at a different site 
1 attack; objective clinical 
evidence of ≥2 lesions 
Dissemination in time, demonstrated by either: 
- Asymptomatic gadolinium-enhancing and 
nonenhancing lesions  
- A new T2 and/or gadolinium-enhancing lesion 
on follow-up MRI 
- Second clinical attack 
1 attack; objective clinical 
evidence of 1 lesion  
Dissemination in space, demonstrated by either: 
- ≥1 T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS*  
- Second clinical attack at a different site  
 
Dissemination in time, demonstrated by either: 
- Asymptomatic gadolinium-enhancing and 
nonenhancing lesions  
- A new T2 and/or gadolinium-enhancing 
lesion(s) on follow-up MRI  
- Second clinical attack 
Insidious neurologic 
progression suggestive  
of MS 
One year of disease progression plus 2 of 3 of the 
following: 
- ≥1 T2 lesions in MS-typical regions in the 
brain* 
- Evidence for DIS in the spinal cord based on 
≥2 T2 lesions in the cord 
- Positive CSF 




Figure 1.2 McDonald 2010 MRI criteria for dissemination in space 
One or more T2-hyperintense lesion (arrows) must be present at least two of four 
CNS locations typically affected in demyelination: (A) periventricular, (B) juxtacortical, 



























Figure 1.3 McDonald 2010 MRI criteria for dissemination in time 
Dissemination in time can be demonstrated by either the simultaneous presence of 
asymptomatic enhancing and non-enhancing lesions on a single scan (figures A and 
B) or a new T2-hyperintense and/or gadolinium-enhancing lesion on a follow up MRI 









The differential diagnosis depends on the clinical setting with different considerations 
in a patient with a CIS, a relapsing-remitting illness or a slowly progressive 
neurological deficit (Miller et al., 2008). Many neurologists use an approach of 
identifying “red flag” clinical (e.g. complete transverse myelopathy, encephalopathy), 
imaging (e.g. meningeal contrast enhancement, normal brain MRI) or laboratory (e.g. 
marked CSF pleocytosis, absence of oligoclonal bands) features when evaluating 
patients with suspected MS (Miller et al., 2008).  
 
Because of the overlapping clinical, MRI and CSF findings two special considerations 
in the differential diagnosis of MS are acute disseminated encephalomyelitis (ADEM) 
and neuromyelitis optica spectrum disorder (NMOSD). 
 
Acute disseminated encephalomyelitis 
ADEM is predominantly a disease in childhood but can occur in adults. The typical 
presentation is with multifocal neurological deficits and encephalopathy, sometimes 
following an infection or vaccination. MRI typically shows bilateral, symmetrical 
lesions in the cerebral white matter, sometimes also involving the deep grey matter 
(Miller et al., 2008). The CSF typically show a lymphocytic pleocytosis and OCBs may 
be present, often transiently. Diagnostic criteria for require the presence of 
encephalopathy in order to differentiate ADEM from MS (Krupp et al., 2013). 
However, MS can also rarely present with an encephalopathic ADEM-like illness 





Neuromyelitis optica spectrum disorder 
NMOSD is an idiopathic inflammatory astrocytopathy of the CNS. Historically, 
NMOSD was misdiagnosed as MS but the discovery of a pathogenic IgG antibody 
directed against the aquaporin-4 (AQP4-IgG) water channel has established NMOSD 
as a specific disease entity (Wingerchuk et al., 2015). The differentiation of MS and 
NMOSD can be difficult, but accurate diagnosis is essential because of differences in 
the disease course and response to treatment (Zekeridou and Lennon, 2015). 
 
NMOSD shows a stronger female predominance than MS (female:male ratio 9:1), 
tends to present in an older age group (mean age at onset 39 years) and is relatively 
more common in non-white populations. (Pandit et al., 2015) The core clinical features 
include optic neuritis (often bilateral and/or associated with poor visual recovery), 
longitudinally-extensive transverse myelitis (with lesions extending over >3 vertebral 
segments on MRI) and intractable nausea, vomiting and hiccups due to lesions in the 
area postrema (Kim et al., 2015; Wingerchuk et al., 2015). CSF findings include a 
lymphocytic pleocytosis, sometimes marked (>50 cells/cm3) and with neutrophils or 
eosinophils. A minority of patients have unmatched OCBs (Jarius et al., 2011).  
 
A first attack of NMOSD can sometimes mimic a CIS with features suggestive of MS 
e.g. acute unilateral optic neuritis or partial transverse myelitis (Flanagan et al., 2015). 
Some patients with NMOSD have brain MRI abnormalities (Matthews et al., 2013) or 
CSF findings (Jarius et al., 2011) suggestive of MS and a subgroup of patients are 
AQP4-IgG seronegative. An accurate diagnosis of NMOSD is essential because 
accrual of disability is relapse-related. Prompt treatment of acute attacks and 
immunosuppression improves outcomes, whereas MS-specific therapies are not 
effective and may exacerbate relapses in NMOSD (Zekeridou and Lennon, 2015).  
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Misdiagnosis of MS 
Rates of misdiagnosis of MS may be as high as 5-10% (Solomon and Weinshenker, 
2013). In a recent survey of MS specialist neurologists in the United States over 95% 
reported seeing one or more patients in the previous year misdiagnosed with MS. 
Many of these patients were receiving inappropriate treatments. The common 
disorders misdiagnosed as MS include small-vessel cerebrovascular disease, 
migraine, functional neurological disorders and fibromyalgia (Solomon et al., 2012). 
Potential causes of MS misdiagnosis include the misinterpretation of clinical findings 
(symptoms not typical of demyelination, absence of objective neurological signs) and 
application of MRI criteria to diagnose MS in inappropriate clinical settings (Solomon 
and Weinshenker, 2013).  
 
1.2.7  Prognosis 
MS is frequently a disabling illness and in most developed countries is the commonest 
cause of neurologic disability in young adults. On average life expectancy is reduced 
by 5-7 years with half of deaths attributable to complications of severe MS (Sadovnick 
et al., 1991).  
 
While many people develop irreversible disability in the long term, others have a much 
milder disease course with periods of sustained remission and little physical disability. 
This was highlighted in a prospective, longitudinal study of patients with CIS (Fisniku 
et al., 2008a). After 20 years, approximately 40% developed SPMS with severe 
disability. However, another 40% of patients had retained a relapsing course and only 
had mild disability. The factors that underpin the development of long term disability 




Measuring disability in MS 
There is a need to monitor disability in people with MS over time in clinical and 
research settings. The Kutrzke Expanded Disability Status Scale (EDSS) is the most 
widely used measure of disability utilised by clinicians, researchers and regulatory 
authorities (Kurtzke, 1983). The EDSS score is calculated by rating the degree of 
neurologic disability across seven functional systems (FS) evaluated in the neurologic 
exam (visual, brainstem, pyramidal, cerebellar, sensory, sphincter and cerebral). The 
results are combined with the measured walking distance and independence with 
activities of daily living. A final score of 0 – 10 is given with higher scores indicating 
more severe disability (Table 1.3).  
 
While the EDSS is easy to apply in research and clinical settings it has a number of 
disadvantages. Firstly, because scores are based on the results of the neurological 
examination the assessment is inherently subjective and vague definitions of what 
qualifies as mild, moderate or severe disability have contributed to high intra and inter-
observer variability. Secondly, the EDSS is heavily weighted towards ambulatory 
disability. Between EDSS 4.0 and 7.0 the score is based entirely on the measured 
walking distance and the need for assistive devices. Although loss of ambulation is 
an important feature of MS-related disability the EDSS does not give equal 








Table 1.3  Expanded Disability Status Scale (EDSS) score (Kurtzke, 1983) 
Score Description 
0 Normal neurological examination 
1.0 No disability, minimal signs in one functional system (FS) 
1.5 No disability, minimal signs on two or more FS 
2.0 Minimal disability in one FS 
2.5 Minimal disability in two FS 
3.0 Moderate disability in one FS or mild disability in three or four FS 
3.5 Moderate disability in two FS or mild disability in five FS 
4.0 Able to walk ≥ 500 m but not unrestricted; severe disability in one FS or 
combinations of less severe disability in other FS 
4.5 Able to walk ≥ 300 m unaided 
5.0 Able to walk ≥ 200 m unaided 
5.5 Able to walk ≥ 100 m unaided 
6.0 Able to walk ≥ 100 m with unilateral assistance  
6.5 Able to walk ≥ 20 m with bilateral assistance 
7.0 Unable to walk 5 m with an aid, essentially restricted to a wheelchair but 
independent  
7.5 Unable to take more than a few steps, restricted to a wheelchair 
8.0 Restricted to wheelchair with effective use of the arms and retains many 
self-care functions 
8.5 Restricted to bed much of the day, some use of the arms 
9.0 Bedbound, able to communicate and eat 
9.5 Bedbound, unable to communicate or swallow 
10 Death due to MS 
 
 
The Multiple Sclerosis Functional Composite (MSFC) was developed to address 
some of the limitations of the EDSS (Cutter et al., 1999). The MSFC incorporates 
three objective measures of neurologic function – the timed 25-foot walk (TWT), the 
9-hole peg test (9HPT) and the paced auditory serial addition test (PASAT). Although 
the MSFC addresses some of the issues with EDSS there are a number of 
disadvantages. The test is time-consuming taking 10 – 15 minutes to complete, 
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depending on patient cooperation and level of disability. Although the MSFC 
incorporates a cognitive measure there is no assessment of visual function and so 
additional tests such as the Sloan low-contrast visual acuity are sometimes added 
(Balcer et al., 2003). Finally, the PASAT is unpopular with patients but may be 
substituted for the symbol digit modalities test (SDMT), an alternative test of 
information processing speed (Smith, 1982). Despite some limitations the MSFC is 
well-validated and correlates well with disease stage, EDSS score, MRI metrics, 
health-related quality of life and employment (Cohen et al., 2012).  
 
Contributions to disability in relapse-onset MS 
Two separate processes drive the accumulation of irreversible disability in relapse-
onset MS. The first is relapses, where inflammatory demyelination results in 
permanent axonal injury with residual neurologic impairment. The second and more 
significant contribution is the onset of SPMS. 
 
Relapses 
Among patients with RRMS, relapses occur unpredictably but on average one relapse 
occurs every two years. Age is an important predictor of relapse rates with higher 
relapse rates reported in children with MS and young adults compared with older 
adults (Tremlett et al., 2008b; Gorman et al., 2009). Hormonal factors, particularly 
around the time of pregnancy (decreased) and the puerperium (increased) exert an 
effect on relapses (Confavreux et al., 1998). The frequency of relapses tends to 
reduce with time and relapses are much less common in patients with established 
SPMS (Paz Soldan et al., 2015). 
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The impact of relapses on accrual of disability was evaluated in a group of patients 
with established RRMS (mean baseline EDSS 2.5) enrolled in the placebo arms of a 
number of randomised control trials (Lublin et al., 2003). EDSS measurements were 
available before, during and after relapses. 42% of patients had a change of ≥0.5 and 
28% had a change of ≥1.0 on the EDSS scale following a relapse (Lublin et al., 2003). 
A clinic-based study from Italy aimed to identify predictors of poor recovery following 
a relapse (Leone et al., 2008). 34% of patients had a change in functional system 
score of ≥1 and 13% had a change of ≥2 points (severe sequelae) after a relapse. 
Predictors of severe sequelae included the relapse severity, the duration of the 
relapse, older age and a greater number of functional systems involved. The number 
of previous relapses was not predictive of relapse severity. In another clinic-based 
study, poor recovery from the first relapse predicted poor recovery from subsequent 
relapses suggesting that in part the variability in recovery from relapses is determined 
by unknown patient and disease-specific factors (Mowry et al., 2009a).  
 
Recovery following a relapse is thought to be related to the degree of axonal loss 
within the symptomatic lesion (Trapp et al., 1998). This has been demonstrated in 
vivo using optical coherence tomography (OCT) in patients with acute optic neuritis 
where the degree of retinal nerve fibre layer thinning correlates with visual outcome 
(Henderson et al., 2010). Persistent conduction block in demyelinated axons and 
failure of remyelination are other possible mechanisms leading to poor recovery. 
 
Secondary progression 
The change in disease course from relapsing to progressive MS is the major 
determinant of long term disability in relapse-onset MS. In natural history studies the 
median time to development of SPMS is 15 – 19 years (Confavreux et al., 2003; 
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Tremlett et al., 2008a; Scalfari et al., 2010; Scalfari et al., 2014). In the London-
Ontario natural history cohort two thirds of patients developed SPMS over a mean 
follow-up period of 28 years (Scalfari et al., 2010; Scalfari et al., 2014).  
 
Patients with SPMS progress through a series of disability milestones that result in 
the need for assistance to walk, loss of ambulation, impairment of upper limb and 
sometimes bulbar function, and ultimately death. In the London-Ontario cohort the 
median time to EDSS 6, 8 and 10 from the onset of the progressive phase was 3, 12 
and 30 years respectively (Scalfari et al., 2010). There is much inter-individual 
variation in the rate of progression in SPMS with periods of stability (plateaus) and 
periods of increased progression. Superimposed relapses can occur in patients with 
SPMS, especially soon after onset of progression and in younger patients (Paz 
Soldan et al., 2015). Age and gender do not appear to affect the course of established 
SPMS (Confavreux et al., 2003). The number of early relapses (first 2-5 years of the 
illness) are associated with a shorter latency to the onset of SPMS but do not 
influence the rate of progression (Confavreux et al., 2000; Scalfari et al., 2014). 
Studies investigating whether superimposed relapses in patients with SPMS 
influence disability progression have produced mixed results (Confavreux et al., 2000; 
Paz Soldan et al., 2015) 
 
Benign MS 
A subgroup of people with relapse-onset MS have a much milder disease course with 
periods of sustained remission and little physical disability. This has been termed 
“benign MS”, a retrospective diagnosis made 15 years after disease onset in patients 
with an EDSS score of ≤3 (Lublin et al., 1996). The concept of benign MS is 
controversial. Firstly, the definition is heavily weighted towards ambulatory disability 
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(as measured by the EDSS), which fails to capture cognitive impairment, fatigue and 
other important sources of disability in people with MS. In one hospital-based study 
half of patients meeting criteria for benign MS had significant cognitive impairment, 
depression and fatigue (Amato et al., 2006). Secondly, the latency to onset of SPMS 
is highly variable and some evidence suggests that the risk increases with time. In 
the London-Ontario natural history cohort the risk of developing SPMS increased with 
time from 53% at 15 years to 69% at 25 years (Scalfari et al., 2014). Another natural 
history study from Gothenburg found that some patients were still developing SPMS 
more than 40 years after disease onset (Skoog et al., 2012).  
 
Against this backdrop a number of lines of evidence do support the concept that 
benign forms of MS exists. Firstly, autopsy studies have found evidence of 
asymptomatic demyelination in patients without known neurologic symptoms during 
life. In autopsy series an estimated 20 – 25% of patients with pathologically confirmed 
demyelination died without a diagnosis of MS (Gilbert and Sadler, 1983). Secondly, 
an increasing number of people are being identfied with the radiologically isolated 
syndrome with evidence of demyelinating lesions on MRI suggestive of MS in the 
absence of clinical symptoms (Okuda et al., 2014). These patients have a relatively 
favourable prognosis with less than half experiening symptoms in the first 5 years of 
follow-up (Okuda et al., 2014). Finally, one third of patients with a CIS do not have 
any further symptoms, even with long term follow up. Up to half of these patients have 
MRI abnormalities that satisify the McDonald 2005 criteria without a second clinical 







Comorbid health problems are common in people with MS including affective 
disorders, hypertension, dyslipidaemia, vascular disease and chronic pulmonary 
disease (Marrie et al., 2015a). Comorbidities may influence the course of the illness. 
More rapid progression of disability has been reported in people with MS who have 
vascular comorbidities (Marrie et al., 2010). Comorbidities also increase the risk of 
hospitalization and death in people with MS (Marrie et al., 2015b; Marrie et al., 2015c). 
 
1.2.8 Treatment 
Disease-modifying treatment (DMT) for RRMS has been available for more than 20 
years. There are currently 15 agents approved by the United States Food and Drug 
Administration and the European Medicines Agency (Wingerchuk and Weinshenker, 
2016). Collectively, these treatments have been shown to reduce relapses and the 
number of new MRI lesions in patients with active RRMS, based on the presence of 
relapses or MRI evidence of disease activity in the 12-24 months prior to starting 
treatment (Wingerchuk and Weinshenker, 2016). The available agents differ in their 
route and frequency of administration, mechanism of action, efficacy and side-effect 
profile (Wingerchuk and Weinshenker, 2016). 
 
While the currently available treatments reduce relapses and MRI disease activity the 
effect on disability is less clear. A number of these agents have been shown to reduce 
confirmed disability progression over follow up periods of 12 – 36 months. However, 
this largely reflects a reduction in disability attributable to the effects of relapses. In 
the longer term most disability is due to the development of SPMS. Because the 
course of MS unfolds over several decades it is not possible to address this issue 
with a randomised-controlled trial, however, a number of retrospective and 
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prospective observational studies suggest a benefit of DMT on long-term disability. A 
21 year follow up of patients enrolled in the pivotal interferon-β1b (Betaseron) trial 
showed a survival advantage in patients randomised to early treatment with interferon 
(Goodin et al., 2012). Injectable treatments (either interferon-β or glatiramer acetate) 
were found to slow progression of disability compared with historical controls over a 
6 year period in a prospective observational study from the United Kingdom (Palace 
et al., 2015).  
 
Treating patients with MS requires a balance of risks and benefits. While the 
established MS therapies (interferon-β, glatiramer acetate) are known to have 
excellent long-term safety, a number of the newer treatments (natalizumab, 
fingolimod, alemtuzumab), although more effective, are associated with significant 
toxicity including opportunistic infections, cardiac arrhythmias and secondary 
autoimmunity. This is relevant when management decisions are being made in young 
adults with a chronic illness with an unpredictable clinical course and uncertainties 
about long-term benefits of treatment.  
 
In order to select treatments for individual patients some neurologists use 
conventional brain MRI findings (T2 lesion load, gadolinium-enhancing lesions) to 
help guide initial selection and escalation of therapy (Wingerchuk and Weinshenker, 
2016). However, the relationship of these measures to long-term disability is limited 
(Kappos et al., 1999; Fisniku et al., 2008a). There is a need for a better understanding 
of what drives long-term disability in MS in order to treat patients with MS more 





1.3  Clinically isolated syndromes and the relationship to multiple  sclerosis  
A CIS is the first clinical manifestation of relapse-onset MS. A CIS is defined as a first 
episode of neurological dysfunction suggestive of demyelination in the absence of 
fever or infection. There has been evolution in the definition of CIS over the last 15 
years as diagnostic criteria for MS have evolved (McDonald et al., 2001; Polman et 
al., 2005; Polman et al., 2011). 
 
1.3.1 Presentation 
The demographic profile of patients with CIS mirrors that of MS. The peak age of 
onset is between 20 and 40 years (mean age approximately 30 years), and CIS is 
more common in females than males (Tintore et al., 2015). The symptoms usually 
evolve subacutely over hours to days and reach their peak within 2 – 3 weeks of 
onset. A characteristic feature is remission with or without treatment with 
corticosteroids. Although a CIS can affect any part of the CNS typical presentations 
include optic neuritis, a brainstem/cerebellar syndrome and partial myelopathy.  
 
Optic neuritis 
Optic neuritis is the first symptom of MS in approximately 20-30% of patients (Toosy 
et al., 2014). Patients typically present with blurring of vision in one eye that may 
progress over hours to days. Pain is common, especially pain on eye movement. The 
examination shows a reduction in visual acuity that is usually mild to moderate (with 
median visual acuity 6/24), impaired colour vision and a relative afferent papillary 
defect. Although a central scotoma is most commonly seen, any type of visual field 
defect can occur. The optic disc may appear swollen or normal in the acute stage. 
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MRI of the optic nerve may show T2 hyperintensity, swelling and enhancement after 
the administration of gadolinium (Toosy et al., 2014).  
 
The “typical” optic neuritis seen in patients with CIS and MS, needs to be 
differentiated from other causes of an acute optic neuropathy such as anterior 
ischaemic optic neuropathy, Leber’s hereditary optic neuropathy, NMOSD or 
neurosarcoidosis plus ophthalmic causes of acute unilateral visual loss. (Toosy et al., 
2014). Atypical features that suggest an alternative aetiology include severe visual 
impairment, absence of pain or very severe pain, a “macular star” or intra-ocular 
inflammation and bilateral involvement (Miller et al., 2008; Toosy et al., 2014). MRI 
can assist in the differential diagnosis; longitudinally-extensive optic nerve lesions or 
involvement of the optic chiasm is suggestive of NMOSD (Kim et al., 2015) and 
prominent optic nerve sheath enhancement is suggestive of neurosarcoidosis (Toosy 
et al., 2014). 
 
Brainstem/cerebellar syndromes 
Brainstem/cerebellar syndromes can take a variety of forms depending on the site of 
the lesion (Miller et al., 2008). Double vision is the most common presentation due to 
an internuclear ophthalmoplegia (often bilateral) or a sixth nerve palsy (Miller et al., 
2008). Other brainstem/cerebellar manifestations include facial sensory loss, facial 
weakness, cerebellar ataxia, and vertigo (Miller et al., 2008). Common sites for 
infratentorial lesions on MRI include the dorsal and ventral surfaces of the pons (in 
contrast to small vessel cerebrovascular disease which typically involves the belly of 




Spinal cord syndromes 
An episode of myelitis presenting with a partial spinal cord syndrome is a common 
CIS presentation. The symptoms are usually sensory in nature and may start in one 
limb and ascend to a level involving the trunk or spread to the contralateral side. 
Lhermitte’s symptom may be present when the lesion involves the cervical cord and 
mild sphincter disturbance is common. A complete transverse myelitis with bilateral 
motor and sensory involvement with a clearly defined sensory level, is not typical of 
CIS/MS and more often occurs in idiopathic transverse myelitis or NMOSD. 
 
In patients with a partial myelitis MRI typically shows a wedge-shaped area of T2-
hyperintensity, often placed eccentrically in the cord and/or abutting the pial surface 
on axial images. Lesions typically extend over 1-2 vertebral bodies, in contrast to 
NMOSD (Kim et al., 2015). 
 
Hemispheric syndromes 
Rarely CIS patients can present with cerebral symptoms such as hemiparesis or a 
visual field defect, sometimes mimicking an acute stroke (Pelayo et al., 2007).  
 
1.3.2 Clinical course  
Although a CIS can be an isolated, monophasic event it is frequently the first 
manifestation of MS. This was highlighted in studies done in the pre-MRI era 
(predominantly in patients with acute optic neuritis) that found that CDMS developed 
in 30 – 75% of patients with CIS with a higher risk reported in studies from the United 
Kingdom (Francis et al., 1987) compared with North America (Rizzo and Lessell, 
1988) or Scandinavia (Sandberg-Wollheim et al., 1990).  
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In evaluating patients with CIS two major clinical questions arise. The first is the risk 
of further clinical episodes and new MRI disease activity (i.e. MS). The second is the 
risk of long-term neurological disability. A number of natural history studies, 
observational clinical-MRI studies and clinical trials have provided important insights 
into the prognosis of patients with CIS. In this section the demographic, genetic and 
environmental, clinical, MRI and body fluid biomarkers that help predict the 
development of CDMS and long-term disability in CIS patients are reviewed. 
 
Risk factors for the development of clinically-definite multiple sclerosis 
Demographic factors 
Younger age is associated with an increased risk of a second clinical attack and 
development of CDMS (Polman et al., 2008; Mowry et al., 2009b; Kuhle et al., 2015; 
Tintore et al., 2015). Younger patients with MS, including children, have a greater 
burden of radiological disease activity (as measured by increase in T2 lesion load 
over time and number of gadolinium-enhancing lesions) potentially explaining this 
finding (Filippi et al., 2001b; Li et al., 2006; Waubant et al., 2009). However, the 
underlying biological mechanisms responsible for this are unclear. 
 
CIS is more common in women than men (Dobson et al., 2012). While some studies 
have reported that female sex is a risk factor for CDMS in CIS patients (Rizzo and 
Lessell, 1988; Optic Neuritis Study Group, 2008; Swanton et al., 2010) others have 
not (Kuhle et al., 2015; Tintore et al., 2015). A recent meta-analysis of nine studies 
found no influence of sex on the rate of conversion to CDMS after a CIS (Dobson et 




There has been relatively little investigation of the role of ethnicity. In a study from 
San Francisco, CIS patients with non-white ethnicity (African American, Hispanic and 
Asian) were at higher risk of CDMS than white patients living in the same 
geographical area (Mowry et al., 2009b). 
 
Genetic and environmental factors 
Major genetic and environmental risk factors for MS including HLA-DRB1*1501  (Kelly 
et al., 1993; Morrissey et al., 1993; Hauser et al., 2000a; Horakova et al., 2011), 
vitamin D insufficiency (Martinelli et al., 2014; Ascherio et al., 2014) and cigarette 
smoking (Di Pauli et al., 2008) have been associated with an increased risk of CDMS 
in CIS patients. The role of EBV infection is uncertain; some studies have reported 
that higher EBV-IgG titres are a risk factor for CDMS (Lunemann et al., 2010), but 
others have not (Kuhle et al., 2015; Munger et al., 2015). 
 
Clinical features 
The risk of CDMS is similar across different CIS subtypes (Morrissey et al., 1993; 
O'Riordan et al., 1998b; Jacobs et al., 2000; Comi et al., 2001; Brex et al., 2002; 
Fisniku et al., 2008a; Polman et al., 2008; Mowry et al., 2009b; Tintore et al., 2010; 
Kuhle et al., 2015; Tintore et al., 2015). Early follow-up of the Barcelona CIS cohort 
suggested that optic neuritis may be associated with a lower risk of developing CDMS 
(Tintore et al., 2005). However, patients with optic neuritis in that study had a low rate 
of asymptomatic T2-hyperintense brain lesions at presentation. After adjustment for 
MRI findings the risk of MS was similar in patients with optic neuritis and other CIS 
presentations (Tintore et al., 2005). These findings were confirmed in a much larger 




Some specific clinical features are associated with a low risk of subsequent MS in 
patients with CIS. These include papillitis, painless visual loss and presence of retinal 
haemorrhages / exudates in patients with optic neuritis (Beck et al., 2003), isolated 
facial sensory loss in brainstem CIS patients (Sastre-Garriga et al., 2010) and a 
complete transverse myelopathy in patients with acute spinal cord syndromes, which 
is atypical and associated with a very low risk of MS (Lipton and Teasdall, 1973). 
 
Cognitive impairment (Zipoli et al., 2010) and fatigue (Runia et al., 2015) in patients 
with CIS may be risk factors for the development of CDMS. 
 
MRI abnormalities 
The presence of asymptomatic T2-hyperintense brain lesions on MRI is the most 
important risk factor for CDMS in patients with CIS (Lee et al., 1991; Morrissey et al., 
1993; O'Riordan et al., 1998b; Tintore et al., 2001; Brex et al., 2002; Minneboo et al., 
2004; Tintoré et al., 2006; Fisniku et al., 2008a; Optic Neuritis Study Group, 2008; 
Tintore et al., 2015). Approximately two-thirds of patients have brain MRI 
abnormalities at the time of presentation with CIS (Fisniku et al., 2008a; Optic Neuritis 
Study Group, 2008; Tintore et al., 2015).  
 
Table 1.4 summarises the results of prospective longitudinal observational studies 
investigating the prognostic significance of asymptomatic T2-hyperintense brain 
lesions on the development of MS over follow-up periods of up to 20 years. 
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Table 1.4 Risk of clinically-definite multiple sclerosis based on baseline brain MRI findings in longitudinal studies of patients with CIS  
Study Year CIS type Number Follow up CDMS (%) 
Abnormal MRI Normal MRI Total 
Tintore et al 2015 Mixed 1015 7 years 56% 7% 39% 
Optic Neuritis 
Study Group 
2008 Optic neuritis 389 15 years 72% 25% 50% 




In CIS patients with an abnormal brain MRI the risk of MS is approximately 60 – 80% 
compared with approximately 10 – 25% in patients with a normal MRI brain at 
presentation (Fisniku et al., 2008a; Optic Neuritis Study Group, 2008; Tintore et al., 
2015).  
 
A higher number of T2 lesions at baseline is associated with a higher risk of CDMS, 
at least over the first 5-7 years after CIS (Morrissey et al., 1993; Optic Neuritis Study 
Group, 1997; O'Riordan et al., 1998b; Beck et al., 2003; Tintoré et al., 2006; Swanton 
et al., 2010; Tintore et al., 2015). In the Barcelona CIS cohort followed up over a mean 
of almost 6 years, the hazards ratio for development of CDMS increased from 5.7 
(95% CI  3.5 – 9.4) in patients with 1 – 3 T2 lesions, to 8.7 (5.4 – 14.2) with 4 – 9 T2 
lesions and 12.7 (9.1 – 19.7) with 10 or more T2 lesions (Tintore et al., 2015). Similar 
results were found in a cohort of patients with optic neuritis followed up over a period 
of 6 years, although in that study measures of lesion location and activity were better 
predictors of CDMS than lesion number in a multivariate analysis (Swanton et al., 
2010).  
 
The effect of T2 lesion number may be less important in the longer term. This was 
illustrated in a cohort followed up at approximately 5 yearly intervals over the first 20 
year after CIS. After 5 years the risk of CDMS was higher in patients with four or more 
T2 brain lesions at baseline (Morrissey et al., 1993). However, at 14 and 20 years the 
risk of CDMS was similar in patients with 1 – 3, 4 – 10 and more than 10 T2 lesions 
at presentation (Brex et al., 2002; Fisniku et al., 2008a). Similar findings were reported 
in the Optic Neuritis Treatment Trial where a higher a number of T2 lesions at baseline 
was association with a higher risk of CDMS at 5 years (Optic Neuritis Study Group, 
1997) but not at 15 years follow-up (Optic Neuritis Study Group, 2008). 
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The periventricular region is the most common site for T2 brain lesions in CIS patients 
(Brex et al., 1999) and one or more periventricular lesions was the strongest baseline 
MRI predictor of CDMS in patients with optic neuritis followed up over 6 years, 
independent of other measures of lesion load, location and activity (Swanton et al., 
2010). Juxtacortical lesions are a relatively specific finding and have also been found 
to be associated with the development of CDMS (Barkhof et al., 1997). Infratentorial 
(Tintore et al., 2010) and spinal cord lesions (Sombekke et al., 2013) occur in up to 
half of patients with CIS and are associated with an increased risk of CDMS. The 
value of lesion location is reflected in current diagnostic criteria for MS which 
emphasise the importance of lesion location over lesion load (Polman et al., 2011). 
 
A core feature of MS is that CNS lesions are disseminated in time. The presence of 
gadolinium-enhancing and non-enhancing lesions and/or a new T2 lesion provides 
evidence for DIT using MRI (Dalton et al., 2003; Tur et al., 2008; Rovira et al., 2009). 
These findings are highly predictive of the development of CDMS in CIS patients, 
independent of other MRI findings (Swanton et al., 2010).  
 
A number of non-conventional MRI measures have been studied in CIS patients. 
Whole brain and grey matter atrophy, elevated NAWM myo-inositol concentration, 
reduced grey matter MTR, and cortical lesions have all be associated with the early 
development of CDMS over the first 2-3 years after a CIS (Dalton et al., 2002a; Dalton 
et al., 2004; Fernando et al., 2004; Fernando et al., 2005; Filippi et al., 2010; 
Calabrese et al., 2011; Perez-Miralles et al., 2013). In a multimodal MRI study 
investigating the predictive value of baseline MRI abnormalities, conventional MRI 
measures (particularly lesion location and activity) were associated with the 
development of CDMS after 6 years in a multivariable analysis, whereas the non-
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conventional MRI measures (whole brain and tissue-specific atrophy, magentization 
transfer ratio and spectroscopy) were not. The presence of one or more intracortical 
lesions has been shown to predict CDMS, independent of T2 lesion load (Filippi et 
al., 2010). However, the sensitivity of this finding was low and only one third of CIS 
patients had one or more intracortical lesions (Filippi et al., 2010).  
 
Cerebrospinal fluid biomarkers 
The presence of unmatched IgG OCBs in the CSF is predictive of conversion from 
CIS to CDMS (Sandberg-Wollheim et al., 1990; Morrissey et al., 1993; Cole et al., 
1998; Tintore et al., 2008; Dobson et al., 2013; Kuhle et al., 2015; Tintore et al., 2015). 
Some studies have found that the prognostic significance of OCBs may be eclipsed 
by brain MRI findings (Morrissey et al., 1993), although a recent study in over 1000 
CIS patients found that presence of OCBs was associated with development of 
CDMS independent of brain T2 lesion load (Tintore et al., 2015). A normal brain MRI 
and negative OCBs is associated with a very low-risk of CDMS (Tintore et al., 2008). 
 
CSF biomarkers other than oligoclonal bands are actively being investigated 
(Comabella and Montalban, 2014). Recent studies have found that higher levels of 
CSF chitinase 3-like 1, neurofilament light chain and soluble CD27 predict conversion 
to CDMS in CIS patients (Brettschneider et al., 2010; Comabella et al., 2010; 
Arrambide et al., 2016).   
 
Neurophysiologic abnormalities 
Although abnormalities in evoked potentials are often seen in CIS patients, the 
prognostic value for development of CDMS is limited (Pelayo et al., 2010).  
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Risk factors for the development of disability 
Demographic factors 
Older age at onset has been consistently associated with shorter times to 
development of significant disability in relapse-onset MS, principally because of a 
shorter time to onset of SPMS (Eriksson et al., 2003; Koch et al., 2010; Scalfari et al., 
2011; Scalfari et al., 2014). Similarly, male sex is associated with a more disabling 
course (Confavreux et al., 2003), possibly because of the higher proportion of males 
with PPMS.    
 
Prospective CIS studies have not found age or sex to be predictive of future disability 
(Swanton et al., 2009; Tintore et al., 2015), although this might reflect the relatively 
short duration of follow-up compared with natural history studies.  
 
Genetic and environmental factors 
Whether genetic factors influence the course of MS is uncertain. A number of cross-
sectional studies have not found an association between HLA-DRB1*1501 status and 
disability when assessed using the EDSS (Masterman et al., 2000; Hensiek et al., 
2002; International Multiple Sclerosis Genetics Consortium et al., 2011; Moutsianas 
et al., 2015). There have been no previous studies investigating the relationship of 
HLA-DRB1*1501 (or other genetic factors) and long-term disability in CIS patients.     
 
Vitamin D insufficiency may be a risk factor for disability progression. In a clinical trial 
of high-risk CIS patients vitamin D levels of <50 nmol/L at presentation was 
associated with higher disability after 5 years and a trend towards a faster rate of 
brain atrophy (Ascherio et al., 2014).  
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Cigarette smoking has been reported to be associated with faster progression of 
disability in people with established MS (Manouchehrinia et al., 2013) but not with 
MRI measures of disease progression in patients with CIS or early RRMS, at least in 
the short-term (Munger et al., 2015; Kvistad et al., 2016).  
 
Clinical features 
Natural history studies suggest that the long-term course of CIS patients with optic 
neuritis or sensory symptoms may be more favourable that those with motor 
symptoms at onset (Confavreux et al., 2003; Eriksson et al., 2003). However, these 
studies considered patients with relapse and progressive-onset MS together. In 
studies restricted to patients with relapse-onset MS the initial presenting symptoms 
appear to have less prognostic value (Tremlett et al., 2008a; Scalfari et al., 2014). In 
a prospective CIS cohort followed for 20 years disability was similar at follow-up 
irrespective of CIS topography (Fisniku et al., 2008a).  
 
Incomplete recovery in CIS patients may be a marker of worse prognosis and shorter 
time to onset of SPMS (Eriksson et al., 2003).  
 
MRI abnormalities 
Brain T2 lesion load at the time of CIS is moderately predictive of future disability 
(O'Riordan et al., 1998b; Brex et al., 2002; Tintoré et al., 2006; Fisniku et al., 2008a; 
Tintore et al., 2015). In the Barcelona CIS cohort, patients with 10 or more T2 lesions 
at baseline were three times as likely to reach EDSS 3 over a mean follow-up period 
of almost 7 years (Tintore et al., 2015). No increase in the risk of disability was seen 
in patients with 1 – 3 or 4 – 9 T2 lesion at baseline (Tintore et al., 2015). In the London 
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CIS cohort followed up over 20 years the risk of EDSS 3 or EDSS 6 was higher in 
patients with a greater number of T2 lesions at baseline. However, while disability 
was overall more common with an increasing number of lesions a third of patients 
with 10 or more lesions baseline accrued minimal neurologic disability (EDSS <3) 
over 20 years, while nearly a quarter of patients with a normal baseline MRI had an 
EDSS ≥3 (Fisniku et al., 2008a). 
 
The change in T2 lesion load over time may be a better predictor of disability than 
baseline T2 lesion number. New T2 lesions after 3 months and change in lesion load 
over the first year after a CIS are associated with disability 6 years later (Swanton et 
al., 2009; Di Filippo et al., 2010). In the London cohort followed up over 20 years both 
clinically and with MRI, the change in T2 lesion volume over the first 5 years was 
significantly greater in patients who developed SPMS (Fisniku et al., 2008a). The 
correlation coefficient for change in T2 lesion volume over 5 years and disability after 
20 years was higher than for baseline T2 lesion load (r 0.61 vs 0.48). This is consistent 
with the findings of natural history studies that the number of early relapses (the 
clinical correlate of T2 lesions) is predictive of disability and shorter time to 
development of SPMS (Confavreux et al., 2003; Scalfari et al., 2014).  
 
Lesion location appears to be a better predictor of disability that measures of lesion 
load over the first 5-8 years after a CIS (Minneboo et al., 2004; Swanton et al., 2009; 
Tintore et al., 2010). In a small cohort of CIS patients from Amsterdam the presence 
of two or more infratentorial lesions on the baseline MRI was associated with disability 
after 8 years (Minneboo et al., 2004). Similar findings were reported in a larger CIS 
cohort from Barcelona; one or more baseline infratentorial lesion doubled the risk of 
reaching EDSS 3 or more after 7 years. This increase in risk was driven by brainstem 
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rather than cerebellar lesions (Tintore et al., 2010). In a study of patients with optic 
neuritis with brain and spinal cord MRI at the time of CIS, spinal cord lesions were 
found to be the best predictor of disability after 6 years (Swanton et al., 2009).  
 
Gadolinium-enhancing lesions are predictive of relapses and development of CDMS 
(Kappos et al., 1999; Swanton et al., 2009) but not disability, at least in the short to 
medium-term (Swanton et al., 2009).  
 
In established MS a number of number non-conventional MRI measures have been 
correlated with disability progression over time including brain and spinal cord 
atrophy, grey matter MTR and grey matter lesion load (Agosta et al., 2006; Lukas et 
al., 2010; Calabrese et al., 2012; Lukas et al., 2015). While similar abnormalities have 
been found in patients with CIS they have not been found to be associated with 
disability over follow-up periods of 3 – 6 years (Dalton et al., 2004; Fernando et al., 
2004; Fernando et al., 2005; Swanton et al., 2009), but longer follow-up is required to 
determine the prognostic value of these measures. 
 
Cerebrospinal fluid biomarkers 
OCBs are associated with an increased risk of disability in the first 6 years after a 
CIS, independent of brain MRI abnormalities (Tintore et al., 2015).  
 
Neurophysiologic abnormalities 
Abnormalities in multimodal evoked potentials are associated with future disability in 




Risk factors for the development of CDMS and disability in CIS patients are 
summarised in Table 1.5. 
 
Table 1.5 Risk factors of the development of CDMS and disability in CIS patients  
 Clinically-definite MS Disability 




Genetic HLA DRB1*15:01  
Environmental Vitamin D insufficiency 
Smoking 
Vitamin D insufficiency 
Clinical  Non-optic neuritis CIS 
Cognitive impairment 
Fatigue 
Motor symptoms at onset 
Poor recovery from CIS 
Number of early relapses 




New T2 lesions over time 
>10 T2 brain lesions 
Infratentorial and spinal 
cord lesions 
Change in T2 lesion load 
over first 5 years 
Cerebrospinal fluid IgG oligoclonal bands 
Neurofilament light chain 
CHI3L-1 




Treatment with high-dose corticosteroids hastens the recovery from an episode of 
acute optic neuritis but does not influence the degree of recovery or the subsequent 
risk of developing MS (Optic Neuritis Study Group, 2008). These results have been 
generalised to other CIS presentations and corticosteroid treatment is usually 
considered in CIS patients with disabling symptoms. 
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Disease-modifying therapies used to treat MS have been investigated in high-risk CIS 
patients with asymptomatic brain MRI abnormalities suggestive of demyelination 
(Jacobs et al., 2000; Comi et al., 2001; Kappos et al., 2006; Comi et al., 2009; Comi 
et al., 2012; Miller et al., 2014; Leist et al., 2014). Collectively these studies have 
shown that treatment delays the time to a second clinical attack and reduces the 
number of new T2 brain lesions over 2 – 4 years of follow-up (Table 1.6). Whether 
there is any long-term advantage to early initiation of DMT at the time of presentation 
with CIS is uncertain. The BENEFIT study randomised 468 patients with high-risk CIS 
to interferon β-1b 250 mcg alternate days or placebo (Kappos et al., 2006). After 24 
months there was a 38% reduction in the risk of CDMS and positive effects on a 
number of secondary MRI endpoints. Participants had the option to switch to open-
label interferon β-1b at the end of the study or after the development of CDMS. At 3 
years there was a 40% reduction in confirmed disability progression in patients 
randomised to early treatment with interferon β-1b (Kappos et al., 2007), however, 
this was no longer apparent after 5 years (Kappos et al., 2009). In a recently 
completed 11 year follow-up, disability was similar in patients randomised to early 
treatment and those who started treatment after 24 months with a median EDSS 1.5 
in both groups (Kappos et al., 2016). More patients in the delayed treatment group 
developed SPMS compared with the early treatment group (8.3% vs 4.5%), although 
this was not statistically significant. PASAT scores were higher in the early treatment 
group suggesting a possible benefit on cognitive outcomes.  
 
The findings of observational studies have confirmed the findings of randomised 
controlled trials. Early treatment with DMT reduces the risk of CDMS and may reduce 




Table 1.6  Randomised controlled trials of disease-modifying therapies in patients with CIS.  





(Jacobs et al., 2000) 
IFN β-1a 30 mcg weekly vs placebo 36 months 383 35% 50% RR 0.56 (0.38-0.81) 
ETOMS  
(Comi et al., 2001) 
IFN β-1a 22 mcg weekly vs placebo 24 months 309 34% 45% OR 0.61 (0.37-0.99) 
BENEFIT  
(Kappos et al., 2006) 
IFN β-1b 250 mcg alternate days vs 
placebo 
24 months 468 28% 45% HR 0.50 (0.36-0.70) 
REFLEX  
(Comi et al., 2012) 
IFN β-1a 44 mcg TIW vs IFN β-1a 
44 mcg weekly vs placebo 




HR 0.48 (0.31-0.73) 
HR 0.53 (0.35-0.79) 
PreCISe  
(Comi et al., 2009) 
Glatiramer acetate 20 mg daily vs 
placebo 
36 months 461 25% 43% HR 0.55 (0.40-0.77) 
TOPIC  
(Miller et al., 2014) 
Teriflunomide 14mg vs 
teriflunomide 7mg daily vs placebo 




HR 0.57 (0.38-0.87)                          
HR 0.63 (0.42-0.95) 
ORACLE  
(Leist et al., 2014) 
Cladribine 5.25 mg/kg vs cladribine 
3.5 mg/kg vs placebo 




HR 0.38 (0.25-0.58) 
HR 0.33 (0.21-0.51) 
 
Abbreviations: CDMS = clinically-definite MS, IFN = interferon, HR = hazard ratio, OR = odds ratio, RR = rate ratio, TIW = three times weekly 
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1.4 Rationale for this thesis 
MS is a common neurological disorder in young adults with a highly variable clinical 
course. In the longer term many patients with relapse-onset MS will develop 
significant neurological disability but others have a much milder disease course. The 
mechanisms responsible for disease course heterogeneity in MS remain poorly 
understood, especially the factors important in the development of SPMS. 
Understanding what course a person’s MS is likely to take is a priority around the time 
of their first symptoms when neurologists are counselling patients about prognosis 
and making treatment decisions.  
 
Against this background the major aims of this thesis are: (1) to improve the diagnosis 
of MS using MRI to facilitate an early, accurate diagnosis; (2) to identify early MRI 
predictors of long-term disability in relapse-onset MS; and (3) to identify the 
pathological changes that underpin disease course heterogeneity in relapse-onset 
MS using conventional and novel MRI techniques. To address these aims I conducted 
a clinical, MRI and genetic study in a group of people with CIS who have been 
followed up prospectively over the last 15 years. The patients were all recruited within 
3 months of CIS and seen for scheduled follow-up irrespective of clinical status over 
the first 5 years after disease onset. I conducted a long-term follow-up of this cohort 
approximately 15 years after presentation with CIS. I analysed data collected over a 
15 year period with the major results presented in this thesis.   
 
This introductory chapter provides background to MS and particularly the difficulties 
in predicting long-term disease at the time of onset. Chapter 2 provides an overview 
of the use of MRI to understand the pathological basis of MS. In Chapter 3 the 
characteristics of the CIS cohort I studied are described with the major results of the 
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follow-up study presented in subsequent chapters. Chapters 4 and 5 concern the 
diagnosis of MS in CIS patients, including the influence of changing diagnostic criteria 
for MS and possible changes to diagnostic criteria to improve the diagnosis of MS in 
people with CIS. Chapters 6 and 7 investigate early MRI abnormalities and how they 
relate to the development of neurological disability with a focus on the prognostic 
value of spinal cord MRI. In Chapter 8, I investigate the influence of HLA-DRB1*15:01 
(the most important genetic risk factor for MS) for the development of long-term 
disability and MRI-detected brain tissue damage. Finally, in Chapter 9 I apply sodium 
MRI, a novel metabolic imaging technique to investigate disease mechanisms 




















In the last 30 years MRI has emerged as an important tool for accurately and 
reproducibly imaging key pathological changes in the brain, spinal cord and optic 
nerve in people with MS in vivo (Filippi et al., 2012). MRI is now the central 
investigation for making the diagnosis of MS (Polman et al., 2011; Rovira et al., 2015) 
and in monitoring the course of the disease (Wattjes et al., 2015). MRI has facilitated 
the development of disease-modifying treatments for relapsing forms of MS and 
provided insights into the pathological changes relevant to disease progression and 
disability.  
 
The major pathological changes in MS include focal areas of demyelination in white 
and grey matter, diffuse injury within normal-appearing tissues and widespread 
neuroaxonal loss (Popescu and Lucchinetti, 2012). A number of conventional and 
non-conventional MRI measures are sensitive to the detection of these pathological 
abnormalities. These are reviewed in this chapter with emphasis on techniques 
applied in this thesis. 
 
2.2 White matter lesions 
White matter lesions on MRI appear hyperintense on proton density (PD) and T2-
weighted sequences (Figure 2.1). MS lesions are typically small (<1cm in diameter) 
and may appear round or ovoid (Fazekas et al., 1999). Brain lesions in MS have a 
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predilection for certain anatomical sites including the periventricular white matter, the 
corpus callosum, the subcortical U-fibres abutting the cerebral cortex (juxtacortex) 
and the brainstem/cerebellum (Fazekas et al., 1999). Focal white matter lesions seen 
on MRI are the radiological correlate of plaques seen pathologically in patients with 
MS (Filippi et al., 2012). White matter lesions visible on conventional MRI are not 
pathologically specific and reflect varying degrees of inflammation, demyelination, 
astrogliosis and axonal loss within focal lesions (Filippi et al., 2012). 
 
 
Figure 2.1 White matter lesions in multiple sclerosis. 
T2-hyperintense white matter lesions in MS on (A) proton density-weighted, (B) T2-
weighted and (C) FLAIR sequences. 
 
FLAIR improves the sensitivity of MRI for the detection of supratentorial white matter 
lesions, particularly around the lateral ventricles and juxtacortical white matter close 
to the brain-CSF interface (Stevenson et al., 1997). In a combined MRI-pathological 
study, FLAIR detected 71% of pathologically confirmed white matter lesions 
compared with 63% for T2-weighted spin-echo sequences at 1.5T (Geurts et al., 
2005a). 2D-FLAIR may be less sensitive than PD/T2-weighted sequences for 
detection of infratentorial lesions (Stevenson et al., 1997), potentially because FLAIR 
is more prone to artefacts within the posterior fossa (Rovira et al., 2015). Recently, 
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the added utility of a 3D FLAIR with higher resolution and decreased slice thickness 
compared with standard 2D FLAIR and 2D PD/T2-weighted sequences has been 
demonstrated (Gramsch et al., 2015). 3D FLAIR may improve the detection of 
juxtacortical and infratentorial lesions compared with standard 2D sequences 
(Gramsch et al., 2015). 
 
Up to 30% of white matter lesions in MS appear hypointense compared with the 
surrounding NAWM on T1-weighted spin echo sequences (Figure 2.2). These lesions 
are also known as “black holes”. Acute MS lesions may show T1-hypoinensity due to 
the effects of oedema but only half of these lesions evolve into a persistent black hole 
over time (Bagnato et al., 2003). Persistent black holes represent areas of significant 
axonal loss pathologically (van Waesberghe et al., 1999) 
 
 
Figure 2.2 T1-hypintense and T1-isointense white matter lesions. 
White matter lesions in MS on (A) T2-weighted and (B) T1-weighted scans. A subset 




T2-weighted scans are unable to differentiate acute active plaques from chronic 
lesions. A contrast-enhanced T1-weighted scan obtained after the administration of 
a gadolinium contrast agent can be helpful in identifying acute active MS lesions. The 
presence of contrast enhancement indicates breakdown of the blood brain barrier 
within acute lesions (Cotton et al., 2003; Filippi et al., 2012). Lesions may show 
nodular, ring or open-ring patterns of enhancement and the pattern may change as 
the lesion evolves. In a study of patients studied with weekly MRI scanning, the mean 
duration of enhancement was three weeks and so the presence of contrast 
enhancement is helpful in identifying new or acute lesions (Cotton et al., 2003).  
 
A number of technical factors influence the detection of contrast-enhancing lesions 
including the dose of gadolinium given and the timing of the post-contrast scan (Silver 
et al., 1997).  
 
The major safety concern with gadolinium-based contrast agents is nephrogenic 
systemic fibrosis, a rare multisystem fibrosing disorder affecting skin, soft tissues and 
sometimes other organs seen in patients with moderate to severe renal dysfunction 
with a glomerular filtration rate of <30ml/minute (Thomsen, 2016). More recently, a 
number of cases have been reported of gadolinium deposition in the dentate nuclei, 
pons and basal ganglia in patients with repeated exposure to gadolinium-based 
contrast agents to monitor brain tumours and normal renal function (McDonald et al., 
2015). These abnormalities were noted in vivo with hyperintensity on T1-weighted 
images in these structures and confirmed pathologically in a subset of patients 
(McDonald et al., 2015). The clinical significance of gadolinium deposition in these 
structures is uncertain and is under review by the United States Food and Drug 
Administration (United States Food and Drug Administration, 2015). 
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2.3 Grey matter lesions 
Involvement of grey matter is a major finding pathologically in MS (Kutzelnigg et al., 
2005; Lucchinetti et al., 2011; Popescu and Lucchinetti, 2012). Compared with lesions 
in the white matter, grey matter lesions are typically smaller, have poor tissue contrast 
with normal-appearing grey matter and may be obscured by partial volume effects of 
CSF. T2-weighted and FLAIR sequences detect 3% and 5% respectively of 
pathologically-confirmed intracortical lesions, although the sensitivity is higher for 
leukocortical lesions involving both grey and white matter (Geurts et al., 2005a).  
 
Double-inversion recovery (DIR) is a non-conventional MRI technique using inversion 
times that suppress the signal from both CSF and white matter, increasing the 
contrast between grey and white matter (Geurts et al., 2005b). On DIR cortical lesions 
appear hyperintense compared with the normal appearing grey matter. DIR detects 
500% more cortical lesions than T2 spin-echo and 150% more than FLAIR sequences 
(Geurts et al., 2005b). However, the overall sensitivity is low, with less than 20% of 
pathologically-confirmed cortical grey matter lesions visible on DIR (Seewann et al., 
2012). The sensitivity of DIR is significantly higher for leukocortical lesions, compared 
with intracortical or subpial lesions (Seewann et al., 2012).  
 
Another approach to detection of grey matter lesions is phase-sensitive inversion 
recovery (PSIR), a T1-weighted sequence that uses a phase-sensitive reconstruction 
to provide greater contrast between grey and white matter (Figure 2.3). PSIR is more 
sensitive than DIR with a three-fold increase in the detection of cortical grey matter 
lesions (Sethi et al., 2012). However, PSIR remains insensitive to the detection of 
subpial lesions (Sethi et al., 2012).   
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Figure 2.3 Cortical grey matter lesions in multiple sclerosis 
Phase-sensitive inversion recovery scan showing multiple leukocortical and 
intracortical grey matter lesions (arrow heads) at the level of the insula (A) and at the 
cerebral convexity (B) in a person with multiple sclerosis. 
 
 2.4 Spinal cord lesions 
MS commonly affects the spinal cord. An episode of partial myelitis is a common first 
symptom of MS and progressive MS frequently takes the form of a spastic 
paraparesis. Spinal cord MRI is technically more challenging than brain MRI. The 
spinal cord is a much smaller structure than the brain and spinal cord MRI is more 
prone to artefacts due to patient motion, surrounding CSF and the effects of 
respiration and the cardiac cycle (Kearney et al., 2015b).  
 
Spinal cord lesions are found in up to 90% of patients with established MS (Kidd et 
al., 1993; Nijeholt et al., 1998; Lukas et al., 2013). Spinal cord lesions are more 
commonly found in the cervical than thoracic or lumbar spine (Kidd et al., 1993). 
Lesions typically extend over 1 or sometimes 2 segments and are peripherally located 
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in the cord abutting the subpial surface. Like in the brain, spinal cord lesions often 
involve both white and grey matter structures (Kearney et al., 2015c). Spinal cord 
lesions can be detected on PD or T2-weighted images (Figure 2.4). STIR sequences 
are more sensitive to the detection of spinal cord lesions (Thorpe et al., 1994; Rocca 
et al., 1999; Bot et al., 2000), but also more prone to artefacts (Rovira et al., 2015). 
Acquisition of images with at least two types of tissue contrast (PD, T2 or STIR) and 
in two planes (sagittal and axial) is recommended to improve lesion detection and 
accuracy in the spinal cord in MS (Rovira et al., 2015). 
 
Post-contrast T1-weighted spinal cord scans can be helpful in demonstrating acute 
active lesions (Figure 2.4). The number of new, enhancing spinal cord lesions over 
time is much less than in the brain (Thorpe et al., 1996). 
 
Figure 2.4  Spinal cord lesions in multiple sclerosis. 
(A) T2-weighted sagittal scan of the spinal cord showing two T2-hyperintense lesions 
at C2 and C2/C3 (arrows) and (B) post-contrast T1-weighted scans obtained 15 
minutes after the administration of gadolinium showing contrast enhancement in the 




Diffuse spinal cord abnormalities are sometimes seen, particularly on PD-weighted 
scans (Lukas et al., 2013). These are more common in patients with a progressive 
disease course and significant disability (Lukas et al., 2013). 
 
2.5 Brain atrophy 
Brain atrophy is a major feature of MS pathologically and is thought to principally 
reflect neuroaxonal loss within lesions and normal-appearing tissue, although other 
processes such as demyelination and the extent of inflammation also influence brain 
volume in MS (Miller et al., 2002; Rocca et al., 2017). MRI is sensitive to the detection 
of brain tissue loss and this may be visible qualitatively once established with gross 
brain parenchymal atrophy, ventricular enlargement and widening of the cerebral 
sulci (Figure 2.5).  
 
Figure 2.5 Brain atrophy in multiple sclerosis. 
Post-contrast T1-weighted scans in a patient with multiple sclerosis at (A) baseline, 
(B) 1 year, (C) 3 years and (D) 8 years showing brain tissue loss with progressive 
enlargement of the lateral ventricles and sulcal widening. Gadolinium-enhancing 
lesions are also visible.  
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Brain atrophy has been shown to begin early in the course of MS and occurs at a 
similar rate throughout the course of the disease and across different MS subtypes 
(Chard et al., 2002b; Dalton et al., 2004; De Stefano et al., 2007; De Stefano et al., 
2010). Multiple studies have reported a consistent rate of whole brain atrophy in MS 
of 0.5-1%/year compared with 0.1-0.3%/year in healthy controls (De Stefano et al., 
2007). Studies investigating tissue-specific brain atrophy in MS have found that grey 
matter atrophy occurs at a faster rate than white matter atrophy (Chard et al., 2004). 
Grey matter atrophy is more closely linked to disease progression, physical disability 
and cognitive impairment than white matter atrophy (Dalton et al., 2004; Fisher et al., 
2008; Fisniku et al., 2008b; Roosendaal et al., 2011; Filippi et al., 2013). Grey matter 
atrophy has a predilection for certain brain regions. Thalamic and deep grey matter 
atrophy begins early in the course of MS (Henry et al., 2008; Azevedo et al., 2015) 
and occurs at a faster rate than cortical grey matter atrophy in established MS 
(Eshaghi et al., 2016). Within cortical grey matter regions atrophy may progress at 
different rates and the distribution of atrophy may be influenced by the disease 
phenotype (Ceccarelli et al., 2008; Eshaghi et al., 2014).  
 
There are a number of manual, semi-automated and fully automated methods for 
measuring brain volumes and change in volumes over time in MS (Miller et al., 2002; 
Pelletier et al., 2004; Rocca et al., 2017). For accurate assessment of brain volumes 
image contrast is important and T1-weighted scans that provide excellent tissue 
contrast between the brain and the CSF are typically used. Although brain atrophy 
can be measured using standard 2D T1-weighted scans, a high-resolution 3D 
(volumetric) acquisition with near isotropic voxel sizes of ~1mm3 is preferred (Miller et 




Registration-based techniques including Structural Image Evaluation using 
Normalization of Atrophy (SIENA) and Brain Boundary Shift Integral (BBSI) have 
been widely used in observational studies and also in clinical trials to measure brain 
atrophy in MS. SIENA estimates the percentage brain volume change (PBVC) over 
two time points using paired T1-weighted MRI scans (Smith et al., 2002). The first 
step uses a brain extraction tool (BET) to remove the skull and other non-brain tissues 
resulting in a segmented whole brain image (including the cerebellum and upper 
brainstem) and the external skull. The skull (which remains a constant size in adults) 
is used to register two T1-weighted scans in order to normalize for differences in scan 
geometry. In order to estimate the change in brain volume over time SIENA locates 
the edge points of the brain at the brain-CSF interface, including the ventricular 
system. The change in brain edge points between the two scans is used to estimate 
the PBVC. SIENA has been used widely in research studies and also in clinical trials 
to measure brain atrophy over time.  
 
SIENAX is a cross-sectional form of SIENA and involves a similar set of steps. 
Following BET the extracted brain is registered to a standard brain with the external 
skull used to normalize for head size (Smith et al., 2002). SIENAX estimates the 
normalised brain volume (NBV) and through an additional segmentation step the 
normalised grey matter and white matter volume can also be estimated. SIENA and 
SIENAX can be applied to 2D or 3D T1-weighted scans obtained pre or post-contrast 
and with varying slice thickness (Smith et al., 2002; De Stefano et al., 2010). SIENA 
and SIENAX are used in image-analysis presented in Chapters 6, 7 and 8. 
 
BBSI is another registration-based technique used to estimate brain volume changes 
over time in MS (Freeborough and Fox, 1997). The baseline and follow-up images 
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are registered and digital subtraction is used to detect differences in the lateral edges 
of the brain parenchyma and ventricles that are assumed to be the result of changes 
in tissue boundaries due to atrophy (Freeborough and Fox, 1997). Modifications to 
BBSI may improve the detection of brain volume changes with reductions in the 
sample sizes required to test putative disease-modifying drugs in neurodegenerative 
conditions, including MS (Prados et al., 2015). 
 
2.6 Spinal cord atrophy 
Progressive spinal cord atrophy occurs in people with MS and is thought to reflect 
neuroaxonal loss involving white matter tracts and spinal cord grey matter (Evangelou 
et al., 2005). Spinal cord atrophy, usually measured as the upper cervical cord cross-
sectional area (UCCA) on MRI, is associated with disability and is more marked in 
progressive forms of MS (Losseff et al., 1996; Rocca et al., 2011; Lukas et al., 2013; 
Kearney et al., 2014a; Lukas et al., 2015).  
 
As in the brain, spinal cord atrophy is typically measured using T1-weighted 3D 
volumetric scans with an inversion recovery pulse to suppress the signal from CSF 
and improve the delineation of the spinal cord from surrounding structures (Miller et 
al., 2002). Spinal cord atrophy is usually measured in the upper cervical segments 
(C2/C3) where spondylotic changes are uncommon and the CSF spaces are wide, 
improving spinal cord-CSF contrast (Losseff et al., 1996). 
 
The first reproducible method for determining spinal cord atrophy was described by 
Losseff and colleagues. Using this technique sagittally-acquired volumetric scans of 
the cervical cord are reformatted in the axial plane to obtain five contiguous slices at 
79 
 
the level of C2/C3. A region of interest is then drawn manually around the edge of the 
spinal cord and a further region drawn at the outer CSF space in the spinal canal. By 
calculating the mean signal intensity of the spinal cord and CSF the edge of the spinal 
cord can be accurately identified and the mean UCCA over five slices estimated. 
Using this method, progressive spinal cord atrophy has been observed in patients 
with RRMS and progressive MS over follow-up periods of 1-3 years (Stevenson et 
al., 1998; Rashid et al., 2006). The rate of spinal cord atrophy is approximately 
1%/year in established MS with little change in UCCA observed in healthy controls 
(Rashid et al., 2006).  
 
The Losseff method has been superseded by another semi-automated technique 
using an active surface model (Horsfield et al., 2010). Either high-resolution T1-
weighted images acquired in the axial plane or reformatted sagittal images at the level 
of C2/C3 can be used. Using this technique the spinal cord is modelled as a cylinder. 
An operator places a region of interest in the centre of the spinal cord. The active 
surface model algorithm is used to automatically identify cord outline from a radius 
generator. The UCCA is then calculated as a mean over five slices. This approach 
has been found to be more accurate and more reproducible than previous methods 
and has been applied in multicentre studies (Rocca et al., 2011; Kearney et al., 
2014a) and in a recent clinical trial in PPMS (Yaldizli et al., 2015). The sequence of 
steps used in image-analysis for calculating the UCCA using the active surface model 
are shown in Figure 2.6. This technique is applied in analyses presented in Chapters 







Sagittally-acquired images are 
reformatted in the axial plane to 






A region of interest is placed in the 






The active surface model algorithm 
identifies the edge of the spinal cord 




Figure 2.6 Estimating the upper cervical cord cross-sectional area using the 
active surface model. 
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Spinal cord grey matter damage is prominent in MS and more marked in people with 
progressive MS (Kearney et al., 2015c; Kearney et al., 2015d). Grey matter atrophy 
is more marked than atrophy in spinal cord white matter tracts and correlates more 
strongly with disability than the UCCA, cord white matter area or grey matter atrophy 
in the brain (Schlaeger et al., 2014). Fully automated approaches to segmentation of 
spinal cord grey and white matter have now been described that are likely to improve 
the accuracy and reproducibility of this technique (Prados et al., 2016). 
 
2.7 Normal-appearing white and grey matter 
Important pathological changes occur in MS outside MRI-visible focal lesions. These 
include neuroaxonal dysfunction and loss, microglial activation and astrogliosis 
(Popescu and Lucchinetti, 2012). A number of non-conventional MRI measures 
including magnetization transfer imaging (MTI), diffusion MRI and magnetic 
resonance spectroscopy (MRS) are sensitive to these changes. 
  
Magnetization transfer imaging 
Protons exist in two distinct pools – in free water and bound to large macromolecules, 
for example, myelin. The bound protons within macromolecules do not contribute to 
the MR signal in conventional MRI due to faster spin-spin interactions and very short 
relaxation times (Ropele and Fazekas, 2009). However, because they are bound to 
proteins and lipids this pool of protons can provide important information on tissue 
microstructure and pathological abnormalities such as demyelination and axonal loss. 
MTI exploits the transfer of protons between the larger pool in free water and the 
smaller number of bound proteins following a selective radiofrequency saturation 
pulse (Ropele and Fazekas, 2009). The difference between the magnetisation 
transfer before and after a selective radiofrequency saturation pulse is expressed as 
82 
 
the magnetization transfer ratio (MTR). Histopathological studies suggest that MTR 
correlates with myelin and axon counts (Schmierer et al., 2004). 
  
MTI is sensitive to the detection of tissue-damage within NAWM and normal-
appearing grey matter (NAGM), with reductions in MTR in people with MS compared 
with healthy controls (Filippi et al., 1999; Agosta et al., 2006). These abnormalities 
begin early in the course of the disease (Davies et al., 2004; Fernando et al., 2005) 
and are associated with progression of physical disability and cognitive impairment 
over time (Agosta et al., 2006; Hayton et al., 2009; Tur et al., 2011a; Tur et al., 2011b).  
 
Recent work using MTR has found evidence of a gradient of tissue damage in white 
matter and grey matter with more marked MTR abnormalities closer to the brain-CSF 
interface. In periventricular white matter, MTR is reduced compared with healthy 
controls but this difference is most marked in the white matter closest to the lateral 
ventricles (Liu et al., 2015). Similarly, in cortical grey matter reduced MTR is seen in 
the inner and outer cortex compared with healthy controls, but the difference is more 
marked in the outer than the inner cortex (Samson et al., 2014). A preferential 
reduction in outer cortical MTR is consistent with subpial demyelination and neuronal 
loss found post-mortem in people with SPMS (Kutzelnigg et al., 2005; Magliozzi et 
al., 2010). Subsequent work has investigated MTR abnormalities across the whole 
brain, including in the brainstem/cerebellum and the deep grey matter, with similar 
findings of a gradient of MTR abnormality that is maximal closest to the ventricles 
(Pardini et al., 2016). The pathological basis for these observations in unclear but the 
findings could suggest a susceptibility of the tissues at the brain-CSF interface to 
demyelination/neurodegeneration or the presence of pathogenic mediators within the 




Diffusion MRI is a tool for investigating tissue microstructure in vivo by measuring 
water motion within tissues. Free water diffuses equally in all directions and is said to 
be isotropic. In most biological tissues the presence of cell membranes and other 
structures means that water movement is hindered or anisotropic. The diffusion 
properties of a given tissue are therefore largely determined by the tissue’s 
microstructure. For example, in tightly compacted tissues such as white matter, water 
motion is significantly more anisotropic than in less compact structures like the 
cerebral cortex. Pathological processes that disrupt tissue microstructure can 
influence water motion and be detected using diffusion MRI.  
 
The diffusion model most frequently applied in MS is diffusion tensor imaging (DTI) in 
which water is assumed to diffuse through tissues in a Gaussian (normal) distribution 
that can be modelled as a tensor. Based on the directions of water movement (the 
diffusion tensor’s eigenvectors), DTI metrics are calculated that describe tissue 
microstructure, including the fractional anisotropy (FA), mean diffusivity (MD), axial 
diffusivity (AD) and radial diffusivity (RD). A number of studies have reported 
decreases in FA and increases in mean diffusivity MD within NAWM in people with 
MS compared with healthy controls (Werring et al., 2000; Filippi et al., 2001a; Rovaris 
et al., 2002; Ciccarelli et al., 2003). These abnormalities occur early in the course of 
MS, including in patients with CIS (Gallo et al., 2005). More marked diffusion 
abnormalities in the NAWM occur in patients with SPMS compared with patients with 
RRMS (Preziosa et al., 2011). Combined imaging and histopathological studies have 
found correlations of DTI metrics with myelin content and axon counts (Mottershead 
et al., 2003; Schmierer et al., 2007), confirming that DTI abnormalities reflect 
pathological changes relevant to MS.  
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Diffusion MRI data can also be used to investigate damage to specific white matter 
fibre tracts (diffusion tractography) relevant to disability in MS. Damage to the corpus 
callosum in particular has been associated with progression of physical disability and 
cognitive impairment over time (Dineen et al., 2009; Bodini et al., 2013)  
 
Magnetic resonance spectroscopy 
Unlike the other MRI techniques described so far, 1H-MRS provides metabolic rather 
than structural information. Changes in the levels of N-acetylaspartate (NAA, a 
neuroaxonal marker), choline (a marker of cell turnover) and myo-inositol (an 
astroglial marker) reflect pathological processes within a given voxel or voxels. Within 
acute demyelinating lesions there is evidence of a reduction in NAA due to axonal 
injury, increases in choline due to inflammation and/or breakdown of myelin and 
increased lactate due to inflammation (Rovira and Alonso, 2013). MRS is sometimes 
helpful in clinical settings to differentiate tumefactive demyelinating lesions from 
neoplasms (Rovira and Alonso, 2013).  
 
Within NAWM, 1H-MRS displays metabolic changes including a decrease in NAA and 
increase in myo-inositol (Fu et al., 1998; Sarchielli et al., 1999; Chard et al., 2002a; 
Rovira and Alonso, 2013). These abnormalities are thought to reflect neuroaxonal 
loss and astrogliosis respectively, prominent pathological changes seen in NAWM in 
MS (Lucchinetti et al., 2011). Spectroscopic abnormalities begin early in the course 
of MS (Chard et al., 2002a; Sastre-Garriga et al., 2005), including in patients with CIS. 
Increases in myo-inositol (Fernando et al., 2004; Wattjes et al., 2008) and decreases 
in NAA (Wattjes et al., 2008) in NAWM in CIS patients are associated with the 
development of MS. In a large cohort of patients with predominantly RRMS the ratio 
of myo-inositol to NAA in NAWM at baseline was associated with the annualised 
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PBVC and progression over disability measured using the MSFC over 4 years of 
follow-up (Llufriu et al., 2014). These findings suggest that metabolic abnormalities in 
NAWM detected using 1H-MRS reflect pathological changes relevant to disease 
progression in MS. 
 
Metabolic abnormalities in cortical and deep grey matter are also detectable using 
1H-MRS. Reductions in cortical grey matter NAA are most marked in people with 
progressive MS (Adalsteinsson et al., 2003; Sastre-Garriga et al., 2005), while 
spectroscopic abnormalities are found in the deep grey matter even in early RRMS 
(Inglese et al., 2004). 
 
2.8 Sodium MRI 
Sodium (23Na) MRI is a novel metabolic imaging technique applied in this thesis 
(Chapter 9). Sodium is found in all biological tissues and has an essential role in 
tissue homeostasis and maintaining the integrity of cell membranes. In the nervous 
system and the heart, changes in intracellular sodium concentration mediated by 
voltage-gated sodium channels, are responsible for the generation and propagation 
of action potentials. In the brain (and other biological tissues) tissue sodium 
comprises two distinct pools: a larger intracellular compartment (80-85%) with a 
sodium concentration of approximately 10-15mmol and an extracellular compartment 
(15-20%) with a much higher sodium concentration of approximately 140mmol. This 
concentration gradient of intracellular and extracellular sodium is maintained by the 
action of the energy dependent N+/K+-ATPase pump. The N+/K+-ATPase pump is 
present in almost all eukaryotic cells and exchanges three intracellular Na+ ions for 
two extracellular K+ ions. Because this action is against the electrochemical gradient 
of sodium and potassium the action of the N+/K+-ATPase pump requires energy in the 
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form of adenosine triphosphate (ATP). Tissue sodium concentrations may rise when 
there is expansion of the extracellular space (e.g. oedema, tissue destruction) or an 
increase in intracellular sodium because of failure of the N+/K+-ATPase pump. 
Increases in tissue sodium concentration have been found in a number of 
neurological diseases including stroke, glioma and neurodegenerative diseases, as 
well as MS (Madelin and Regatte, 2013), reflecting either an increase in extracellular 
volume, an increase in intracellular sodium concentration, or both.   
 
Like hydrogen, sodium (23Na) had an odd number of protons resulting in a net nuclear 
spin. When exposed to an external magnetic field 23Na will generate radiofrequency 
energy and is MRI visible. The concentration of sodium in biological tissues is many 
times less than hydrogen ions resulting in a significantly lower signal-to-noise ratio 
with longer acquisition times and the need for large voxel sizes than with 1H MRI 
(Petracca et al., 2016a). Sodium displays a bi-exponential relaxation time with the 
major component of the T2 signal very difficult to detect because of a short TE. These 
technical challenges have been overcome with the use of higher field strengths (≥3T) 
and sequences utilising ultra-short TE facilitating signal detection.  
 
1H MRI provides information on tissue structure whereas 23Na MRI quantifies tissue 
sodium concentrations providing information on the functional and metabolic state of 
the tissue being investigated. The tissue sodium concentration is usually quantified 
with the use of phantoms containing agar gels with a known concentration of sodium 
(Figure 2.7). The phantoms are placed within the field of view and tissue sodium 





Figure 2.7 Sodium MRI. 
Axial image at the level of the lateral ventricles obtained using a sodium coil. Two 
phantoms are visible at the lateral edges of the field of view with differing sodium 
concentrations indicated by differences in the signal intensity. 
 
23Na MRI measures total brain sodium and reflects a composite of both extracellular 
and intracellular sodium. The intracellular sodium concentration is of greater 
biological interest since this is the major determinant of cellular function and integrity. 
A number of different approaches have been used to try and suppress the signal from 
extracellular sodium and accurately quantify intracellular sodium concentration 
(Petracca et al., 2016a). Shift reagents do not cross the cell membrane and have 
been used to quantify intracellular sodium in ex vivo and animal studies. These 
substances are toxic and cannot be used in humans. A number of MRI techniques 
have been used, including the use of multiple quantum filters, inversion recovery 
pulses and diffusion-based techniques that exploit differences in the magnetic 
resonance properties of intracellular and extracellular sodium ions.  
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A small number of studies have investigated sodium MRI in MS (Table 2.1). The first 
application of 23Na MRI was in 17 patients with early RRMS (mean disease duration 
5.8 years) and mild disability (median EDSS 2) who were compared with a group of 
age and sex-matched healthy control subjects (Inglese et al., 2010). A region of 
interest analysis was used to compare total sodium concentrations in grey matter, 
NAWM and lesions. Compared with healthy controls the MS patients showed a higher 
total sodium concentration in grey matter and NAWM. Within white matter lesions the 
total sodium concentration was higher in gadolinium-enhancing and non-enhancing 
lesions compared with NAWM.  
 
Zaaroui et al studied a small group of patients (n=23) with very early RRMS with a 
disease duration of <5years and established RRMS with a disease duration of 
>5years (Zaaraoui et al., 2012). Increased total sodium concentration was found in 
white matter lesions in all patients. Patients with established RRMS, but not patients 
with very early RRMS, had increased total sodium concentration in NAWM and grey 
matter compared with healthy control subjects. Grey matter sodium concentration 
was found to correlate EDSS. These findings suggest that early in the course of MS 
increases in sodium concentration are confined to areas of focal damage but over 
time more widespread changes occur in NAWM and grey matter. This is supported 
by a study in 20 patients with CIS (mainly unilateral optic neuritis) where evidence of 
increased total sodium concentration was found in asymptomatic T2 brain lesions but 
not in NAWM or grey matter (Cawley et al., 2016). 
 
Two studies have extended these findings in patients with progressive forms of MS 
(Paling et al., 2013; Maarouf et al., 2014). Paling and colleagues studied 70 patients 
with RRMS, SPMS and PPMS who underwent 23Na MRI and conventional 1H MRI at 
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3T. In keeping with previous studies, MS patients displayed higher total sodium 
concentrations in cortical and deep grey matter and NAWM compared with healthy 
controls. Tissue sodium concentrations were higher in all tissue compartments in 
SPMS patients compared with RRMS patients, although findings were similar in 
PPMS and RRMS patients. Significant correlations were found between tissue 
sodium concentrations and measures of physical disability and cognitive impairment. 
In a multivariable linear regression analysis deep grey matter sodium concentration 
was independently associated with EDSS and walking speed while T1-hypointense 
lesion sodium concentration was associated with performance on the 9HPT and the 
PASAT. In a smaller study involving 20 patients with progressive MS, Maarouf and 
colleagues also found increased grey matter total sodium concentrations in patients 
compared with healthy controls (Maarouf et al., 2014). No differences were found in 
NAWM and no significant correlations were found between tissue sodium 
concentration and disability measures using the EDSS and MSFC. 
 
Finally, Maarouf and colleagues also studied 58 patients with early RRMS who 
underwent detailed neuropsychological testing (Maarouf et al., 2017). 21 patients 
were found to be cognitively impaired and 37 were cognitively preserved. The 
cognitively impaired patients showed higher total sodium concentration in grey matter 
and NAWM compared with patients who were cognitively preserved. In a multivariable 
model, grey matter sodium concentration explained more of the variability in cognition 
that grey matter atrophy. These findings suggest that metabolic abnormalities in 
cortical grey matter are relevant to the development cognitive impairment in MS and 




Table 2.1 Application of sodium MRI in multiple sclerosis: Summary of studies to date 
Study Patient group Sample size Major findings 
Inglese et al RRMS n=17 Increased TSC in lesions, NAWM and grey matter 
Zaaroui et al RRMS n=23 Increased TSC in NAWM and grey matter 
Paling et al RR/SP/PPMS n=70 TSC progressive MS > RRMS 
Associations found between deep grey matter and T1 lesions TSC and 
disability measures 
Maarouf et al SP/PPMS n=20 Higher grey matter TSC in progressive MS  
Eisele et al RRMS n=65 TSC Gd+ lesions > T1-hypointense>T1-isointense lesions 
Cawley et al CIS n=20 TSC increased in asymptomatic T2 brain lesions.  
Maroouf et al RRMS n=58 TSC higher in grey matter and NAWM of cognitively impaired compared with 




MRI is an established research tool used to understand the pathological basis of MS. 
Conventional MRI techniques including T2-weighted and post-contrast T1 weighted 
readily detect focal lesions in MS. A number of non-conventional techniques are 
sensitive to the detection of brain and spinal cord atrophy, grey matter pathology and 
abnormalities in normal-appearing tissues that are relevant to the development of 
disability and disease progression.  
 
A number of the MRI techniques described are applied in this thesis to improve our 
understanding of the prognosis of people with CIS and investigate mechanisms of 
long-term disability in MS. Chapter 3 describes the CIS cohort studied and the MRI 














Clinically isolated syndromes study design 
 
3.1  Introduction 
Subsequent chapters of this thesis concern follow-up of a cohort of patients with CIS 
who have been followed as part of a longitudinal clinical-MRI study since 1995. This 
chapter outlines the study design including patient recruitment, follow-up and 
assessments over a mean time of 15 years since presentation with CIS. 
 
3.2  Study design 
3.2.1 Recruitment, inclusion and exclusion criteria 
Between 1995 and 2004 CIS patients seen at Moorfields Eye Hospital and the 
National Hospital for Neurology and Neurosurgery were invited to take part in a 
longitudinal clinical-MRI study. Patients aged 16 – 50 years with a typical CIS 
presentation suggestive of MS were included in the study. Investigations including 
routine blood tests, serological testing, visual evoked potentials and lumbar puncture 
were done as clinically indicated. All of the patients were assessed clinically and with 
MRI within 3 months of CIS onset (“baseline”).  
 
Patients were excluded if there was a history of any previous neurological symptoms 





3.2.2 Follow-up  
The patients were invited to return for scheduled clinical and MRI follow-up after 3 
months, 1 year and 3 years irrespective of clinical status. Further follow-ups were 
conducted after approximately 5 years (range 4.0 – 11.8 years) and 15 years (range 
10.9 – 19.7 years). During the course of the study patients who developed a 
neurological disorder other than MS were excluded. 
 
An overview of the study, including the number of patients who were assessed at 
each time point clinically and with MRI is shown in Figure 3.1. 
 
3.2.3 Ethical approval and patient consent 
The study was approved by the institutional ethics committees at the National Hospital 
for Neurology and Neurosurgery and Moorfields Eye Hospital. The 15 year follow-up 
study was approved by the National Research Ethics Service (NRES) Committee 
London (City Rd and Hampstead). Written informed consent was obtained from study 
participants at the time of study entry and at each subsequent follow-up visit. 
 
3.2.3 Clinical assessment 
Patients were assessed by a clinical research fellow around the time of CIS (baseline) 
and at each follow-up visit. Dr Jonathan O’Riordan, Dr Peter Brex, Dr Catherine 
Dalton, Dr Kryshani Fernando and Dr Josephine Swanton recruited patients into the 
study and/or conducted the clinical assessments up to 5 years. I re-recruited patients 
at the 15 year follow-up, obtained consent for continued participation in the study and 





Figure 3.1 Clinically isolated syndromes study overview. 
The CIS patients were seen at baseline (within 3 months of symptom onset) and then for scheduled follow up after approximately 3 months, 1 
year, 3 years, 5 years and 15 years. The number of patients who were assessed clinically and with MRI at each time point is shown. 
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At each study visit the patients were asked about new or progressive neurological 
symptoms and were examined neurologically. CDMS was diagnosed prospectively 
when there was a second clinical attack and objective evidence of two separate CNS 
lesions (Poser et al., 1983). At the 15 year follow-up MS was diagnosed using the 
McDonald 2010 criteria, either on clinical grounds or when there was MRI evidence 
of DIS and DIT, or both (Polman et al., 2011).  
 
In patients with MS the disease course was classified at each visit as either RRMS or 
SPMS using the Lublin and Reingold 1996 disease course definitions (Lublin et al., 
1996). 
 
Disability was rated at each visit using the EDSS (Kurtzke, 1983). At the 5 year and 
15 year follow-up the patients were also assessed with the three components of the 
MSFC, including tests of walking speed (TWT), upper limb function (9HPT) and 
information processing speed (PASAT). Additional cognitive testing was done at the 
15 year follow-up including the SDMT (Smith, 1982), tests of visual and verbal 
memory from the Adult Memory and Information Processing Battery (Coughlan and 
Hollows, 1985) and two tests of executive function, the Brixton and Hayling Tests 
(Burgess and Shallice, 1997). The National Adult Reading Test (NART) was used to 
estimate premorbid intelligence (Nelson, 1982).   
 
Patients who were unable or unwilling to attend in person after 5 and 15 years were 
invited to take part in a structured telephone interview to establish disease course 
(CIS, RRMS, SPMS) and disability was measured using the telephone EDSS 
(Lechner-Scott et al., 2003). The telephone EDSS has been validated previously for 
use in clinical trials (Lechner-Scott et al., 2003) and has also been used in previous 
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observational studies (Fisniku et al., 2008a). Although the telephone EDSS shows a 
robust correlation with examined EDSS score at all levels the correlations are 
particularly strong in patients with significant ambulatory problems (EDSS >4).  
 
3.3 MRI acquisition protocol 
3.3.1 Baseline to 5 years 
All MRI scans obtained over the first 5 years of the study were done on the same 1.5T 
Signa scanner (General Electric, Wisconsin, USA). There was a major hardware and 
software upgrade in April 2004, after the last patient was recruited into the study. The 
scanner upgrade affected follow-up MRI scans done after April 2004. 
 
Details of the MRI protocol over the first 5 years of the study are shown in Table 3.1. 
Patients were given 0.1mmol/kg gadolinium-diethylenetriamine pentaacetic acid 
(DTPA) and axial proton-density (PD)/T2-weighted and post-contrast T1-weighted 
fast-spin echo scans of the brain were acquired. Spinal cord MRI included sagittal T2-
weighted and post-contrast T1-weighted scans of the whole spine and a volume 
acquired inversion prepared fast spoiled gradient echo (FSPGR) scan of the cervical 
cord. Brain and spinal cord MRI were obtained at all time points except at the 3 month 
follow-up when brain MRI alone was acquired.  
 
Volumetric 3D-T1-weighted brain MRI, 1H spectroscopy and magnetization transfer 
imaging were added to the study protocol in 1997-1998. These were available in a 
subset of patients but were not analysed as part of this thesis.
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Table 3.1 MRI acquisition parameters: baseline to 5 years. 
 
 Orientation Slice thickness, mm TR, ms TE, ms Matrix 
Brain      




Axial 46 x 3 600 17 256x256 
Spinal cord      
T2/PD-weighted (whole 
cord) 
Sagittal 9 x 3 2500 56/92 512x512 
FSPGR  
(cervical cord) 




3.3.2 15 years 
The MRI scans at 15 years were all done on the same 3T Achieva TX scanner (Philips 
Healthcare, Best, The Netherlands) between January 2014 and December 2015. 
There was no major hardware or software upgrade during the study period. Only brain 
MRI was obtained at 15 years and contrast was not administered. In addition to 
standard PD/T2-weighted, FLAIR and T1-weighted 2D spin echo sequences for 
detection of white matter lesions, an inversion-prepared 3D T1-weighted turbo field 
echo (TFE) scan was also obtained to measure brain atrophy and for tissue 
segmentation. Three novel MRI measures were also obtained: PSIR, DWI and 
sodium MRI. Analysis of the sodium MRI data is presented in Chapter 9. 
 













Table 3.2 MRI acquisition parameters: 15 years 
 
 Orientation Slice thickness, mm TR, ms TE, ms TI, ms Matrix 
1H MRI       
  T2/PD weighted Axial 50 x 3 3500 19/85  240x180 
  FLAIR Axial 50 x 3 8000 125 2400 240x180 
  2D T1-weighted spin echo Axial 50 x 3 625 10  240x180 
  3D T1-weighted TFE Sagittal 180 x 1 6.9 3.1 824 256x256 
  PSIR Axial 75 x 2 7306 13 400 256x256 
  DWI Axial 60 x 2.5 13846 82  76x87 
23Na MRI       
  Sodium scan Axial 80 x 3 120 2.9  80x80 






3.4.1 Lesion number, location and activity 
Scans obtained from baseline to 5 years were reviewed by two neuroradiologists. Dr 
Katherine Miszkiel reviewed all the scans prospectively and counted the number of 
T2-hyperintense brain and spinal cord lesions on PD/T2-weighted scans. The number 
of T2-hyperintense lesions in four mutually-exclusive locations – the periventricular, 
juxtacortical and infratentorial regions in the brain, plus the spinal cord, was recorded. 
Post-contrast T1-weighted scans were used to identify the number of T1-hypointense 
lesions in the brain and the number of GdE lesions in the brain and spinal cord.  
 
Scans obtained at baseline, 1 year and 3 years were re-reviewed by Prof Frederik 
Barkhof as part of analyses presented in Chapter 7. He counted the number of new 
supratentorial and infratentorial lesions seen at the 1 year and 3 year follow up. 
 
3.4.2 Lesion volume 
I identified T2-hyperintense brain lesions on PD-weighted scans obtained at all time 
points in conjunction with T2-weighted and FLAIR scans (available in all patients at 
15 years) to aid in lesion detection. I used a semi-automated edge-finding tool 
(JIM6.0, Xinapse Systems, Aldwincle, UK) to draw around the edge of lesions and 
the T2 lesion volume (T2LV) was calculated by multiplying lesion area by slice 
thickness. The process was repeated using 2D T1-weighted spin echo scans to 




3.4.3 Brain atrophy 
The 2D T1-weighted fast-spin echo scans were used for the volumetric brain 
measures. T1-hypointense lesion masks were used to fill lesions in order to improve 
segmentation accuracy (Prados et al., 2014). Using the baseline MRI scan, the NBV 
was calculated using SIENAX and follow-up scans were registered with the baseline 
MRI scan to calculate the PBVC over time using SIENA (Smith et al., 2002).  
 
Dr Arman Eshaghi, Dr Ferran Prados and Mr John Stutters assisted with the SIENAX 
and SIENA analysis. 
 
3.4.4 Spinal cord atrophy 
Dedicated volumetric spinal cord imaging was available at baseline, 1, 3 and 5 years. 
I calculated the UCCA using the active surface model as described in Chapter 2. 
Firstly, the sagittally-acquired FSPGR scans of the cervical cord were reformatted in 
the axial plane at the level of C2/C3. A region of interest marker was placed in the 
centre of the spinal cord and the active surface model used to calculate the UCCA (in 




The image-analysis used in this thesis involved well-established techniques (lesion 
counts, lesion volume, brain and spinal cord atrophy measures) and intra-rater 
reproducibility was not measured. 
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3.5  Characteristics of the CIS cohort  
A total of 178 patients were included in the study. The baseline characteristics of the 
study patients are shown in Table 3.3.  
 
Table 3.3 Baseline demographic and clinical characteristics of the cohort 
 Values 
Age, mean (SD) 32.3 (7.4) 
Female, n (%) 114 (64) 
White ethnicity, n (%) 145 (81) 
CIS topography, n (%) 
     Optic neuritis 
     Brainstem syndrome 
     Spinal cord syndrome 






Baseline EDSS, median (IQR) 1 (1) 
 
The demographic profile of study patients was typical of people with CIS with a mean 
age of approximately 32 years and two-thirds female. There was an over-
representation of optic neuritis in the cohort; 82% patients in this study compared with 
30 – 40% in other large prospective CIS series (Eriksson et al., 2003; Tintore et al., 
2015). From the total cohort of 178 patients, differing numbers of patients were 
included in various analyses presented in this thesis depending on the availability of 
clinical and MRI data. The inclusion and exclusion criteria for each analysis is 




Earlier and more frequent diagnosis of multiple sclerosis in CIS patients using 
the McDonald criteria 
 
4.1  Introduction 
The McDonald criteria allow MS to be diagnosed in CIS patients when there is MRI 
evidence of dissemination in DIS and DIT (McDonald et al., 2001; Polman et al., 2005; 
Polman et al., 2011). The original criteria published in 2001 were modified in 2005 to 
increase the importance of spinal cord lesions in DIS and simplify the requirements 
for DIT (Polman et al., 2005). There was a further revision in 2010 with a major 
simplification of the requirements for both DIS and DIT, as summarised in Table 1.1 
(Polman et al., 2011).  
 
When applied to patients with CIS the McDonald criteria have been shown to have a 
high sensitivity and specificity for the development of CDMS  over follow-up periods 
of 24-36 months (Dalton et al., 2002b; Swanton et al., 2007; Montalban et al., 2010; 
Runia et al., 2013). The application of the McDonald criteria to patients with a CIS 
should facilitate an earlier diagnosis of MS by using MRI to provide evidence for DIS 
and DIT, rather than waiting for a second clinical attack to occur (Poser et al., 1983). 
However, few previous studies have quantified how much sooner MS can be 




I investigated the time to diagnosis of MS using the various iterations of the McDonald 
criteria in the CIS cohort over the first ~5 years of follow up. I also investigated the 
frequency with which MS could be diagnosed using MRI criteria in patients who had 
no further clinical events over this time (i.e. MRI-only MS). 
 
4.2  Methods 
Patients 
This investigation is based on follow-up of the CIS cohort up to approximately 5 years. 
I included all patients from the cohort with at least one follow-up MRI scan at any time 
point (for demonstration of DIT) and at least 36 months of clinical follow-up.  
 
Clinical assessment 
Patients with CDMS were identified prospectively during scheduled follow-up of the 
cohort. CDMS was diagnosed according to the Poser criteria, requiring a second 
clinical attack with objective evidence of two separate lesions (Poser et al., 1983).  
 
MRI acquisition and image-analysis 
PD/T2-weighted and post-contrast T1-weighted scans done at the time of 
presentation and at follow-up were analysed. The number, location and activity (i.e. 
presence of gadolinium-enhancement) of brain and spinal cord lesions was reported 




Application of MRI criteria to diagnose MS 
I retrospectively assigned a diagnosis of McDonald MS using the 2001, 2005 or 2010 
criteria using clinical and MRI data obtained over ~5 years of follow-up (McDonald et 
al., 2001; Polman et al., 2005; Polman et al., 2011). MS was diagnosed when there 
was MRI evidence of DIS and DIT or on clinical grounds (i.e. at the time of a second 
clinical attack), whichever occurred first. 
 
Statistical analysis 
The time to diagnosis of MS using the four different diagnostic criteria (Poser criteria 
and McDonald 2001, 2005 and 2010 criteria) was compared using a Kaplan-Meier 
survival analysis. Times to diagnosis of MS were skewed. Differences in means and 
proportions of patients were compared using the Wilcox signed-rank test and 
McNemar’s test respectively with p values <0.05 considered significant.  
 
4.3  Results 
From the 178 patients included in the study, 157 (88%) had sufficient clinical and MRI 
follow up to be included in this analysis. The reasons for exclusion were <36 months 
clinical follow-up (n=11), no follow-up MRI scan (n=8) and a disorder other than MS 
(n=2).  
 
The baseline clinical and MRI characteristics of the patients included in this analysis 
grouped by diagnosis at follow-up is shown in Table 4.1. 129 (82%) patients 
presented with optic neuritis and 28 (18%) patients had other presentations 
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(brainstem/cerebellar, spinal cord or hemispheric syndromes). The mean follow-up 
was 5.8 years (range 3.0 – 11.9 years).  
 
Table 4.1 Baseline clinical and MRI characteristics of patients stratified by 






Age, mean (SD) 32.3 (7.9) 32.8 (7.2) 
Female, n (%) 53 (75)     47 (55) 
Optic neuritis, n (%) 56 (79) 73 (85) 
Baseline MRI findings, median (range) 
  
     Brain T2 lesion number 11 (0 - 142) 0 (0 - 57) 
     GdE lesion number 0 (0 - 21) 0 (0 - 13) 
     Spinal cord lesion number 1 (0 -11) 0 (0 - 5) 
 
Only one patient received DMT prior to the development of CDMS. The patient started 
glatiramer acetate 7 months after presenting with optic neuritis. Five months later she 
relapsed with a spinal cord syndrome and a diagnosis of CDMS was made. 
 
Patients who developed CDMS 
71 (45%) patients had a second clinical attack over the ~5 year follow-up period and 
were classified as CDMS. Figure 4.1 shows a Kaplan-Meier survival curve for the time 
to diagnosis of MS using the Poser and McDonald criteria in patients who had a 
second clinical attack. The mean time to development of CDMS was 23.1 months 
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compared with 12.0, 10.5 and 6.2 months using the 2001, 2005 and 2010 McDonald 
criteria respectively (p<0.001 for all comparisons with time to CDMS).  
 
Using the McDonald criteria 36 (51%), 40 (56%) and 54 (76%) of patients who 
developed CDMS could be diagnosed with MS using the 2001, 2005 and 2010 MRI 
criteria within three months of CIS onset.  
 
32 (45%) patients who developed CDMS had asymptomatic gadolinium-enhancing 
and non-enhancing lesions on the first MRI scan and could be diagnosed with MS 





Figure 4.1      Kaplan-Meier survival curve showing time to diagnosis of MS using Poser and McDonald criteria 
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Patients who remained CIS 
86 (55%) patients remained CIS (i.e. did not have a second clinical attack over the 
~5 years of follow-up). 24 (28%), 26 (30%) and 36 (42%) CIS patients satisfied 2001, 
2005 and 2010 MRI criteria for McDonald MS (MRI-only MS) but did not have a 
second clinical episode. A significantly greater number of CIS patients had MRI-only 
conversion to MS when the 2010 criteria were applied compared with the 2001 
(p<0.001) and 2005 criteria (p = 0.001).  
 
The majority of patients with MRI-only MS satisfied the McDonald within 12 months 
of symptom onset; 18 (75%), 18 (69%) and 26 (72%) patients using the 2001, 2005 
and 2010 criteria respectively. 
 
4.4  Discussion 
In patients with CIS a diagnosis of MS can be made significantly earlier using the 
McDonald MRI criteria to provide evidence for DIS and DIT rather than waiting for a 
second clinical attack. However, a third of CIS patients who had no further clinical 
attacks over a mean follow up period of ~5 years also satisfied MRI criteria for a 
diagnosis of MS.  
 
I found that with each revision of the McDonald criteria, a diagnosis of MS can be 
made at a significantly earlier time point. Among patients who ultimately developed 
CDMS, the mean time to diagnosis of MS halved from 12.0 months with the 2001 
criteria to 6.2 months with the 2010 criteria. This reflects a time gain of 16.9 months 
when compared with the mean time to a second clinical attack and a diagnosis of 
CDMS. Although a number of studies have investigated the sensitivity, specificity and 
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accuracy of the McDonald criteria in different CIS cohorts, few have quantified how 
much sooner a diagnosis of MS can be made (Thouvenot et al., 2012; Runia et al., 
2013). In a clinic-based series of CIS patients from The Netherlands, the mean time 
to diagnosis of 2010 and 2005 McDonald MS was 23.6 and 26.1 months compared 
with 27.9 months for CDMS (Runia et al., 2013). However, spinal cord imaging was 
not done which is important for determining DIS (particularly when applying the 
McDonald 2010 criteria), and not all patients had follow up MRI scans to demonstrate 
DIT. In a small cohort of 49 CIS patients from France, reported in abstract form at the 
ECTRIMS 2012 meeting, the mean time to diagnosis of MS was 151 and 321 days 
for the 2010 and 2005 criteria respectively, compared with 500 days for CDMS, which 
is similar to my findings (Thouvenot et al., 2012).  
 
The time gain with each revision of the McDonald criteria reflects the less stringent 
requirements for DIS and DIT as MRI criteria have evolved (McDonald et al., 2001; 
Polman et al., 2005; Polman et al., 2011). The Magnetic Resonance Imaging in 
Multiple Sclerosis (MAGNIMS) study group evaluated the performance of the 2001 
and 2005 criteria in a large multi-centre European CIS cohort that included a subset 
of patients reported here (Swanton et al., 2007). Patients had a baseline MRI scan 
(within 3 months of CIS onset) and a follow up MRI after approximately 3 months. 
They found a sensitivity of 47.1% and 60.0% for the 2001 and 2005 criteria 
respectively for the development of CDMS at three years. The changes to the 
requirements for DIS and DIT that were incorporated into the 2010 criteria have been 
shown to be more sensitive than earlier iterations of the McDonald criteria for a 
diagnosis of CDMS over follow-up periods of up to 36 months (Swanton et al., 2007; 
Rovira et al., 2009; Montalban et al., 2010). I found that the successive iterations of 
the McDonald criteria have allowed an earlier diagnosis of MS. Importantly, 45% of 
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patients who ultimately developed CDMS in this cohort could be diagnosed with MS 
using the 2010 McDonald criteria with a single MRI scan at the time of presentation.  
 
Establishing a diagnosis of MS at an earlier time point is desirable for patients and 
treating neurologists. Natural history studies suggest that events early in the course 
of MS, including the time to the second clinical attack and the number of relapses in 
the first few years of the illness, are important predictors of long-term disability 
(Confavreux et al., 2003; Scalfari et al., 2010). An early and accurate diagnosis of MS 
may also facilitate early initiation of treatments that reduce relapses rates and accrual 
of disability (Wingerchuk and Weinshenker, 2016). 
 
A significant number of CIS patients satisfy MRI criteria for a diagnosis of MS in the 
absence of further neurological symptoms, at least of the first 5 years or so after 
presentation. Long-term follow-up studies have shown that 18 – 28% of CIS patients 
with MRI abnormalities at baseline do not develop CDMS (Fisniku et al., 2008; Optic 
Neuritis Study Group, 2008). It is therefore not surprising that when applying the 
McDonald criteria that a proportion of patients with CIS have MRI-only conversion to 
MS, even with follow up of up to 20 years (Chard et al., 2011). The number of CIS 
patients with MRI-only conversion to MS has increased with each revision of the 
McDonald criteria. I found that 42% of CIS patients who did not have a second clinical 
attack satisfied McDonald 2010 criteria during follow up, usually within 12 months of 
CIS onset. Whether these patients have a mild form of MS that remains largely 
subclinical is unknown. They may still be at risk of long term disability from late 
relapses or the development of SPMS, the so called “single-attack progressive MS” 
phenotype (Kremenchutzky et al., 2006). These patients may also be at risk of 
cognitive impairment, fatigue and affective disorders that can occur in people with 
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benign MS and in the radiologically isolated syndrome, even in the absence of 
significant physical disability (Amato et al., 2006; Amato et al., 2012). 
 
Recent studies have suggested that the prognosis of relapse-onset MS in 
contemporary patient cohorts may be rather better than in natural history studies 
conducted in the pre-MRI era (Confavreux et al., 2003; Scalfari et al., 2010). In a 
population-based study from France, 244 patients with relapse-onset MS were 
followed up prospectively over 10 years after CIS and only 8% reached EDSS 6 
(Kerbrat et al., 2015). Similarly, Capra and colleagues studied the accrual of disability 
in relapse-onset MS patients seen at a single Italian MS centre since 1980 (Capra et 
al.). The patients were grouped into epochs of 5 years from 1980 to 2016 and the age 
and rate at which patients reached EDSS 6 was noted. Between 1980 and 1995 the 
age at EDSS 6 was stable. However, since 1996 the age at which EDSS 6 was 
reached has progressively increased in each 5 yearly epoch. While treatment with 
DMT is likely to be a major factor contributing to these observations the possibility 
arises that the McDonald criteria are identifying patients with milder forms of MS. 
There is the potential for the natural history of relapse-onset MS to be favourably 
modified by changes to the diagnostic criteria, independent of any effect of DMT, 
referred to as the Will-Rogers phenomenon (Sormani et al., 2008).  
 
This study has some limitations. Firstly, participants had scheduled MRI follow up 
over the first ~5 years after CIS onset, irrespective of clinical status. In routine clinical 
practice CIS patients would usually have a diagnostic MRI at presentation then a 
follow up MRI if required to demonstrate dissemination in time, rather than repeated 
MRI scans. However, the majority of CIS patients who satisfied the McDonald MRI 
criteria (including those with MRI-only MS) did so within 12 months of CIS onset 
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suggesting that my findings are not simply a function of the intensity of MRI follow up. 
Secondly, this cohort is biased towards patients with optic neuritis. It has been 
suggested that optic neuritis may be more benign prognosis than brainstem or spinal 
cord syndromes (Tintore et al., 2005; Tintore et al., 2015), potentially accounting for 
the significant number of patients in this study with MRI-only MS. However, more than 
80% of the patients with optic neuritis in the study had abnormal brain MRI at 
presentation indicating a high-risk group for the development of CDMS. Finally it is 
possible that with longer follow up the proportion of CDMS patients will increase, 
although most people with MS experience a second attack in the first 2-3 years after 
a CIS.  
 
4.5 Conclusions 
The McDonald criteria allow MS to be diagnosed sooner and more often in patients 
with CIS. While the McDonald criteria do facilitate an earlier diagnosis of MS, up to 1 
in 3 CIS patients who satisfy the McDonald 2010 MRI criteria for a diagnosis of MS 
do not have further clinical events, at least in the medium-term. Changes to the 
diagnostic criteria for MS may be one of the factors contributing to an improved 
prognosis of MS in the treatment era. 
 
The incorporation of MRI into diagnostic criteria represents a significant advance in 
the management of people with MS. However, further modifications to MRI criteria for 
diagnosing MS are likely in the future. In Chapter 5 I investigate two proposed 






Modifications to MRI criteria to improve the diagnosis of MS in people with 
clinically isolated syndromes 
 
5.1 Introduction 
There has been significant evolution of the diagnostic criteria for MS over the last 15 
years (McDonald et al., 2001; Polman et al., 2005; Polman et al., 2011). As presented 
in Chapter 4 the McDonald criteria are helpful in establishing a diagnosis of MS at an 
earlier time point. However, fewer than half of CIS patients who develop MS can be 
diagnosed at the time of presentation with a single contrast-enhanced MRI scan of 
the brain and spinal cord using current MRI criteria (Rovira et al., 2009).  
 
Recently, the MAGNIMS group has recommended further changes to MRI criteria to 
improve the diagnosis of MS in CIS patients (Filippi et al., 2016). These changes 
include the inclusion of lesions in the symptomatic region, optic nerve and cerebral 
cortex in DIS, and an increase in the number of lesions required in the periventricular 
region to confirm DIS from 1 to 3. In this chapter I investigate two of the proposed 
changes to DIS criteria in the CIS cohort:  
 
1. Should lesions in the symptomatic site should be included in DIS criteria? 
 
2. Does increasing the number of periventricular lesions required for DIS 




5.2 Should lesions in the symptomatic region be included in dissemination 
in space in patients with clinically isolated syndromes? 
 
5.2.1 Introduction 
In the 2010 revisions to the McDonald criteria there was a major simplification of the 
requirements for DIS (Polman et al., 2011). The presence of one or more T2-
hyperintense lesions in two of four sites typically affected in demyelination 
(periventricular, juxtacortical, infratentorial, spinal cord) provides MRI evidence for 
DIS (Polman et al., 2011). When the patient’s symptoms are referable to the 
brainstem/cerebellum or spinal cord, then lesions in the symptomatic region are 
excluded (Polman et al., 2011). The criteria are ambiguous as to whether all lesions 
in the symptomatic region should be excluded or only the symptomatic lesion (Rovira 
et al., 2015).  
 
The rationale for exclusion of symptomatic lesions in DIS was to maximise the 
specificity of MRI criteria by requiring MRI evidence of at least two asymptomatic 
lesions to establish DIS (Swanton et al., 2006; Swanton et al., 2007). However, in 
previous diagnostic criteria for MS, whether clinical criteria (Poser et al., 1983) or 
incorporating MRI (McDonald et al., 2001; Polman et al., 2005), symptomatic lesions 
have always contributed to DIS. The exclusion of lesions in the symptomatic region 
may reduce the sensitivity of the McDonald 2010 criteria in patients with 
brainstem/cerebellar and spinal cord syndromes (Ruet et al., 2011; Kang et al., 2014), 




I wanted to investigate whether inclusion of lesions in the symptomatic region 
improves the performance of DIS criteria for a diagnosis CDMS in patients with 




Patients from the CIS cohort who presented with brainstem/cerebellar or spinal 
syndromes were included in this analysis (n=32). Two patients were excluded; one 
with myelitis who developed NMOSD and one with a brainstem syndrome who was 
lost to follow-up.  
 
Clinical assessment 
The patients were followed prospectively for the development of CDMS. The date of 
the second clinical attack was recorded and used to determine the time to diagnosis 
of CDMS.  
 
MRI acquisition and image-analysis 
PD/T2-weighted and post-contrast T1-weighted scans of the brain and spinal cord 
obtained at baseline and a follow-up PD/T2-weighted and post-contrast T1-weighted 
brain scan after approximately 3–12 months were analysed. The number and location 
of T2-hyperintnse lesions and the number of contrast-enhancing lesions was 






I retrospectively applied three DIS criteria to the baseline MRI scans: 
1. The McDonald 2010 DIS criteria with lesions in the symptomatic region 
excluded (Polman et al., 2011) 
 
2. Modified criteria 1: The McDonald 2010 DIS criteria modified to include 
asymptomatic lesions in the symptomatic region. For example, a cerebellar 
hemisphere lesion in a patient with bilateral internuclear ophthalmoplegia.  
 
3. Modified criteria 2: The McDonald 2010 DIS criteria modified to include any 
lesion in the symptomatic region in DIS. For example, a single spinal cord 
lesion in a patient with myelitis. 
 
DIT criteria 
The McDonald 2010 DIT criteria were also applied retrospectively, requiring either the 
simultaneous presence of gadolinium-enhancing and non-enhancing lesions on the 
same MRI scan or a gadolinium-enhancing and/or new T2-hyperintense lesion on the 
follow-up MRI done after 3 or 12 months (Polman et al., 2011). 
 
Statistical analysis 
The sensitivity, specificity and accuracy of the three DIS criteria (alone and in 
combination with DIT criteria) for the development of CDMS and 95% confidence 
intervals were calculated. I also analysed the time to diagnosis of MS based on clinical 
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evidence alone (CDMS) or using the different MRI criteria (each requiring both DIS 
and DIT). The times to diagnosis of MS were not normally distributed and comparison 
was made using the one-sample Wilcoxon signed-rank test. 
 
5.2.3 Results 
30 patients were included in this analysis. Table 5.1 shows the baseline demographic, 
clinical and MRI findings. 23 (77%) patients had one or more T2-hyperintense lesions 
in the symptomatic region. The symptomatic lesion was able to be localised in 22 
(73%) patients based on the neurological examination findings, the presence of 
contrast-enhancement, or both. 11 (37%) patients had one or more asymptomatic 
lesion in the symptomatic region.  
 










Age, mean (SD) 30.6 (8.3) 32.6 (9.9) 31.25 (8.8) 
Female, n (%) 14 (70) 4 (40) 18 (60) 
Number of lesions in 
the symptomatic site 
     0 lesions 
     1 lesion 

















During follow-up 15 (50%) patients developed CDMS. None of the patients received 
disease-modifying treatment prior to developing CDMS.  
 
Figure 5.1 shows a Kaplan-Meier survival curve with the time to diagnosis of CDMS 
based on the number of lesions in the symptomatic region. CDMS developed in 1/7 
(14%) patients with a normal MRI of the symptomatic region, 7/12 (58%) patients with 




Figure 5.1 Kaplan-Meier survival curve showing time to diagnosis of clinically-




Table 5.2 shows the performance of the McDonald 2010 DIS criteria and the two 
modified criteria alone and in combination with DIT criteria for the development of 
CDMS. All of the DIS criteria had high sensitivity and specificity for the development 
of CDMS (Table 5.2). However, the two modified criteria were more sensitive and 
more accurate than the McDonald 2010 DIS criteria. All three criteria had the same 
specificity. The inclusion of any lesion in the symptomatic region had the highest 
overall sensitivity and accuracy for the development of CDMS. 
 
Table 5.2 Performance of the McDonald 2010 DIS criteria and the modified DIS 







DIS criteria only    





























DIS + DIT criteria combined 
     McDonald 2010 criteria 67% 73% 70% 
 























The mean time to diagnosis of MS (requiring both DIS and DIT) was: (i) CDMS: 24.9 
months; (ii) McDonald 2010 criteria: 8.9 months, (iii) McDonald 2010 DIS criteria 
modified to include asymptomatic lesions in the symptomatic region: 6.7 months; and 
(iv) McDonald 2010 DIS criteria modified to include any lesion in the symptomatic 
region: 4.8 months. The McDonald criteria and the two modified criteria allowed for 
an earlier diagnosis of MS compared with the time to development of CDMS (p<0.001 
for all comparisons). However, the time to diagnosis was not significantly different 
when the modified criteria were compared with the McDonald 2010 criteria.  
 
5.2.4 Discussion 
I found that inclusion of lesions in the symptomatic region in patients with clinically 
isolated brainstem/cerebellar and spinal cord syndromes improves the overall 
performance of DIS criteria for a diagnosis of CDMS, with no drop in specificity. 
 
This study provides evidence to support the recommendation of the MAGNIMS group 
that lesions in the symptomatic region should contribute to DIS (Filippi et al., 2016). I 
found that inclusion of both asymptomatic and symptomatic lesions in the 
symptomatic region increased the sensitivity of DIS criteria for the development of 
CDMS. However, modified DIS criteria that include any lesion in the symptomatic 
region may be preferable, firstly because the sensitivity was higher and secondly 
because the criteria would be easier to apply in a clinical setting. Determining whether 
a lesion is symptomatic or asymptomatic is sometimes difficult and not always 




The findings of this analysis are supported by other studies that have investigated the 
prognostic significance of symptomatic lesions in patients with CIS (Caucheteux et 
al., 2015; Tintore et al., 2016). Caucheteux and colleagues studied 146 CIS patients 
with a well-defined symptomatic lesion on MRI (including patients with acute optic 
neuritis). Patients in whom a symptomatic lesion could not be identified on MRI were 
excluded. The presence of a well-defined symptomatic lesion plus at least one other 
asymptomatic lesion typical of demyelination (or any white matter lesion in 
combination with positive CSF) had a very high sensitivity for the development of MS 
(Caucheteux et al., 2015). The prognostic significance of the symptomatic lesion was 
also highlighted in analyses from the Barcelona CIS cohort. A single symptomatic 
lesion in patients with brainstem/cerebellar or spinal cord syndromes carried a similar 
risk of CDMS as an asymptomatic brain lesion in patients with optic neuritis, and the 
risk was significantly higher than in CIS patients with a normal MRI at presentation 
(Tintore et al., 2016). Similarly, in my investigation patients with a single lesion in the 
symptomatic region were at significantly higher risk of CDMS than patients with no 
lesions, although the risk was lower than in patients with two or more lesions in the 
symptomatic region. 
 
Some limitations of this study need to be noted. Firstly, the patients studied all had 
syndromes that were typical of a first demyelinating event suggestive of MS, such as 
bilateral internuclear ophthalmoplegia and partial myelitis. The McDonald MRI criteria 
should only be applied to patients with typical CIS syndromes and care should be 
taken to exclude conditions that might mimic MS. Secondly, I tested the two modified 
DIS criteria in a relatively small cohort of patients. This is reflected in the large 
confidence intervals for sensitivity, specificity and accuracy for the McDonald DIS 
criteria and the modified DIS criteria. However, the results are encouraging and the 
criteria should be tested in a larger, multi-centre CIS cohort. 
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5.3 Periventricular lesion number in dissemination in space criteria in 
patients with clinically isolated syndrome 
 
5.3.1 Introduction 
The McDonald 2010 criteria give equal weighting to asymptomatic T2-hyperintense 
periventricular, juxtacortical, infratentorial regions and spinal cord lesions when 
determining DIS (Polman et al., 2011). Although commonly seen in people with CIS 
and MS, periventricular lesions are not a specific finding and can also be seen in other 
inflammatory disorders, small vessel cerebrovascular disease, migraine and healthy 
aging (Fazekas et al., 1988; Nielsen et al., 2005; Absinta et al., 2012; Liu et al., 2013). 
 
The use of ≥1 periventricular lesion in DIS criteria has never been formally tested and 
earlier iterations of the McDonald criteria required ≥3 periventricular lesions 
(McDonald et al., 2001; Polman et al., 2005). This was based on the work of Barkhof 
and colleagues who found that ≥3 periventricular lesions provided the optimal cut-off 
in terms of sensitivity and specificity for development of CDMS in CIS patients using 
receiver operator curve characteristics (Barkhof et al., 1997). However, in that study 
the prognostic value of brain MRI abnormalities was considered in isolation, whereas 
current diagnostic criteria require evidence of DIS in at least two sites plus DIT to 
make a diagnosis of MS (Polman et al., 2011). 
 
The MAGNIMS group has recently proposed that the number of lesions required to 
confirm DIS in the periventricular region be increased from ≥1 to ≥3 (Filippi et al., 
2016). This recommendation was based on expert opinion that a single periventricular 
lesion was not sufficiently specific enough to determine whether the lesion was due 
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to demyelination or another pathology, particularly if both symptomatic and 
asymptomatic lesions are included in DIS (Filippi et al., 2016). For example, in a 
middle-aged patient presenting with a brainstem or spinal cord syndrome, a single 
periventricular brain lesion may be insufficient to say there is evidence of DIS. 
 
I wanted to investigate the role of periventricular lesion number in DIS. I examined 
the performance of ≥1, ≥2 and ≥3 periventricular lesions in DIS criteria for the 
diagnosis of CDMS in order to determine whether increasing the number of 
periventricular lesions improves the specificity or accuracy of MRI criteria for a 




I included patients from the CIS cohort who had MRI scans at baseline and a follow-
up MRI scan within 12 months to demonstrate DIT. All of the patients had at least 36 
months of clinical follow-up.  
 
Clinical assessment 
The patients were followed up prospectively for the development of CDMS. 
 
MRI acquisition and image-analysis 
MRI scans obtained at baseline (brain and spinal cord) and after 3 - 12 months (brain 




I retrospectively applied the McDonald 2010 DIS criteria requiring ≥1 asymptomatic 
lesion in two or more sites (periventricular, juxtacortical, infratentorial and spinal cord). 
I then applied two modified DIS criteria requiring ≥2 or ≥3 periventricular lesions to 
satisfy DIS in the periventricular region. All other requirements of the McDonald 2010 
criteria were unchanged. 
 
The three sets of DIS criteria with varying numbers of periventricular lesions were 
tested separately in the subgroup of patients who had imaging of the symptomatic 
region (n=31) to investigate the influence of periventricular lesion number when 
symptomatic lesions are included in DIS. In addition to the 30 patients with 
brainstem/cerebellar and spinal cord syndromes described in section 5.2, I also 




The McDonald 2010 DIT criteria were applied retrospectively in combination with the 
DIS criteria above with varying numbers of periventricular lesions. 
 
Statistical analysis 
I investigated the frequency of ≥1, ≥2 and ≥3 periventricular lesions on baseline MRI 
scans and the positive predictive value (PPV) of periventricular lesion number for the 
development of CDMS. I calculated the sensitivity, specificity and accuracy with 95% 
confidence intervals of DIS criteria with ≥1, ≥2 and ≥3 periventricular lesions (alone 




155 CIS patients (mean age 32.2 years, 66% female) were included, 124 patients 
with optic neuritis and 31 patients with a non-optic neuritis presentation who had 
imaging of the symptomatic region (brainstem/cerebellar syndrome n=20, spinal cord 
syndrome n=10, hemispheric syndrome n=1).  
 
During follow-up 93 (60%) patients developed CDMS. The positive predictive value 
(PPV) of periventricular lesion number for the development of CDMS is shown in 
Table 5.3. A single periventricular lesion had a very high PPV for CDMS, irrespective 
of other baseline MRI findings.  
 
Table 5.3  Number of periventricular lesions at baseline and positive predictive 
value (PPV) of periventricular lesions for the development of CDMS. 
 






     0 lesions, n (%) 53 (34) 14 (15) 26% 
     1 lesion, n (%) 22 (15) 15 (16) 68% 
     2 lesions, n (%) 12 (8) 9 (10) 75% 





The performance of DIS criteria using ≥1, ≥2 and ≥3 periventricular lesions for 
development of CDMS is shown in Table 5.4. One or more periventricular lesion had 
the highest sensitivity and accuracy but the specificity was lower than with DIS criteria 
requiring ≥2 or ≥3 periventricular lesions. When DIS was combined with DIT criteria, 
the sensitivity and accuracy of ≥1 periventricular lesion was higher than ≥2 or ≥3 
periventricular lesions and the specificity was the same. 
 
Table 5.4 Performance of diagnostic criteria for development of clinically-definite 









     ≥1 PV lesion 80% 73% 77% 
 


















DIS + DIT combined 
     ≥1 PV lesion 62% 79% 69% 
 






















The results were similar when lesions in the symptomatic region were included in DIS 
in the subgroup of patients who had imaging of the symptomatic region (n=31); ≥1 
periventricular lesion was more sensitive and more accurate than ≥2 or ≥3 
periventricular lesions and there was no overall change in specificity when DIS was 
considered in conjunction with DIT (Table 5.5). 
 
Table 5.5 Performance of diagnostic criteria for development of clinically-definite 
MS with varying numbers of periventricular lesions and inclusion of lesions in the 









     ≥1 PV lesion 87% 69% 71% 
 


















DIS + DIT combined 
     ≥1 PV lesion 80% 75% 77% 
 























Increasing the number of periventricular lesions required for DIS may reduce the 
sensitivity of the MRI criteria for a diagnosis of CDMS, possibly reflecting the lower 
lesion load at this earliest clinical stage of MS. Although a high sensitivity facilitates 
an early diagnosis, a high specificity is also important, in order to avoid misdiagnosis 
of MS. I found that DIS criteria requiring ≥1 or ≥2 PV lesions were more sensitive but 
less specific than DIS criteria requiring ≥3 periventricular lesions. However, when DIS 
criteria was combined with DIT, the specificity of the 2010 McDonald criteria for 
CDMS was the same whether the minimum number of PV lesions was 1, 2 or 3.  
 
I separately investigated the effect of varying periventricular lesion number when 
lesions in the symptomatic site were included in DIS in the small subgroup of patients 
with a non-optic neuritis presentation (n=31). An increase in the number of 
periventricular lesions required for DIS yielded similar findings to those reported in 
the whole cohort. A larger cohort should be studied to more definitively investigate 
the effect of including symptomatic region lesions with varying number of 
periventricular lesions, ideally in combination with other changes to DIS 
recommended by MAGNIMS (Filippi et al., 2016). 
 
I studied a group of young adults with well-defined clinical presentations typical of 
demyelination (mainly acute optic neuritis) in whom the pre-test probability of MS was 
high. How MRI criteria perform outside this setting, for example, in people with 
atypical presentations, in young children (<12 years) or in older adults (>50 years) is 
uncertain. In this setting the likelihood of alternative diagnoses other than MS may be 
higher. Periventricular lesions occur in many disorders, including migraine (Absinta 
et al., 2012; Liu et al., 2013) and small vessel cerebrovascular disease (Nielsen et al., 
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2005), and a previous study found that ≥3 periventricular lesions was the best MRI 
brain measure to differentiate MS from other neurological disorders (Nielsen et al., 
2005).  
 
MRI criteria are intended for use in patients in whom a diagnosis of MS is clinically 
suspected, rather than to differentiate MS from other neurological disorders and 
should only be applied in settings where MS is strongly suspected, such as a young 
adult with a typical CIS. In this group of patients I found that increasing the number of 
periventricular lesions required for DIS may not improve the performance of MRI 
criteria for MS. 
 
5.4 Conclusions 
The McDonald criteria have evolved significantly over the last 15 years and further 
changes are likely as the evidence base for MRI criteria grows. The findings 
presented in this chapter support the inclusion of lesions in the symptomatic region in 
DIS in patients with brainstem/cerebellar and spinal cord syndromes. However, an 
increase in the number of periventricular lesions required for DIS from ≥1 to ≥3 does 
not enhance the diagnostic accuracy and may potentially reduce the performance of 
MRI criteria, at least in young adult patients with typical CIS presentations.  
 
My findings highlight the high prognostic value of conventional MRI abnormalities in 
predicting the development of CDMS in patients with CIS. In Chapters 6 and 7 I 
investigate how these early MRI measures used to establish a diagnosis of MS are 





Spinal cord lesions and atrophy are associated with the development of 
disability over the first 5 years after a clinically isolated syndrome 
 
6.1  Introduction 
In people with MS, disability is commonly referable to the spinal cord resulting in 
weakness, sensory alteration, sphincter problems and neuropathic pain (Swingler 
and Compston, 1992). Pathological studies investigating spinal cord damage in MS 
have found evidence of focal lesions involving grey and white matter, neuroaxonal 
loss and atrophy (Kearney et al., 2015b). MRI often detects spinal cord abnormalities 
in established MS (Kidd et al., 1993; Kearney et al., 2015b); focal T2-hyperintense 
lesions are seen in 75% or more of patients, most commonly in the cervical cord (Kidd 
et al., 1993; Nijeholt et al., 1998; Lukas et al., 2013). Spinal cord atrophy can also be 
detected in vivo using MRI by measuring the UCCA, and has robust correlations with 
physical disability (Losseff et al., 1996; Nijeholt et al., 1998; Stevenson et al., 1998; 
Lin et al., 2003; Rashid et al., 2006; Furby et al., 2008; Bonati et al., 2011; Rocca et 
al., 2011; Lukas et al., 2013; Kearney et al., 2014a; Lukas et al., 2015). 
 
Spinal cord MRI abnormalities are also seen in people with CIS. Up to half of CIS 
patients have asymptomatic spinal cord lesions (O'Riordan et al., 1998a; Sombekke 
et al., 2013) and these can be helpful in establishing a diagnosis of MS (Polman et 
al., 2011). Spinal cord lesions may have prognostic value and the presence of spinal 
cord lesions in CIS patients is associated with an increased risk of disability over the 




Spinal cord atrophy has been previously reported in CIS patients with abnormal brain 
MRI (Brex et al., 2001; Biberacher et al., 2015), a group known to be at high-risk for 
MS (Fisniku et al., 2008a; Tintore et al., 2015). Only one previous study has 
investigated spinal cord atrophy longitudinally in patients with CIS and no change in 
UCCA was found over a follow-up period of one year (Brex et al., 2001). This 
contrasts with findings in patients with established MS where progressive spinal cord 
atrophy is evident over follow-up periods of 12–36 months (Lin et al., 2003; Rashid et 
al., 2006; Lukas et al., 2015) and may be associated with progression of disability (Lin 
et al., 2003; Lukas et al., 2015).  
 
I wanted to investigate longitudinal changes in spinal cord lesions and UCCA over 
the first 5 years after CIS to determine whether spinal cord involvement is one of the 
mechanisms responsible for disability progression in early relapse-onset MS. 
 
6.2  Methods 
Patients 
I included patients from the CIS cohort who had brain and spinal cord MRI at the time 
of presentation and at follow-up after 3-5 years. I excluded patients who presented 
with a spinal cord CIS in order to investigate the significance of clinically silent, early 
spinal cord MRI abnormalities present at the time of CIS. 
 
Clinical assessments 
MS was diagnosed using the McDonald 2010 criteria (Polman et al., 2011). Disability 
was assessed at baseline and follow-up in all patients using the EDSS (Kurtzke, 
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1983). A subgroup of patients were also assessed at follow-up with the TWT and 
9HPT, components of the MSFC (Cutter et al., 1999).  
 
MRI acquisition and image-analysis 
MRI of the brain and spinal cord was obtained at baseline (within 3 month of CIS 
onset) and at follow-up after 3-5 years. All of the scans were done on the same 1.5 T 
Signa scanner (General Electric, Wisconsin, USA). There was a major hardware 
upgrade during the study. Some of the follow-up MRI scans were obtained after the 
scanner upgrade and this was considered in the statistical analysis (see below). 
 
Brain MRI measures 
I identified T2-hyperintense brain lesions on PD/T2-weighted scans and T1-
hypointense brain lesions on post-contrast T1-weighted scans. A semi-automated 
edge-finding tool (JIM6, Xinapse systems, Aldwincle, UK) was used to outline lesions 
and to calculate T2LV and T1LV. The lesion load at baseline and the change in T2LV 
and T1LV from baseline to follow-up was recorded. 
 
I calculated NBV at baseline using SIENAX and the PBVC between baseline and 
follow-up using SIENA from T1-weighted fast spin echo scans after lesion filling 
(Smith et al., 2002; Prados et al., 2014). SIENAX and SIENA analyses were done 
using FMRIB Software Library (FSL) version 5.0.2 with the assistance of Dr Ferran 





Spinal cord MRI measures 
The number of spinal cord lesions was identified from sagittal PD/T2-weighted scans 
of the whole cord by Dr Katherine Miszkiel. The number of spinal cord lesions at 












Figure 6.1 Spinal cord lesions. 
Sagittal T2-weighted scans of the whole spine in a CIS patient. At baseline (A) a 
single spinal cord lesion is visible at T8/9. At follow-up (B) after 5 years a new lesion 
is visible at the level of C2. 
 
For spinal cord atrophy, I calculated the UCCA at baseline and follow-up from 
dedicated volumetric scans of the cervical cord (Figure 6.2). The sagittally-acquired 




the level of the C2/C3 disc. An active surface model was then used to measure the 
mean UCCA over the five slices, as described in Chapter 2 (Horsfield et al., 2010; 
Rocca et al., 2011; Kearney et al., 2014b). The change in UCCA between baseline 
and follow-up (in mm2) was calculated. The analyses were done using JIM6.   
 
 









Figure 6.2 Spinal cord atrophy 
Reformatted axial images at the level of C2/C3 used to calculate the UCCA over a 
mean of five slices at baseline (A) and follow-up after 5 years (B). 
 
Statistical analysis 
I grouped the patients based on their clinical status after 5 years as CIS, MS with 
EDSS <3 and MS with EDSS ≥3. Univariable comparisons of MRI measures between 




the non-parametric Wilcoxon rank sum test for lesion and brain atrophy measures, 
due to their skewed distribution. Linear regression was used for comparisons of 
UCCA, with adjustment for age and sex.   
 
Multiple linear regression models were used to identify independent MRI predictors 
of physical disability at follow-up (EDSS, TWT, 9HPT). Separate models were 
constructed for brain and spinal cord MRI measures in order to compare the 
proportion of variance explained using the R-square (R2) statistic and to restrict the 
number of covariates. Only variables with p<0.08 were retained in models. The 
predictor variables from the separate brain and spinal cord models were then 
combined, and manual backwards stepwise elimination used to find the best overall 
combined model. The omitted MRI variables were then entered singly and retained if 
p<0.08.  
 
Disease duration was included as a covariate in all models in order to account for 
differences in the duration of follow-up. The potential effect of a scanner upgrade 
during the follow-up period was assessed by adjusting for those subjects whose 
baseline and follow-up straddled the upgrade. Potential confounding by age and sex 
was examined by entering these into the final models. The results of the final models 
were confirmed using a non-parametric bias-corrected and accelerated bootstrap with 








I included 131 patients from the CIS cohort in this analysis. The reasons for exclusion 
were spinal cord CIS (n=10), no follow-up MRI scan at 3 or 5 years (n=35) and 
diagnosis other than MS (n=2). The patients included in this analysis comprised 114 
(87%) patients with optic neuritis, 16 (12%) patients with a brainstem/cerebellar 
syndrome and 1 (1%) patient with a hemispheric syndrome. The mean duration of 
follow-up was 5.3 years (range 3.0–7.9 years).  
 
93 (71%) patients were diagnosed with MS using the McDonald 2010 criteria. 15 
(16%) patients had an EDSS score of ≥3  at follow-up (median EDSS 3.5, range 3–
6.5), and were classified as disabled. Four of these patients had developed SPMS. 
78 (84%) MS patients had not developed significant disability (median EDSS 1, range 
0–2.5). Disability was similar after 5 years in patients with optic neuritis and other CIS 
presentations (median EDSS 1 in both groups). During follow-up 23 (18%) patients 
started DMT, either beta interferon or glatiramer acetate.  
 
The baseline characteristics of the patients included in this analysis grouped by 
clinical status at approximately 5 years is shown in Table 6.1.                                                   
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Table 6.1  Baseline demographic characteristics and MRI findings at baseline and follow grouped by clinical status after 5 years. 
 
 
All data presented as mean (SD) unless otherwise stated 




   
CIS at 5 years 
(n=38) 





EDSS < 3 
(n=78) 
EDSS ≥ 3 
(n=15) 
   Age, years 32.6 (7.5) 32.5 (6.9) 32.8 (7.9) 31.5 (7.4) 0.597 
   Female, n (%) 83 (63) 18 (47) 55 (71) 10 (67) 0.766 
   Optic neuritis, n (%)  114 (87) 34 (89) 69 (88) 11 (73) 0.122 
   Baseline EDSS, median (IQR) 1 (1) 1 (1) 1 (1) 1 (1.75) 0.069 
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Brain MRI abnormalities 
Brain MRI findings at baseline and at follow-up are shown in Table 6.2. MS patients 
classified as disabled at follow-up (EDSS ≥3) had a greater T2LV at baseline (mean 
5.12 vs 1.72 ml, p<0.001) and follow-up (18.20 vs 4.89 ml, p<0.001) compared with 
the MS patients without significant disability. The findings were similar for brain T1LV 
at baseline (0.65 vs 0.21ml, p=0.009) and at follow-up (5.06 vs 0.64ml, p=0.031).  
 
The MS patients showed significantly greater brain atrophy compared with the 
patients who remained CIS (annualised PBVC -0.40 vs -0.26%, p=0.009), and there 
was significantly greater brain atrophy in the MS patients who were disabled at follow-
up compared with those without disability (annualised PBVC -0.67 vs -0.35%, 
p=0.047). 
 
Spinal cord MRI abnormalities 
Spinal cord MRI measures at baseline and follow-up are shown in Table 6.2. 
 
Spinal cord lesions 
None of the patients who remained CIS had spinal cord lesions at baseline or follow-
up. Among the patients who were diagnosed with MS, the number of spinal cord 
lesions at baseline (median [range] 2 [0 – 7] vs 0 [0 – 5], p=0.001) and at follow-up 
(median [range] 5 [1 – 14] vs 1 [0 – 9], p<0.001) was higher in patients with disability 
compared with those without significant disability.  
 
There was no difference in the number of spinal cord lesions at baseline or follow-up 






Spinal cord atrophy 
The mean UCCA at baseline and follow-up grouped by clinical status at ~5years is 
shown in Figure 6.3.  
 
After adjusting for age and sex there was no significant difference in the UCCA at 
baseline in patients who developed MS compared with those who remained CIS, 
(unadjusted means 74.66 vs 78.25 mm2, adjusted difference -2.21 mm2, p=0.11), or 
in MS patients with and without disability at follow-up (unadjusted means 76.65 vs 
74.27 mm2, adjusted difference 2.22 mm2, p=0.27). The mean annualised change in 
UCCA showed significantly more atrophy in patients with MS compared with those 
who remained CIS (unadjusted means -0.42 vs -0.09 mm2/year, adjusted difference 
-0.37 mm2/year, p<0.001), and in MS patients with disability compared with those 
without significant disability (unadjusted means -0.91 vs -0.32 mm2/year, adjusted 
difference -0.59 mm2/year, p<0.001).  
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Table 6.2  Baseline demographic characteristics and MRI findings at baseline and follow up grouped by clinical status after 5 years. 
 
All data presented as mean (SD)  
† p values for comparisons between MS patients with EDSS <3 and ≥3 at follow-up.  
   
CIS at 5 years 
(n=38) 






EDSS < 3 
(n=78) 
EDSS ≥ 3 
(n=15) 
Baseline MRI measures        
   Brain T2LV, ml  1.63 (3.0) 0.06 (0.1) 1.72 (2.9) 5.12 (4.1) <0.001 
   Brain T1LV, ml  0.20 (0.6) 0 (0) 0.21 (0.6) 0.65 (1.1) 0.009 
   NBV, cm3 1576 (72) 1580 (66) 1582 (68) 1549 (82) 0.210 
   SC lesion number, n  0.54 (1.2) 0 (0) 0.50 (0.9) 2.07 (1.9)  <0.001 
   UCCA, mm2  75.70 (7.8) 78.25 (7.2) 74.27 (7.7) 76.65 (7.8) 0.270 
Annualised change in MRI measures   
    Δ Brain T2LV, ml 0.56 (1.3) 0 (0) 0.51 (0.8) 2.28 (2.8) <0.001 
    Δ Brain T1LV, ml 0.12 (0.5) 0 (0) 0.07 (0.1) 0.67 (1.4) 0.031 
    PBVC, % -0.37 (0.3) -0.26 (0.2) -0.35 (0.3) -0.67 (0.5) 0.047 
    Δ  SC lesion number, n 0 (0.3) 0 (0) 0 (0.4) 0.83 (1.1) <0.001 




Figure 6.3  Change in upper cervical cord area from baseline to 5 years grouped by disability status at follow-up 
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Independent associations between MRI measures and disability 
Multivariable regression models were constructed that included brain MRI measures 
only, spinal cord MRI measures only and the combination of both in order to 
determine independent associations between MRI measures and disability at follow-
up (Tables 6.3, 6.4 and 6.5). EDSS scores were available for all patients at follow-up. 
Walking speed and 9HPT scores were available for 101 (77%) patients.  
 
Multivariable regression analysis: EDSS at follow-up 
Independent associations between MRI measures and EDSS at follow-up are shown 
in Table 6.3. In the brain MRI-only model the change in T2LV, the squared change in 
T2LV and PBVC were independently associated with EDSS at follow-up (R2=0.39). 
Change in T2LV showed evidence of a non-linear association with EDSS, and the 
squared term was retained in models. The small negative coefficient for the squared 
change in T2LV suggests a levelling off of the association between T2LV and EDSS 
as T2LV increases.  
 
In the spinal cord-only model baseline spinal cord lesion number, change in spinal 
cord lesion number and change in UCCA were independently associated with EDSS 
at follow-up (R2=0.53).  
 
When the brain and spinal cord MRI measures were combined all the MRI measures 
from the separate models above remained significant. Combining brain and spinal 
cord MRI measures only modestly increased the predictive power of the model 
(adjusted R2=0.61) compared to spinal cord measures alone (adjusted R2=0.51). 
Bootstrapping confirmed the regression results, except for baseline UCCA in the 




Table 6.3 Multiple linear regression models investigating independent associations of MRI measures with EDSS after 5 years (n=131) 
 
*Bootstrap confidence interval and p-value. 
MRI measure          Coefficient 95% CI p R2 (Adjusted R2) 
Brain MRI measures    0.39 (0.37) 
     Change in T2LV 0.19 0.12, 0.26 <0.001  
     Squared Change in T2LV -0.0032 -0.0047, -0.0017 <0.001  
     PBVC -0.14 -0.25, -0.02 0.020  
Spinal cord MRI measures    0.53 (0.51) 
     Baseline SC lesion number 0.40 0.26 , 0.54 <0.001  
     Change in SC lesion number 0.19 0.11, 0.28 <0.001  
     Change in UCCA -0.15 -0.21, -0.09 <0.001  
Brain and spinal cord MRI measures combined    0.64 (0.61) 
     Change in T2LV 0.10 0.04, 0.16 0.002  
     Squared Change in T2LV -0.0017 -0.0029, -0.00039 0.011  
     PBVC -0.11 -0.21, -0.02 0.018  
     Baseline SC lesion number 0.37 0.24, 0.50 <0.001  
     Change in SC lesion number 0.12 0.04, 0.21 0.004  





     Change in UCCA -0.11 -0.18  -0.05 <0.001  
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Spinal cord lesion number was the only baseline MRI measure associated with EDSS 
at follow-up. Univariably, baseline spinal cord lesion number explained a significant 
proportion of the variability in EDSS at follow-up (adjusted R2=0.24).  
 
 
Multivariable regression analysis: TWT and 9HPT at follow-up 
Associations between MRI measures and walking speed at 5 years are shown in 
Table 6.4. In the brain-only model the change in T2LV and with borderline significance 
baseline NBV were associated with walking speed at follow-up (R2=0.13). Baseline 
spinal cord lesion number and change in UCCA were associated with walking speed 
in the spinal cord-only model (R2=0.26). In the combined model only change in T2LV 
and baseline spinal cord lesion number remained significant (R2=0.29).  
 
Associations between MRI measures and upper limb dexterity measured using the 
9HPT are shown in Table 6.5. In the brain-only model the change in T2LV and 
baseline NBV were independently associated with 9HPT speed (R2=0.27). In the 
spinal cord-only model baseline spinal cord lesion number and the change in UCCA 
were independently associated with 9HPT speed (R2=0.34). In the combined model 
all of the brain and spinal cord MRI measures from the two separate models remained 
significant (R2=0.41).  
 
For both the TWT and 9HPT the findings were similar to EDSS: spinal cord MRI 
measures explained more of the variation in walking speed and 9HPT performance 
at 5 years than brain MRI measures, and the combination of both only modestly 
increased the predictive power of the models over spinal cord MRI measures alone 
(Table 6.4). Baseline spinal cord lesion number and the change in T2LV were 
consistently associated with all three measures of physical disability at follow-up.  
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MRI measure          Coefficient 95% CI p R2 (Adjusted R2) 
Brain MRI measures    0.13 (0.11) 
     Change in T2LV -0.004 -0.007, -0.004 0.002  
     Baseline NBV 1.32-7 -2.86-7, 2.68-7 0.055  
Spinal cord MRI measures    0.26 (0.24) 
     Baseline SC lesion number -0.015 -0.023, -0.008 <0.001  
     Change in UCCA 0.004 0..007, 0.001 0.004  
Brain and spinal cord MRI measures combined    0.29 (0.26) 
     Change in T2LV -0.004 -0.006, -0.002 0.001  
     Baseline SC lesion number -0.019 -0.026, -0.011 <0.001  
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Table 6.5 Multiple linear regression models investigating independent associations of MRI measures with 9HPT speed at 5 years (n=101) 
 
. 
MRI measure          Coefficient 95% CI p R2 (Adjusted R2) 
Brain MRI measures    0.27 (0.25) 
     Change in T2LV -0.0004 -0.0006, -0.0002 <0.001  
     Baseline NBV 4.78-8 2.51-8, 7.04-8 <0.001  
Spinal cord MRI measures    0.34 (0.32) 
     Baseline SC lesion number -0.002 -0.004, -0.001 0.001  
     Change in UCCA 0.001 0.001, 0.002 <0.001  
Brain and spinal cord MRI measures combined    0.41 (0.38) 
     Change in T2LV -0.0002 -0.0004, -0.0001 0.008  
     Baseline NBV 2.83-8 6.29-9, 5.03-8 0.012  
     Baseline SC lesion number -0.002 -0.003, -0.001 0.003  
     Change in UCCA 0.0007 0.0002, 0.0012 0.007  
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Effect of covariates on multivariate linear regression models 
Age, sex and scanner upgrade all had a negligible effect on regression coefficients 
and were not retained in the models. Because of differences in the length of follow-
up from presentation with CIS (range 3.0 – 7.9) disease duration was retained as a 
covariate in the models. 
 
None of the models were adjusted for DMT use. Patients who started DMT had 
greater disability at follow-up (mean EDSS 2.28 vs 1.21, p<0.001), likely reflecting 
reverse causality with more severely affected patients receiving treatment. This is 
consistent with a greater change in T2LV (9.19 vs 2.15ml, p<0.001), PBVC (-3.24 vs 
-1.82%, p=0.003), baseline spinal cord lesion number (median 2 vs 0, p<0.001), and 
change in UCCA (-2.88 vs 1.50 mm2 p=0.034) in patients who received DMT 
compared with patients who were not treated. Since these differences also likely 
reflect reverse causality, adjustment for DMT is not appropriate (Weinberg, 1993), 
with a DMT covariate tending to “steal” the effect of MRI variables.  
 
6.4  Discussion 
I found that spinal cord MRI abnormalities explained more of the variability in physical 
disability approximately 5 years after CIS than brain MRI measures. These findings 
suggest that spinal cord abnormalities, detected using MRI, may be important in the 
evolution of disability in the first few years after a non-spinal CIS. 
 
A number of studies in patients with established MS have found a poor correlation 
between spinal cord lesion load and disability (Kidd et al., 1993; Nijeholt et al., 1998; 
Lukas et al., 2013). Previous studies have largely been cross-sectional in nature and 
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included MS patients with different disease durations and clinical courses, whereas 
the cohort of patients I studied have been followed longitudinally from the time of first 
presentation with CIS.  
 
Because of their location close to pathways involved in walking, balance and 
sensation, spinal cord lesions may be more likely to cause physical impairment than 
brain lesions. New spinal cord lesions seen on MRI are more likely to be symptomatic 
than new brain lesions (Thorpe et al., 1996) and an incomplete recovery is more 
common following a spinal cord relapse (Leone et al., 2008). The spinal cord lesions 
seen at baseline in this group of patients with a non-spinal CIS were all asymptomatic. 
How they contribute to future disability is unclear, although one potential explanation 
is that axonal loss in focal lesions reduces the functional reserve to prevent 
permanent deficits when new pathological changes develop in the future. Whether 
the importance of focal spinal cord lesion accumulation lessens over time, particularly 
after the onset of secondary progression, is uncertain. Previous studies in patients 
with progressive MS have found no relationship between spinal cord lesions and 
disability (Nijeholt et al., 1998; Lukas et al., 2013).  
 
The change in UCCA was independently associated with EDSS and 9HPT 
performance at follow-up. Spinal cord atrophy in MS is thought to reflect neuroaxonal 
arising from axonal transection and Wallerian degeneration from focal lesions but also 
diffuse changes in the normal-appearing grey and white matter (Kearney et al., 
2015b). Spinal cord atrophy, as measured by the UCCA, has been correlated with 
disability in established MS (Losseff et al., 1996; Nijeholt et al., 1998; Stevenson et 
al., 1998; Furby et al., 2008; Bonati et al., 2011; Rocca et al., 2011; Lukas et al., 2013; 
Kearney et al., 2014a). Previous studies have suggested that spinal cord atrophy 
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begins early in the course of MS (Brex et al., 2001; Rashid et al., 2006; Biberacher et 
al., 2015). I found that UCCA at the time of CIS was associated with EDSS at follow-
up, although only with borderline significance. 
 
There have been few longitudinal studies of spinal cord atrophy in people with CIS 
and early RRMS. In a pilot study that included patients from this cohort cohort no 
change in UCCA was seen over a follow-up period of one year (Brex et al., 2001). In 
a small study of patients with early RRMS (disease duration <3 years), the rate of 
spinal cord atrophy was significantly greater than in healthy controls, however, there 
was no correlation between cord atrophy and change in disability over 3 years 
(Rashid et al., 2006). This contrasts with my findings that significantly greater spinal 
cord atrophy occurred in MS patients, and that the change in UCCA was associated 
with EDSS at follow-up. These differences might be explained by the longer duration 
of follow-up, the larger sample size or the use of a more robust method for detecting 
spinal cord atrophy (Losseff et al., 1996; Horsfield et al., 2010; Kearney et al., 2014b).  
 
Spinal cord imaging is more technically challenging than brain MRI and does require 
additional scan time. In clinical practice spinal cord MRI is not always used in the 
diagnosis and monitoring of patients with MS. Recent European and North American 
guidelines recommend spinal cord imaging in CIS patients presenting with a spinal 
cord syndrome and in patients where brain MRI is not diagnostic of MS (Rovira et al., 
2015; Traboulsee et al., 2016). Whether routine spinal cord imaging should be done 
in patients with a non-spinal CIS is controversial (Hutchinson, 2014). My findings 
suggest that spinal cord imaging may not only be helpful diagnostically (Sombekke et 
al., 2013), but may also provide significant prognostic information when counselling 
patients with a CIS and early RRMS about how their condition might progress.  
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Overall the spinal cord MRI measures explained more of the variability in physical 
disability at 5 years than the brain MRI measures. Of the brain MRI measures 
investigated, the change in T2LV from baseline to follow-up was independently 
associated with EDSS, walking speed and hand dexterity at follow-up. These findings 
are in keeping with other studies that have found that change in T2 lesion load over 
time is associated with later disability in patients with CIS and early MS (Fisniku et 
al., 2008a; Swanton et al., 2009; Di Filippo et al., 2010).   
 
Some limitations should be noted. Firstly, disability at 5 years was measured using 
tests that primarily assess walking (EDSS, TWT) and upper limb function (9HPT). 
These metrics are likely to be more heavily influenced by spinal cord disease, 
potentially explaining the stronger relationship with spinal cord than brain MRI 
measures. Secondly, measures of lesion load but not lesion location were 
investigated in the multivariable models. Infratentorial brain lesions may have greater 
functional consequences than supatentorial lesions and previous studies have found 
that infratentorial lesions are associated with the development of disability in patients 
with CIS (Minneboo et al., 2004; Tintore et al., 2010). Similarly, in the spinal cord the 
location of lesions (cervical, thoracic or lumbar) may influence the clinical symptoms 
and the resulting disability. Finally, I excluded people who presented with a spinal 
cord CIS in order to investigate the prognostic significance of early, asymptomatic 
spinal cord involvement in CIS patients. There were too few patients with clinically 
isolated myelitis in the cohort to separately investigate the influence of asymptomatic 







I found that spinal cord MRI measures were more strongly associated with physical 
disability than brain MRI measures in the first 5 years after a non-spinal CIS. These 
findings suggest that spinal cord lesions and atrophy may be important in the 
evolution of disability in early relapse-onset MS.  
 
Over the first 5 years of follow-up relatively few patients in the cohort developed 
significant disability and only four had SPMS. In the next chapter I investigate the 
prognostic significance of a number of conventional MRI measures (including spinal 
cord lesion number) and the development of disability and secondary progressive 















Early MRI predictors of long-term disability and secondary progressive 
disease course in patients with clinically isolated syndrome 
7.1  Introduction 
Natural history studies have identified demographic and clinical factors associated 
with shorter latency to the onset of SPMS and development of irreversible disability 
in relapse-onset MS. These include older age, male sex, a motor presentation, poor 
recovery from the initial attack, a shorter interval between the first and second attack 
and a higher number of relapses in the first few years after disease onset (Eriksson 
et al., 2003; Scalfari et al., 2010; Scalfari et al., 2014). These factors are associated 
with a worse prognosis in large populations of people with established relapse-onset 
MS, but have limited utility in counselling individual patients about long-term 
prognosis. 
 
In people with CIS, conventional MRI is helpful in predicting a second clinical attack 
and MS; up to 80% of CIS patients with asymptomatic T2-hyperinetnse brain lesions 
develop CDMS compared with approximately 20% of patients with a normal brain 
MRI (Fisniku et al., 2008a; Optic Neuritis Study Group, 2008; Tintore et al., 2015). 
However, the relationship between brain T2 lesion load and long-term disability is less 
robust. Previous studies with long-term follow up have only found a modest 
relationship between brain T2 lesion load at the time of presentation with CIS and 
physical disability 15 – 20 years later (Fisniku et al., 2008a; Optic Neuritis Study 
Group, 2008). The change in brain T2 lesion load, particularly in the first few years 
after disease onset, may have a stronger relationship with long-term disease course, 
albeit still limited (Fisniku et al., 2008a). There is a need for better prognostic markers 
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to help predict future disability and personalise treatment plans in people with CIS 
and early RRMS. 
 
Conventional MRI measures other than T2 lesion load, including lesion location and 
activity may be better predictors of future disability, at least in the short to medium 
term. The presence of asymptomatic infratentorial (Minneboo et al., 2004; Swanton 
et al., 2009; Tintore et al., 2010), spinal cord (Swanton et al., 2009; Arrambide et al., 
2017) and gadolinium-enhancing lesions (Swanton et al., 2009; Di Filippo et al., 2010) 
are associated with the development of disability over the first 3 – 7 years after a CIS. 
Whether these factors are important in the evolution of disability in the longer term, 
when MS-related disability is mainly determined by the onset of secondary 
progression rather than the effects of individual relapses, is uncertain (Scalfari et al., 
2014). In addition to the short duration of follow-up, previous studies have been 
limited to subgroups of CIS patients, for example acute optic neuritis (Swanton et al., 
2009); have considered the prognostic significance of individual MRI measures (e.g. 
infratentorial lesions) in isolation, rather than in combination with other potentially 
important MRI abnormalities (Minneboo et al., 2004; Tintore et al., 2010); and most 
have not included spinal cord imaging (Minneboo et al., 2004; Fisniku et al., 2008a; 
Di Filippo et al., 2010; Tintore et al., 2010; Tintore et al., 2015). In Chapter 6 I found 
that spinal cord lesions and atrophy were more strongly associated with disability 5 
years after a CIS than brain MRI abnormalities. 
 
The aim of this analysis was to identify early MRI predictors of long-term outcomes in 
relapse-onset MS. I wanted to investigate the relationship of early brain and spinal 
cord lesions plus atrophy in patients with CIS with disability and secondary 
progressive disease course in the longer term. 
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7.2  Methods 
Patients 
All patients in the CIS cohort who were followed up after approximately 15 years were 
included in this investigation. Patients who developed a condition other than MS 
during follow-up were excluded. 
 
Clinical assessment 
MS was diagnosed using the McDonald 2010 criteria (Polman et al., 2011). Disease 
course was classified as RRMS or SPMS using the Lublin and Reingold 1996 disease 
course definitions (Lublin et al., 1996). Disability was assessed using the EDSS score 
(Kurtzke, 1983). In patients who were unable to attend in person for a follow-up visit, 
I assessed clinical status and disability by telephone interview that included the 
telephone EDSS (Lechner-Scott et al., 2003). 
 
MRI acquisition and image-analysis 
MRI scans of the brain and spinal cord obtained at baseline, 1 year and 3 years were 
included in this analysis. The number of supratentorial, infratentorial and spinal cord 
T2 lesions at baseline and the number of new lesions at 1 and 3 years were analysed, 
along with the number of gadolinium-enhancing lesions (brain and spinal cord 




Figure 7.1 Representative images of patients classified as CIS, RRMS and SPMS at 15 years. MRI scans obtained at baseline (the time of 
CIS), 1 year and 3 years were analysed.  
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The NBV at baseline was measured using SIENAX and the PBVC from baseline to 1 
year and baseline to 3 years using SIENA. The UCCA was measured at baseline, 1 
year and 3 years using the active surface model. The absolute change and 
percentage change in UCCA from baseline to 1 year and baseline to 3 years was 
calculated. The methods for determining brain and spinal cord atrophy are described 
in more detail in earlier chapters.  
 
Statistical analysis 
Univariable linear regression was used to compare differences in MRI measures at 
baseline, 1 year and 3 years based on disease course at 15 years (CIS, RRMS, 
SPMS). 
 
Multivariable logistic and linear regression models were used to identify independent 
MRI predictors of SPMS disease course and disability (measured using the EDSS) at 
15 years. For each of the two outcomes three separate models were constructed 
using MRI data available from each of the three time points: 
 
i. Baseline model – predictor variables were supratentorial, infratentorial, spinal 
cord and gadolinium-enhancing lesion number (investigating both binary 
[0/1+] and categorical [0/1/2+] groupings); and NBV and UCCA as continuous 
variables.   
 
ii. 1 year model – baseline MRI predictors (again using binary and categorical 
groupings) plus the change in supratentorial, infratentorial and spinal cord 
lesion number at 1 year, the number of gadolinium-enhancing lesions at 1 
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year; and as continuous variables the PBVC from baseline to 1 year and the 
change in UCCA from baseline to 1 year. 
 
iii. 3 year model – baseline and 1 year MRI predictors (again using binary and 
categorical groupings) plus the change in supratentorial, infratentorial and 
spinal cord lesion number at 3 years, the number of gadolinium-enhancing 
lesions at 3 year; and as continuous variables the PBVC from baseline to 3 
years and the change in UCCA from baseline to 3 year. 
 
For the multivariable logistic regression of the binary outcome of SPMS at 15 years, 
models were built using manual backwards stepwise elimination of variables with 
p>0.08; to the final model each of the omitted variables was added singly, and 
retained if p<0.08.  Additionally, the following potential confounders were tested, and 
retained only if they materially affected either the MRI coefficients or their p values: 
age at onset, gender, type of CIS presentation and disease duration (time from CIS 
onset to 15 year follow-up assessment). These potential confounders all had a 
negligible impact, so were not included the final reported models. The model C-
statistic (range 0.5 [no predictive power] to 1 [perfect prediction]) was used to 
measure the performance of the models.   
 
The same process was used to build linear regression models for 15-year EDSS, but 
using the R2 statistic to measure predictive performance. Although the linear 
regression residuals showed no obvious non-normality, as a precaution the EDSS 
model inferences were checked using a non-parametric bias-corrected and 
accelerated bootstrap with 2000 replications (Carpenter and Bithell, 2000). Statistical 
significance is reported as p<0.05. 
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7.3  Results 
178 patients were recruited into the study and 166 (93%) were followed up after a 
mean of 15.1 years (range 11.2 – 19.7 years). Two patients were diagnosed with 
NMOSD during follow-up (one each with myelitis and optic neuritis) and were 
excluded, leaving 164 patients.  
 
The baseline demographic and clinical profile of the patients followed up at 15 years 
and the patients lost to follow-up is shown in Table 7.1. Among the 12 (7%) patients 
lost to follow-up, males were over-represented, but other baseline characteristics 
were similar. 
 
Table 7.1  Baseline clinical and demographic characteristics of the CIS cohort  
 
15 year follow-up+ 
(n=164) 
Lost to follow-up 
(n=12) 
Age, mean (SD) 32.2 (7.6) 33.5 (4.9) 
Female, n (%) 109 (66) 3 (25) 
Presentation, n (%)   
       Optic neuritis 134 (82) 10 (83) 
       Brainstem syndrome 19 (11.5) 2 (17) 
       Spinal cord syndrome 10 (6) 0 (0) 
       Hemispheric syndrome 1 (0.5) 0 (0) 
Baseline EDSS, median (IQR) 1 (1) 1 (1) 
Abnormal brain MRI, n (%) 125 (76) 9 (75) 
Abnormal spinal MRI, n (%) 58 (35) 2 (17) 




Disease course and disability at 15 years was assessed by telephone interview in 47 
(29%) patients. The reasons for telephone interview were patient choice (n=34), living 
overseas (n=8), severe disability (n=3) and pregnancy (n=2).  
 
Development of multiple sclerosis  
119 (73%) patients developed MS and 45 (27%) patients remained CIS. Among the 
119 patients with MS, 101 (85%) had clinically-definite or clinically-probable MS using 
the Poser criteria and 18 (15%) patients satisfied the McDonald 2010 MRI criteria for 
MS, but did not experience a second clinical attack during follow-up. The number of 
patients who developed MS was similar in patients who presented with optic neuritis 
(74%), brainstem/cerebellar (65%) and spinal cord (64%) syndromes. Disease course 
in the MS patients at 15 years was classified as RRMS in 94 (79%) patients and 
SPMS in 25 (21%) patients.  
 
34 (29%) MS patients were receiving DMT at the time of follow-up or had been 
exposed to one or more DMTs in the past, including beta interferon (n=22), glatiramer 
acetate (n=11), natalizumab (n=5), fingolimod (n=4), dimethylfumarate (n=1), 
teriflunomide (n=1) and alemtuzumab (n=1). 
 
Development of disability 
The median EDSS at follow-up was 0 (range 0 – 1) in patients who remained CIS and 
2.0 (range 0 – 10) in patients with MS. A wide range of disability encompassing all 
levels of the EDSS was seen in the patients with MS (Figure 7.2). Three patients had 




Figure 7.2         EDSS scores after 15 years in the patients who developed multiple sclerosis (n=119) 
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The median EDSS at follow-up was similar in patients with different CIS topographies: 
optic neuritis 1.5 (range 0 – 10), brainstem syndrome 1.5 (range 0 – 10) and spinal cord 
syndrome 2.5 (range 0 – 8.5). 
 
Baseline MRI findings 
The baseline brain MRI showed one or more asymptomatic T2-hyperintense lesion(s) in 
125 (76%) patients. MS developed in 111 of 125 (89%) patients with an abnormal brain 
MRI at baseline and 8 of 39 (21%) with a normal brain MRI. The median EDSS at 15 
years was 2 (range 0 – 10) in patients with an abnormal baseline brain MRI and 0 (range 
0 – 4) in patients with a normal brain MRI. 
 
The baseline spinal cord MRI showed one or more asymptomatic T2-hyperintense 
lesion(s) in 58 (35%) patients. MS developed in all 58 (100%) patients with an abnormal 
spinal cord MRI at baseline and in 62 of 106 (58%) patients with a normal spinal cord 
MRI. The median EDSS at 15 years was 2.5 (range 0 – 10) in patients with an abnormal 
baseline spinal cord MRI and 1.5 (range 0 – 9) in patients with a normal spinal cord MRI. 
 
The baseline MRI findings grouped by disease course at 15 years are shown in Table 
7.2. Compared with the patients with RRMS at follow-up, the SPMS patients showed a 
greater number of spinal cord lesions (1.60 vs 1.00, p=0.007) and a trend towards a 
higher number of gadolinium-enhancing lesions (2.72 vs 1.29, p=0.084) at baseline. 
There were no differences in the brain or spinal cord volumetric measures at baseline.  
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Table 7.2 Baseline MRI findings grouped by clinical status at 15 years. 
  
CIS at 15 years 
(n=45) 
MS at 15 years   







Supratentorial lesions, n 0.58 (1.3) 16.72 (23.0) 18.33 (19.3) 0.630 12.53 (20.3) 
Infratentorial lesions, n 0 (0) 0.98 (1.3) 2.32 (3.8) 0.133 0.94 (1.9) 
Spinal cord lesions, n 0 (0) 1 (1.8) 1.60 (1.7) 0.007 0.82 (1.6) 
GdE lesions, n 0 (0) 1.29 (3.1) 2.72 (4.9) 0.084 1.15 (3.1) 
NBV, cm3 1589 (76) 1589 (69) 1562 (84) 0.723 1585 (74) 
UCCA, mm2 77.56 (7.2) 74.64 (7.7) 76.35 (6.5) 0.678 75.77 (7.5) 
All data presented as mean (SD) 







Follow-up MRI findings 
The MRI findings at 1 year and 3 years are shown in Tables 7.3 and 7.4. 
 
At 1 year the patients who developed SPMS showed a higher number of new 
supratentorial (16.50 vs 3.92, p<0.001), infratentorial (2.30 vs 0.24, p<0.001) and spinal 
cord (0.85 vs 0.23, p=0.001) lesions compared with the patients with RRMS after 15 
years. The patients with SPMS at follow-up also had a higher number of gadolinium-
enhancing lesions at 1 year (3.70 vs 0.85, p=0.005) compared with those with RRMS.  
 
The findings at 3 years were similar: the patients with SPMS had a higher number of new 
supratentorial, infratentorial and spinal cord lesions compared with those with RRMS 
(Table 7.4). However, the number of gadolinium-enhancing lesions at 3 years was similar 
in the two groups.  
 
The rate of brain atrophy was similar at 1 and 3 years in patients with SPMS and RRMS 
at follow-up (Tables 7.3 and 7.4). A faster rate of spinal cord atrophy from baseline to 3 
years was observed in the patients who developed SPMS compared with those with 




Table 7.3 Follow-up MRI findings at 1 year grouped by clinical status at 15 years. 
  
CIS at 15 years 
(n=37) 
              MS at 15 years   







New supratentorial lesions, n 0 (0) 3.92 (5.6) 16.5 (28.1) <0.001 4.71 (12.5) 
New Infratentorial lesions, n 0 (0) 0.24 (0.7) 2.3 (3.5) <0.001 0.48 (1.6) 
New Spinal cord lesions, n 0 (0) 0.23(0.6) 0.85 (0.93) 0.001 0.26 (0.6) 
GdE lesions, n 0 (0) 0.85 (1.8) 3.70 (8.2) 0.005 1.04 (3.6) 
PBVC, % -0.11 (0.3) -0.42 (0.5) -0.46 (0.7) 0.772 -0.34 (0.5) 
Percentage UCCA change, %  -0.03 (1.14) -0.36 (2.2) -1.50 (2.8) 0.057 -0.44 (2.1) 
All data presented as mean (SD) 







Table 7.4 Follow-up MRI findings at 3 years grouped by clinical status at 15 years. 
  
CIS at 15 years 
(n=35) 
              MS at 15 years   







New supratentorial lesions, n 
New Infratentorial lesions, n 
New Spinal cord lesions, n 
GdE lesions, n 
PBVC, % 































All data presented as mean (SD) 





MRI predictors of SPMS: multivariable logistic regression analysis 
The results of the multivariable logistic regression analysis investigating early MRI 
predictors of SPMS at 15 years are presented in Table 7.5. In the baseline MRI model 
gadolinium-enhancing lesions and spinal cord lesions were independently associated 
with SPMS at 15 years (C-statistic 0.76). In patients with no gadolinium-enhancing 
lesions and no spinal cord lesions at baseline the estimated risk of SPMS at 15 years 
was 5.3% (95% CI 1.1 – 9.5%), compared with 45.5% (95% CI 24.7 – 66.4%) in those 
with at least one spinal cord lesion and two or more gadolinium-enhancing lesions.  
 
In the model incorporating baseline and follow-up MRI data over 1 year, baseline 
gadolinium-enhancing lesions remained significant and the number of new spinal 
cord and infratentorial lesions at 1 year were independently associated with SPMS 
(C-statistic 0.86). In patients with no gadolinium-enhancing lesions at baseline and 
no new spinal or infratentorial lesions after 1 year the estimated risk of SPMS after 
15 years was 3.0% (95%CI 0 – 6.2%), compared with 85.2% (95% CI 67.7 – 100%) 
in people with two or more gadolinium-enhancing lesions at baseline and new spinal 
and infratentorial lesions at 1 year. 
 
Finally, in the model incorporating all MRI data from baseline to 3 years, new spinal 
cord lesions and with borderline significance new infratentorial lesions between 
baseline and 3 years were associated with SPMS course at 15 years (C-statistic 
0.89). In patients with no new spinal or infratentorial lesions over the first 3 years after 
CIS the estimated risk of SPMS after 15 years was 0.9% (95%CI 0 – 2.7%), compared 
with 53.1% (31.7 – 74.6%) in patients with new spinal and infratentorial lesions. 
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Table 7.5 Multivariable logistic regression models investigating early MRI predictors of secondary progressive disease course after 15 years. 
 
 
 Odds ratio 95% CI p C-statistic 
Baseline (n=164) 
   Baseline GdE lesions 
      1 
      2+ 

















Baseline – 1 year (n=136) 
   Baseline GdE lesions 
      1 
      2+ 
   New spinal cord lesions 




















Baseline – 3 years (n=121) 
   New spinal cord lesions 














MRI predictors of disability: multivariable linear regression analysis 
The results of the multivariable linear regression models investigating independent 
MRI predictors of disability at follow-up are shown in Table 7.6. 
 
In the model investigating baseline MRI predictors of long-term disability, baseline 
supatentorial lesions, gadolinium-enhancing lesions and spinal cord lesions were 
independently associated with EDSS at 15 years (R2=0.31).  
 
In the 1 year model, baseline gadolinium-enhancing lesions and spinal cord lesions 
remained significant, and in the smaller group of patients with MRI follow-up at 1 year 
(n=136) the baseline NBV was also borderline significant. New supatentorial, 
infratentorial and spinal cord lesions at 1 year were also independently associated 
with disability at 15 years (R2=0.48). 
 
Finally, in the model investigating all time points over the first 3 years after CIS, 
baseline gadolinium-enhancing lesions and spinal cord lesions remained significant 
predictors of disability at 15 years, and new spinal cord lesions and the PBVC at 3 








Table 7.6 Multivariable linear regression models investigating MRI predictors of EDSS at 15 years. 
MRI measure          Coefficient 95% CI p R2 (Adjusted R2) 
Baseline (n=164)    0.31 (0.30) 
     Baseline spinal cord lesions 1.53 0.84, 2.23 <0.001  
     Baseline GdE lesions 1.32 0.58, 2.06 0.001  
     Baseline supratentorial lesions 0.96 0.20, 1.71 0.014  
 
Baseline – 1 year (n=136) 
    
0.48 (0.45) 
     Baseline spinal cord lesions 0.71 0.03, 1.38 0.040  
     Baseline GdE lesions 
     Baseline NBV  











     New infratentorial lesions 1 year 









Baseline – 3 years (n=121) 
    
0.58 (0.56) 
     Baseline spinal cord lesions 0.88 0.21, 1.54 0.011  
     Baseline GdE lesions 1.04 0.36, 1.72 0.003  
     New spinal cord lesions 3 years 
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7.4  Discussion 
I investigated early brain and spinal cord abnormalities over the first 3 years after CIS 
to identify the most robust predictors of long-term disability and secondary 
progressive disease course at 15 years. The major findings of this analysis include: 
(1) a consistent association of spinal cord lesions, both at the time of presentation 
with CIS and new spinal cord lesions over the first 3 years of follow-up, with physical 
disability and disease course after 15 years; (2) an association of asymptomatic 
gadolinium-enhancing lesions at the time of CIS with long-term disease outcomes; 
(3) a stronger association of lesional MRI measures in the earliest stages of relapse-
onset MS with later disability and secondary progression compared with measures of 
brain and spinal cord atrophy. 
 
Previous studies have suggested that lesions in clinically-eloquent sites, such as the 
brainstem, cerebellum and spinal cord, may be important predictors of later disability 
in CIS patients, at least in the short to medium term (Minneboo et al., 2004; Swanton 
et al., 2009; Tintore et al., 2010). I found that asymptomatic spinal cord lesions were 
the only baseline MRI predictor of disability after ~5 years in patients with a non-spinal 
CIS (Chapter 6). The importance of spinal cord lesions in the longer term is confirmed 
in this same cohort of patients with long-term follow-up: spinal cord lesions at baseline 
were associated with disability and the development of SPMS at 15 years. The 
importance of spinal cord lesions present at the time of CIS is highlighted in the 
models incorporating changes in MRI measures over 1 and 3 years after CIS. 
Baseline spinal cord lesions remained a significant predictor of EDSS at 15 years 
independent of changes in brain and spinal cord lesions and atrophy at 1 and 3 years. 
In addition to the spinal cord lesions seen at the time of CIS onset, the number of new 
spinal cord lesions after 1 year and 3 years was also independently associated with 
disability and SPMS at 15 years. Collectively these findings suggest that early spinal 
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cord damage is an important mechanism underlying both development of disability 
and secondary progression in early relapse-onset MS.  
 
Pathological studies have found evidence of substantial axonal loss within chronic 
spinal cord lesions in MS (Lovas et al., 2000) and this may result in more widespread 
neuroaxonal loss at distant sites due to the effects of Wallerian degeneration 
(Dziedzic et al., 2010). Neuroaxonal loss within spinal cord pathways involved in 
locomotion, sensation and sphincter function may have important functional 
consequences, ultimately resulting in physical disability. In a recent study that 
quantified cervical cord lesion load on axial images with high in-plane resolution, 
patients with SPMS had a higher spinal cord lesion load compared RRMS patients, 
even after adjusting for differences in disease duration (Kearney et al., 2015a). These 
findings support the concept that focal spinal cord damage may be one of the factors 
involved in the development of secondary progression in relapse-onset MS. 
 
Like the spinal cord, the brainstem and cerebellum contain pathways critical for 
balance and locomotion. Two previous studies found that infratentorial lesions seen 
at the time of presentation with CIS are associated with physical disability in the short 
to medium term (Minneboo et al., 2004; Tintore et al., 2010). Infratentorial lesions 
seen at baseline were not independently associated with long-term outcomes, 
possibly because the effect is eclipsed by the impact of spinal cord lesions. However, 
accrual of new infratentorial lesions over time was associated with disability and 
secondary progressive disease course at 15 years, confirming the prognostic 




Gadolinium-enhancing lesions at the time of presentation with CIS were also 
associated with disability and the development of secondary progressive course after 
15 years. Importantly, in the models examining MRI predictors of EDSS at follow-up, 
the association of gadolinium-enhancing lesions remained even after including 
changes in MRI measures at 1 and 3 years. Gadolinium-enhancing lesions reflect 
areas of acute inflammatory activity associated with breakdown of the blood-brain 
barrier (Filippi et al., 2012). A meta-analysis of observational studies and patients 
enrolled in the placebo arms of clinical trials found that gadolinium-enhancing lesions 
are predictive of relapse rates in the short-term (Kappos et al., 1999). The association 
of early gadolinium-enhancing lesions with long-term disability is consistent with 
findings from natural history studies showing that the number of early relapses in the 
first few years after disease onset is associated with long-term disability and 
development of SPMS in relapse-onset MS (Confavreux et al., 2003; Scalfari et al., 
2014). 
 
In this cohort of patients followed prospectively from CIS onset, lesional MRI 
measures, particularly lesion location (spinal cord, infratentorial) and lesion activity 
(i.e. gadolinium-enhancement), were more consistently associated with disability and 
secondary progressive disease course at 15 years than early brain or spinal cord 
atrophy. A similar rate of whole brain atrophy was observed over the first 3 years after 
CIS onset in patients who developed MS irrespective of disease course at 15 years. 
This is consistent with previous studies showing that brain atrophy begins early in the 
course of MS and progresses at a similar rate throughout the course of the illness, 
irrespective of disease phenotype or disease duration (De Stefano et al., 2010). The 
PBVC from baseline to 3 years, however, was independently associated with 
disability after 15 years, although not with the development of SPMS. Significant 
spinal cord atrophy was also observed over the first 3 years after CIS, with a faster 
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rate of spinal cord atrophy in patients with SPMS at 15 years compared with those 
with RRMS. Early changes in spinal cord atrophy (up to 3 years) were not 
independently associated with outcomes after 15 years, at least when considered in 
conjunction with other MRI measures. This contrasts with the findings presented in 
Chapter 6 that change in UCCA was associated with physical disability, although in 
that analysis change in UCCA over a longer period (~5 years) was investigated rather 
than over 1 and 3 years in these models.  
 
A wide range of disability was observed at 15 years reflecting the variable prognosis 
of relapse-onset MS. Disability was overall low at 15 years: only 1 in 4 patients had 
an EDSS of 3 or more at follow-up and only 1 in 7 developed SPMS. This contrasts 
with the much worse prognosis reported in natural history studies done in the 1970s 
and 1980s (Confavreux et al., 2003; Tremlett et al., 2006; Scalfari et al., 2010; Scalfari 
et al., 2014). For example, in the London-Ontario cohort, half of patients required 
unilateral assistance to walk 15 years after disease onset (Scalfari et al., 2014). There 
are a number of possible explanations for the differences in the rate of disability 
progression. Firstly, I studied a group of people who were followed prospectively from 
disease onset at the time of presentation with a CIS. The patients were followed up 
irrespective of disease status and not through a hospital-based MS clinic, potentially 
biased towards more severely affected patients. Secondly, patients with optic neuritis 
are over-represented in this cohort. Optic neuritis usually accounts for 30-40% of 
people with CIS, compared with 80% in the cohort that I studied (Tintore et al., 2015). 
Some studies have suggested that optic neuritis may be associated with a better 
prognosis compared with other CIS presentations (Eriksson et al., 2003; Tintore et 
al., 2005; Tintore et al., 2015). However, more than three quarters of the patients with 
optic neuritis in this cohort had an abnormal baseline MRI scan indicating a group at 
high-risk for the development of MS and future disability. Thirdly, during the course of 
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the study DMT for RRMS became available in the United Kingdom. These treatments 
reduce relapse rates and may reduce progression of disability over time, improving 
the prognosis of people with MS. Less than a third of patients in the study received 
DMT, and most patients who were treated received first-line injectable therapies (beta 
interferon or glatiramer acetate) rather than the more potent oral or monoclonal 
antibody therapies. Like in Chapter 6 no adjustment was made for DMT in the 
multivariable models because criteria for treating patients in the United Kingdom at 
the time of the study required two attacks in two years so more severely affected 
patients received treatment leading to reverse causality. Finally, the diagnosis of MS 
was made using the McDonald criteria and includes people who in the past would 
have been labelled as having CIS rather than MS. The so-called Will-Rogers 
phenomenon describes the apparent improvement in prognosis with changes to 
diagnostic criteria (Sormani et al., 2008), as discussed in Chapter 4. However, the 
rate of SPMS was still low at 15 years in patients in whom the diagnosis of MS was 
clinically-definite (<25%). My findings of a more favourable long-term outcome than 
would be expected from natural history studies is consistent with other contemporary 
observational cohort studies (Fisniku et al., 2008a; Kerbrat et al., 2015; Tintore et al., 
2015; Cree et al., 2016).  
 
The strengths of this study include the prospective design, the longitudinal MRI 
acquisition (including both brain and spinal cord), the uniquely long follow-up duration 
and high rate of follow-up after 15 years. Some limitations also need to be noted. 
Firstly, the two outcome measures used, the EDSS and secondary progression, are 
both heavily weighted towards ambulatory disability. Cognitive impairment, fatigue 
and affective disorders commonly occur in people with MS even in the absence of 
significant physical disability (Amato et al., 2006). Cognitive testing was done in 
patients who retuned in person for the 15 year follow-up and analyses are ongoing. 
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Secondly, clinical status after 15 years was assessed in a significant number of 
patients by telephone interview because not all patients were able to return for a 
follow-up visit to be examined in person. The use of telephone EDSS has been 
validated previously for use in clinical trials (Lechner-Scott et al., 2003) and has also 
been used in previous longitudinal clinical-MRI studies (Fisniku et al., 2008a). Thirdly, 
as discussed earlier, the CIS cohort studied is mainly comprised of people with optic 
neuritis. Validation of the predictive models in other CIS cohorts, particularly cohorts 
with a more representative number of patients with brainstem/cerebellar and spinal 
cord syndromes would be of interest. Finally, although the mean duration of follow-up 
was over 15 years the course of MS often unfolds over much longer and the number 
of people developing secondary progression and worsening disability in this cohort is 
likely to increase with time (Skoog et al., 2012; Scalfari et al., 2014). However, the 
findings do identify early MRI predictors associated with a more aggressive course 
over the first 15 years after disease onset and may potentially help inform treatment 
decisions in patients with CIS and early relapse-onset MS. 
 
7.5 Conclusions 
MRI abnormalities seen around the time of presentation with CIS and over the first 
few years after disease onset may be helpful in predicting the development of long-
term disability and secondary progression in early relapse-onset MS. Early changes 
in spinal cord and infratentorial lesion load plus the number of gadolinium-enhancing 
lesions seen around the time of presentation with CIS displayed the most consistent 
association with disability and secondary progressive disease course at 15 years. 
These findings suggest that the accrual of focal lesions in clinically-eloquent sites and 
the extent of early inflammatory disease activity may be important mechanisms that 
contribute to long-term disability and secondary progression in relapse-onset MS.  
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In keeping with previous studies a wide range of clinical outcomes was observed in 
this cohort of patients followed for approximately 15 years after disease onset. The 
underlying biological factors responsible for disease course heterogeneity in MS 
remain poorly understood. In Chapter 8 I investigate how HLA DRB1:15*01, the most 





















HLA-DRB1*1501 is associated with the development of disability and MRI-




Over 100 genetic loci have been identified that influence susceptibility to MS, many 
of which are implicated in immune system processes relevant to the pathogenesis of 
MS (International Multiple Sclerosis Genetics Consortium et al., 2013) The extended 
HLA-DRB1*1501 haplotype is the most important genetic risk factor for MS 
(Moutsianas et al., 2015). In Northern European populations up to half of people with 
MS carry at least one HLA-DRB1*1501 allele (compared with 10-20% of healthy 
controls), and HLA-DRB1*1501 positivity is associated with an approximately 
threefold increase in the risk of developing MS (Moutsianas et al., 2015).  
 
The course of MS is highly variable with significant inter-individual variation in disease 
onset, relapse rates, MRI abnormalities and long-term disability. Genetic factors may 
be one of the mechanisms responsible for these differences (Hensiek et al., 2007). 
The HLA-DRB1*1501 allele has consistently been associated with younger age at 
disease onset (Masterman et al., 2000; Hensiek et al., 2002; International Multiple 
Sclerosis Genetics Consortium et al., 2011; Moutsianas et al., 2015), with each copy 
of the HLA-DRB1*1501 allele decreasing age at onset by approximately 11 months 
(International Multiple Sclerosis Genetics Consortium et al., 2011). However, a 
number of studies have found no relationship between HLA-DRB1*1501 and disease 
course (relapse or progressive-onset MS) or disease severity measured using the 
EDSS or the Multiple Sclerosis Severity Score (MSSS) (Masterman et al., 2000; 
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Hensiek et al., 2002; International Multiple Sclerosis Genetics Consortium et al., 
2011; Moutsianas et al., 2015).  
 
A number of studies have investigated the influence of the HLA-DRB1*1501 allele on 
MRI-detected brain and spinal cord pathology in patients with CIS, relapse-onset MS 
and PPMS, with inconsistent findings (Hauser et al., 2000b; Zivadinov et al., 2003; 
Zivadinov et al., 2007; Okuda et al., 2009; Sombekke et al., 2009; Horakova et al., 
2011; Van der Walt et al., 2011; Tur et al., 2014; Isobe et al., 2016; Yaldizli et al., 
2016b). Some studies have found more focal T2-hyperintense lesions (Hauser et al., 
2000b; Okuda et al., 2009; Sombekke et al., 2009; Horakova et al., 2011; Tur et al., 
2014), brain atrophy (Zivadinov et al., 2007; Okuda et al., 2009; Isobe et al., 2016), 
and microstructural tissue damage (Okuda et al., 2009; Tur et al., 2014) in HLA-
DRB1*1501-positive compared with HLA-DRB1*1501-negative patients, but others 
have not (Zivadinov et al., 2003; Van der Walt et al., 2011; Yaldizli et al., 2016b). 
Previous studies have largely been cross-sectional in nature and included 
heterogeneous cohorts of MS patients with varying disease courses and disease 
duration, potentially explaining these conflicting findings.  
 
The aim of this work was to investigate the influence of HLA-DRB1*1501 on the 
development of disability and MRI measures of inflammation and neurodegeneration. 
I wanted to investigate whether HLA-DRB1*1501 may be one of the factors 
responsible for disease course heterogeneity in a well-characterised, prospective 
recruited CIS cohort who were deeply phenotyped with MRI over the first 15 years 







I included patients from the CIS cohort in this analysis who provided a blood sample 
that was able to be used for genotyping (n=107) as part of the 15 year follow-up. 




MS was diagnosed using the McDonald 2010 criteria (Polman et al., 2011) and 
disease course was classified using the Lublin and Reingold 1996 criteria (Lublin et 
al., 1996). Disability was assessed at each time point using the EDSS (Kurtzke, 1983) 
and at the 15 year follow-up using the TWT, 9HPT, PASAT (Cutter et al., 1999) and 
the SDMT (Smith, 1982). 
 
MRI acquisition and image-analysis 
The patients underwent PD/T2-weighted and post-contrast T1-weighted MRI scans 
of the brain and whole spinal cord at baseline, 1, 3 and 5 years on the same 1.5T 
Signa scanner (General Electric, Wisconsin, USA). There was a major hardware and 
software upgrade during the study period that was considered in statistical analyses 
(see below). At 15 years the patients underwent MRI brain only with PD/T2-weighted 
and T1-weighted scans without contrast. The 15 year MRI scans were all done on the 
same 3T Achieva TX scanner (Philips Healthcare, Best, The Netherlands). Technical 




MRI measures analysed for this investigation included: brain T2LV, brain T1LV, brain 
gadolinium-enhancing lesion number, brain atrophy (NBV at baseline and the PBVC 
over time), spinal cord lesion number and the UCCA. 
 
Genotyping 
Genomic DNA was extracted from whole blood using standard techniques. Sanger 
sequencing was used to identify the rs3135388 single nucleotide polymorphism 
(SNP). The A allele of rs3135388 is strongly associated with HLA-DRB1*1501 and 
patients heterozygous or homozygous for the A allele are inferred to be HLA-
DRB1*1501-positive (Benesova et al., 2013). All genotyping was done by Dr Andreea 
Manole, Neurogeneticist, who was blinded to the clinical status and MRI findings. 
 
Statistical analysis 
Mixed-effects models were used to assess differences at baseline and over time in 
the MRI measures between HLA-DRB1*1501-positive and HLA-DRB1*1501-
negative patients, with the MRI measure of interest as the dependent variable. Linear 
mixed-effects models were used for all MRI measures except for gadolinium-
enhancing lesion number, for which a Poisson mixed-effects model was used. The 
independent variables included time (in years), genotype (HLA-DRB1*1501-positive 
or negative) and an interaction term ‘time X genotype’. All models were adjusted for 
age, sex, scanner upgrade and scanner type (1.5 T or 3 T).  
 
The mixed-effects models were used to examine differences at baseline and over 
time in the MRI measures between HLA-DRB1*1501-positive and HLA-DRB1*1501-
negative patients. When the p value for the regression coefficient for genotype was 
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<0.05, it was assumed that differences in MRI measures at baseline between the 
HLA-DRB1*1501-positive and HLA-DRB1*1501-negative groups were significantly 
different. When the p value for the regression coefficient of the interaction term ‘time 
X genotype’ was <0.05, it was assumed that there were significant differences in the 
change in MRI measures over time in the HLA-DRB1*1501-positive and HLA-
DRB1*1501-negative groups. Bootstrapping with 1000 replicates was applied to 
confirm confidence intervals and p values in the final models. 
 
8.3 Results 
The cohort of 107 CIS patients comprised 89 (83%) with optic neuritis, 12 (11%) with 
a brainstem/cerebellar syndrome, 5 (5%) with partial myelitis and 1 (1%) patient with 
a hemispheric syndrome.  
 
Fifty-two (49%) patients were HLA-DRB1*1501-positive (49 [94%] heterozygous, 3 
[6%] homozygous) and 55 (51%) were HLA-DRB1*1501-negative. The baseline 
demographic and clinical profile of the cohort grouped by HLA-DRB1*1501 status is 
shown in Table 9.1. The HLA-DRB1*1501-positive patients were younger than the 
HLA-DRB1*1501-negative patients (mean age 31.1 vs 34.4 years, p=0.036) at the 







Table 8.1 Baseline demographic and clinical characteristics of the genotyped 









Age, years 31.1 (7.0) 34.4 (7.8) 0.036 
Female, n (%) 36 (65) 40 (73) 0.535 
Optic neuritis, n (%) 45 (87) 44 (80) 0.439 
White ethnicity, n (%) 44 (85) 48 (87) 0.692 
Baseline EDSS, median (IQR) 1 (0.63) 1 (0.5) 0.306 
 
Development of multiple sclerosis 
Figure 8.1 shows the clinical course at 15 years grouped by HLA-DRB1*1501 status. 
MS developed in 47/52 (90%) HLA-DRB1*1501-positive patients and 41/55 (75%) 
HLA-DRB1*1501-negative patients (odds ratio=3.21, 95%CI 1.07 – 9.68, p=0.032). 
SPMS developed in 11/52 (21%) HLA-DRB1*1501-positive patients and 7/55 (13%) 
HLA-DRB1*1501-negative patients (odds ratio=1.84, 95%CI 0.65 – 5.18, p=0.248). 
 
The mean time to a second clinical attack was 18.7 months in HLA-DRB1*1501-
positive patients and 24.2 months in HLA-DRB1*1501-negative patients, but this was 











 Figure 8.1 Clinical course at 15 years grouped by HLA-DRB1*1501 status.  
185 
 
Development of disability 
Disability was low in both groups after 15 years; the median EDSS was 2 (range 0 – 
10) in the HLA-DRB1*1501-positive group and 1.5 (range 0 – 10) in the HLA-
DRB1*1501-negative group. Figure 8.2 shows the rate of change over time in the 
EDSS in HLA-DRB1*1501-positive and negative patients. The HLA-DRB1*1501-
positive patients showed faster progression of disability compared with the HLA-
DRB1*1501-negative patients (annualised change in EDSS 0.14/year vs 0.08/year, 
p<0.025).  
 
Figure 8.2 Change in EDSS over time grouped by HLA-DRB1*1501 status. 
 
At 15 years the HLA-DRB1*1501-postive patients had slower walking speed (mean 
0.17 vs 0.20 feet/second, p=0.025) and worse performance on the PASAT (mean Z 
score -0.73 vs -0.23, p=0.050) and the SDMT (mean Z score -1.01 vs -0.32, p=0.039) 
compared with HLA-DRB1*1501-negative patients.  
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Baseline MRI findings 
Baseline MRI findings grouped by HLA-DRB1*1501 status are shown in Table 8.2. 
The HLA-DRB1*1501 -positive patients had a higher T2LV (mean 2.50 ml vs 1.14 ml, 
p<0.01) at baseline and a greater number of GdE lesions (mean 1.90 vs 0.51, 
p<0.001) compared with the HLA-DRB1*1501-negative patients. These differences 
remained even after excluding patients who remained CIS after 15 years. 
 
The T1LV, number of spinal cord lesions, NBV and UCCA were similar in both groups 
at baseline. 
 
Longitudinal changes in MRI measures: All patients 
The longitudinal changes in MRI measures in the HLA-DRB1*1501-positive and HLA-
DRB1*1501-negative patients is shown in Table 8.3. 
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Table 8.2  Baseline MRI findings grouped by HLA-DRB1*1501 status in the whole cohort and the subgroup of patients who developed MS.  

















T2LV, ml 2.50 (4.31) 1.15 (2.17) <0.01 2.73 (4.47) 1.52 (2.40) <0.01 
T1LV, ml 0.29 (0.71) 0.12 (0.47) NS 0.32 (0.75) 0.16 (0.54) NS 
GdE lesion number, n 1.90 (3.76) 0.51 (1.49) <0.001 2.11 (3.91) 0.68 (1.69) 0.016 
NBV, cm3 1579 (69) 1581 (74) 0.640 1580 (70) 1578 (76) 0.662 
SC lesion number, n 0.98 (1.41) 0.89 (1.84) NS 1.09 (1.44) 1.20 (2.17) NS 
UCCA, mm2 75.56 (7.97) 75.17 (7.41) NS 75.55 (8.10) 74.28 (6.79) NS 
 
† Approximate p values obtained from bootstrap analysis for all variables except gadolinium-enhancing lesion number and NBV which were 
examined using univariable linear regression.  











 Rate of change (95% CI) p† Rate of change (95% CI) p† 
T2LV, ml 0.79 (0.57, 1.07) < 0.01 0.34 (0.23, 0.68) <0.01 < 0.025 
T1LV, ml 0.23 (0.18, 0.30) < 0.01 0.11 (0.08, 0.16) <0.01 < 0.01 
PBVC, % -0.43 (-0.50, -0.36) <0.01 -0.31 (-0.39, -0.25) <0.01 <0.05 
SC lesion number, n 0.27 (0.19, 0.39) <0.01 0.19 (0.11, 0.32) <0.01 NS 
UCCA, mm2 -0.45 (-0.58, -0.25) <0.01 -0.23 (-0.43, -0.09) <0.01 <0.05 
 
† Approximate p values obtained from bootstrap analysis.  





Brain MRI measures 
The T2LV increased in both groups over time (Figure 8.3), but the annualised change 
in T2LV was significantly higher in the HLA-DRB1*1501-positive patients compared 
with the HLA-DRB1*1501-negative patients (adjusted difference 0.45 ml/year, 95%CI 
0.11 to 0.71, p<0.025).  
 
The T1LV also increased in both groups over time (Figure 8.3), but the annualised 
change in T1LV was significantly higher in HLA-DRB1*1501-positive patients 
compared with the HLA-DRB1*1501-negative patients (adjusted difference 0.13 























Figure 8.3 Change in brain lesion load over time in HLA-DRB1*1501-positive and HLA-DRB1*1501-negative patients. 
Brain lesion load increased in both groups over time, however, the rate of increase in T2LV and T1LV was significantly faster in the HLA-





Figure 8.4 shows the change in GdE lesion number over time by HLA-DRB1*1501 
status over the first ~5 years of follow-up (gadolinium was not given at the 15 year 
follow-up). In the Poisson model the HLA-DRB1*1501-positive patients had a higher 
number of GdE at all time points compared with those who were HLA-DRB1*1501-
negative (incident rate ratio [IRR] = 4.45, 95%CI 1.82 to 10.91, p=0.001).  
 
 
Figure 8.4 Change in gadolinium-enhancing lesion number over time in HLA-
DRB1*1501-positive and HLA-DRB1*1501-negative patients 
 
Both the HLA-DRB1*1501-positive and HLA-DRB1*1501-negative patients had 
evidence of brain atrophy over time (Figure 8.5) but the annualised PBVC measured 
using SIENA was significantly greater in HLA-DRB1*1501-positive compared with 
HLA-DRB1*1501-negative patients (adjusted difference -0.12%/year, 95%CI -0.19 to 




Figure 8.5 PBVC over time in HLA-DRB1*1501-positive and HLA-DRB1*1501-
negative patients. 
 
Given the observed differences in T2 lesion load in HLA-DRB1*1501-positive and 
HLA-DRB1*1501-negative patients the brain atrophy models were repeated after 
adjusting for T2LV. The results were similar: the annualised PBVC was signif icantly 
greater in the HLA-DRB1*1501-positive compared with the HLA-DRB1*1501-
negative patients (adjusted difference -0.12%/year, 95%CI -0.20 to -0.02, p<0.05) 
 
Spinal cord MRI measures 
The number of spinal cord lesions increased over time in both the HLA-DRB1*1501-
positive and HLA-DRB1*1501-negative patients over the first ~5 years of follow-up 




number over time in the HLA-DRB1*1501-positive patients, but this was not 
significant (adjusted difference 0.07 ml/year, 95%CI -0.32 to 0.38, p>0.05).  
 
Although the UCCA was similar between the two groups at baseline, the HLA-
DRB1*1501-positive group had evidence of greater spinal cord atrophy compared 
with HLA-DRB1*1501-negative patients (adjusted difference -0.22 mm2/year, 95%CI 



















Spinal cord lesions Spinal cord atrophy 
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Longitudinal changes in MRI measures: MS patients only 
Patients who remained CIS were over-represented in the HLA-DRB1*1501-negative 
group. All analyses were repeated after excluding patients who remained CIS after 
15 years (Table 8.4).  
 
In the subgroup of patients with MS at 15 years the findings were similar to the whole 
study cohort. The HLA-DRB1*1501-postive MS patients had a greater annualised 
change in T2LV (adjusted difference 0.52 ml/year, 95%CI 0.24 to 0.70, p<0.01) and 
T1LV (adjusted difference 0.17 ml/year, 95%CI 0.11 to 0.24, p<0.01) compared with 
the HLA-DRB1*1501-negative patients. The HLA-DRB1*1501-positive MS patients 
also had a higher number of GdE lesions at each time point (IRR = 3.20, 95%CI 1.36 
to 7.50, p=0.007).  
 
The results of the brain and spinal cord atrophy were also similar in the subgroup of 
patients with MS after 15 years. The HLA-DRB1*1501-positive MS patients had a 
greater annualised change in PBVC (adjusted difference -0.14%/year, 95%CI -0.26 
to -0.11, p<0.01) and UCCA (adjusted difference -0.19 mm2/year, 95%CI -0.34 to -
0.13, p<0.05) compared with the HLA-DRB1*1501-negative MS patients. 
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 Rate of change (95% CI) p† Rate of change (95% CI) p† 
T2LV, ml 0.93 (0.67, 1.18) <0.01 0.41 (0.30, 0.59) <0.01 <0.01 
T1LV, ml 0.20 (0.14, 0.28) <0.01 0.11 (0.08, 0.16) <0.05 <0.01 
PBVC, % -0.46 (-0.53, -0.39) <0.01 -0.29 (-0.41, -0.19) <0.01 <0.01 
SC lesion number, n 0.30 (0.20, 0.43) <0.01 0.26 (0.15, 0.43) <0.01 NS 
UCCA, mm2 -0.49 (-0.65, -0.26) <0.01 -0.30 (-0.54, -0.13) <0.01 <0.05 
 
† Approximate p values obtained from bootstrap analysis.  







The extent to which genetic factors contribute to disease course heterogeneity in MS 
is unresolved. In this prospective, longitudinal study of CIS patients I found evidence 
that HLA-DRB1*1501 allele may influence disease course, including (1) an earlier 
age at disease onset; (2) an increased risk of conversion to MS; (3) an increased rate 
of disability progression over time, measured using the EDSS, and worse cognitive 
performance at 15 years; (4) a higher brain T2 lesion load at the time of presentation 
with CIS and a faster increase in T2LV over time; (5) a higher number of gadolinium-
enhancing lesions at all time points over the first ~5 years of follow-up; and (6) 
evidence of a faster rate of brain and spinal cord atrophy, even after adjusting for 
differences in brain T2 lesion load.   
 
I found that brain T2 lesion load was higher in HLA-DRB1*1501-positive compared 
with HLA-DRB1*1501-negative patients at the time of CIS. Although brain T2LV 
increased in both groups over time, the rate of increase was faster in in HLA-
DRB1*1501-positive than in HLA-DRB1*1501-negative patients. In keeping with 
these findings, brain gadolinium-enhancing lesion number was also higher in the 
HLA-DRB1*1501-positive group at the time of presentation and at all subsequent 
follow-up time points. Importantly, these differences were maintained after excluding 
people who remained CIS after 15 years, suggesting that the observed differences 
were not simply due to an over-representation of CIS patients with a monophasic 
disease course in the HLA-DRB1*1501-negative group. 
 
Conventional MRI is highly sensitive to the detection of focal inflammatory pathology 
in MS (Filippi et al., 2012). T2-hyperinetnse lesions reflect areas of focal 
demyelination, astrogliosis and axonal loss, with contrast-enhancement on T1-
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weighted images indicating the presence of blood-brain barrier dysfunction in acute 
demyelinating lesions (Filippi et al., 2012). HLA-DRB1*1501 and other class II human 
leukocyte antigen alleles are involved in immune processes such as antigen 
presentation and T cell activation that could plausibly influence inflammatory disease 
activity in MS. The finding of a more inflammatory disease phenotype in HLA-
DRB1*1501-positive patients is supported by other radiological, immunological and 
pathological studies. Previous MRI studies in patients with CIS (Hauser et al., 2000b; 
Horakova et al., 2011), RRMS (Okuda et al., 2009) and PPMS (Tur et al., 2014) have 
reported a greater brain T2 lesion load in HLA-DRB1*1501-positive compared with 
HLA-DRB1*1501-negative patients when assessed cross-sectionally. A single 
previous longitudinal study found a greater change in brain T2LV in HLA-DRB1*1501-
positive compared with HLA-DRB1*1501-negative patients with PPMS over a follow-
up period of 5 years, in keeping with the findings presented here in patients with CIS 
and early RRMS (Tur et al., 2014). A number of studies have found an association 
between HLA-DRB1*1501 and cerebrospinal fluid IgG oligoclonal bands (Masterman 
et al., 2000; Mero et al., 2013) and this has been confirmed in a recent large study 
conducted by the International MS Genetics Consortium (Goris et al., 2015). Finally, 
a recent post-mortem study found that HLA-DRB1*1501 carriage was associated with 
a greater extent of demyelination within focal spinal cord lesions and a greater 
inflammation in brain lesions and in normal-appearing tissues (DeLuca et al., 2013; 
Yates et al., 2015).   
 
Although the NBV was similar in HLA-DRB1*1501-positive and negative patients at 
baseline I found that the HLA-DRB1*1501-positive patients had a faster rate of whole 
brain atrophy over the first 15 years after CIS. A faster rate of spinal cord atrophy, 
measured as change in the UCCA, was also observed in HLA-DRB1*1501-positive 
group over the first ~5 years of follow-up. Previous MRI studies have found evidence 
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of greater whole brain atrophy (Okuda et al., 2009) and subcortical grey matter 
atrophy (Isobe et al., 2016) in HLA-DRB1*1501-positive compared with HLA-
DRB1*1501-negative patients, plus evidence of more microstructural tissue damage 
assessed using 1H magnetic resonance spectroscopy and MTI in normal-appearing 
tissues (Okuda et al., 2009; Tur et al., 2014).  
 
It is uncertain whether the observed differences in brain atrophy and microstructural 
tissue damage in the HLA-DRB1*1501-positive group is due to a more inflammatory 
disease phenotype or due to an independent effect on neurodegeneration. Focal 
demyelinating lesions result in significant neuroaxonal loss (Trapp et al., 1998) and 
early changes in brain T2 lesion load on MRI are associated with the development of 
later brain atrophy in MS (Chard et al., 2003). After adjusting for brain T2 lesion load, 
I found that differences in whole brain and spinal cord atrophy between the HLA-
DRB1*1501-positive and negative were maintained. However, conventional MRI is 
insensitive to the detection of diffuse inflammation within normal-appearing tissues 
and the meninges that may be relevant to disability progression and tissue damage 
in MS (Kutzelnigg et al., 2005; Magliozzi et al., 2007; Magliozzi et al., 2010). A 
previous post-mortem study has suggested a greater extent of diffuse parenchymal 
and meningeal inflammation in patients who carry the HLA-DRB1*1501 allele 
(DeLuca et al., 2013) that may partly contribute to the faster rate of brain and spinal 
cord atrophy observed. 
 
In contrast to brain MRI findings, I found no significant association of HLA-DRB1*1501 
status with spinal cord lesion number, although the number of new spinal cord lesions 
was overall higher in HLA-DRB1*1501-positive compared with HLA-DRB1*1501-
negative patients. This contrasts with two previous MRI studies that reported greater 
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spinal cord involvement in HLA-DRB1*1501-positive compared with HLA-
DRB1*1501-negative MS patients with more focal and diffuse spinal cord lesions 
(Sombekke et al., 2009; Qiu et al., 2011). I counted spinal cord lesion number using 
sagittal T2-weighted scans only, which is known to under-estimate the number of cord 
lesions (Kearney et al., 2015b), and the presence of diffuse spinal cord lesions was 
not recorded, although these are uncommon in CIS and early RRMS (Bot et al., 
2004a). In a previous post-mortem study the number of spinal cord lesions was similar 
in HLA-DRB1*1501-positive and negative patients, however, the extent of lesions 
measured by the area of demyelinating plaques was significantly greater in patients 
who carried the HLA-DRB1*1501 allele (DeLuca et al., 2013). 
 
I found that HLA-DRB1*1501 is a risk factor for conversion to MS in patients with CIS, 
probably reflecting the higher proportion of patients in the HLA-DRB1*1501 group 
with asymptomatic T2 brain lesions at presentation (Kelly et al., 1993). Although there 
was a trend towards a shorter time to a second clinical attack in HLA-DRB1*1501-
positive compared with HLA-DRB1*1501-negative patients, this was not statistically 
significant. In keeping with previous retrospective studies I also found that HLA-
DRB1*1501 is associated with a younger age at disease onset (Masterman et al., 
2000; Hensiek et al., 2002; International Multiple Sclerosis Genetics Consortium et 
al., 2011). How HLA-DRB1*1501 might influence age of onset in MS is uncertain. Age 
is strongly linked to inflammatory disease activity in MS; relapse rates and MRI 
measures of disease activity are greater in children than adults with MS (Gorman et 
al., 2009) and relapse rates in adults are more strongly linked to age than disease 
duration (Kalincik et al., 2013; Scalfari et al., 2016). One possibility is that more 
inflammatory disease activity in HLA-DRB1*1501-postive patients might result in a 
shorter latency to disease onset, and this is supported by the finding of more 
inflammatory MRI phenotype in the HLA-DRB1*1501-positive patients in this study. 
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Other than age at disease onset, previous studies have not found an association of 
HLA-DRB1*1501 with disease course, at least when assessed cross-sectionally in 
patients with established MS (Masterman et al., 2000; Hensiek et al., 2002; 
International Multiple Sclerosis Genetics Consortium et al., 2011; Van der Walt et al., 
2011; International Multiple Sclerosis Genetics Consortium et al., 2013; Moutsianas 
et al., 2015). In contrast to previous studies I found evidence that HLA-DRB1*1501 
was associated with a faster rate of disability progression over the 15 year follow-up 
period measured using EDSS. At 15 years the HLA-DRB1*1501-positive patients also 
had slower walking speed and worse performance in tests of information processing 
speed compared with the HLA-DRB1*1501-negative group. 
 
The main limitation of this study is the small sample size. A number of much larger 
studies have not consistently found an association between HLA-DRB1*1501 status 
and MS phenotype, other than age at disease onset and presence of CSF oligoclonal 
bands (International Multiple Sclerosis Genetics Consortium et al., 2011; International 
Multiple Sclerosis Genetics Consortium et al., 2013; Moutsianas et al., 2015). In 
contrast to most previous studies I studied a homogeneous cohort of patients, all 
followed prospectively from the time of presentation with CIS. The patients were 
deeply phenotyped with MRI (in addition to clinical assessments) including MRI 
measures of inflammation and neurodegeneration. Importantly, the patients were 
studied longitudinally over the first 15 years after CIS, unlike previous MRI studies 
that have largely been cross-sectional in nature (Hauser et al., 2000b; Zivadinov et 
al., 2003; Okuda et al., 2009; Sombekke et al., 2009; Van der Walt et al., 2011; Yaldizli 
et al., 2016b). The findings are similar to a previous longitudinal study of patients with 
early PPMS (disease duration < 5 years) who had several MRI scans over a follow-
up period of 5 years (Tur et al., 2014). In that study HLA-DRB1*1501-positive PPMS 
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patients had a greater T2 lesion load at each time point and faster accumulation of 
tissue injury in grey matter and NAWM measured using MTR.  
 
A further possible limitation is the over-representation of patients with optic neuritis in 
this cohort. In some studies patients with optic neuritis have been found to have a 
more favourable course than patients with brainstem and spinal cord syndromes 
(Tintore et al., 2005). However, the frequency of HLA-DRB1*1501 positivity is similar 
in patients with optic neuritis and other CIS presentations (Kelly et al., 1993; Horakova 
et al., 2011) and the high proportion of patients with optic neuritis in our cohort is 
unlikely to account for the observed differences between HLA-DRB1*1501-positive 
and negative patients. 
 
8.5 Conclusions 
These findings provide evidence that HLA-DRB1*1501 influences the rate of disability 
progression, the accumulation of new brain lesions and brain and spinal cord atrophy. 
HLA-DRB1*1501 may be one of the mechanisms underlying disease course 
heterogeneity in patients with relapse-onset MS.    
 
In the next chapter I investigate energy failure, another possible mechanism for 
long-term disability and disease progression in MS using sodium MRI, a novel 







Grey matter sodium accumulation is associated with long-term disability and 
cognitive impairment in relapse-onset multiple sclerosis 
 
9.1 Introduction 
Energy failure is thought to be central to the pathophysiology of MS and may provide 
a link between demyelination and neurodegeneration (Lassmann et al., 2012), the 
two pathological hallmarks of MS. Following inflammatory demyelination, 
compensatory electrophysiological changes occur in demyelinated axons in order to 
preserve neuroaxonal function, at least in the short term. There is up-regulation of 
sodium channels to maintain conduction with redistribution of sodium channels 
across the axolemma. The high energy requirements of the Na+/K+-ATPase pump, 
potentially compounded by primary mitochondrial dysfunction in MS (Lassmann et 
al., 2012), may overwhelm neuronal ATP production resulting in failure of the Na+/K+-
ATPase pump and intracellular sodium accumulation. Energy failure may give rise to 
neuroaxonal dysfunction and ultimately cell death, and is thought to be an important 
mechanism contributing to disability and disease progression in MS (Lassmann et al., 
2012). 
 
Sodium (23Na) MRI is a novel imaging technique able to quantify tissue sodium 
concentrations in vivo, providing metabolic rather than structural information in 
tissues. 23Na MRI has been applied previously in a small number of studies in people 
with relapsing and progressive forms of MS (Inglese et al., 2010; Zaaraoui et al., 
2012; Paling et al., 2013; Maarouf et al., 2014; Maarouf et al., 2017). Collectively 
these studies have found evidence of brain sodium accumulation within lesions and 
normal-appearing tissues in MS, most marked in patients with progressive forms of 
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MS (Paling et al., 2013) and in patients with greater physical disability and cognitive 
impairment (Zaaraoui et al., 2012; Paling et al., 2013; Maarouf et al., 2017). These 
findings suggest that metabolic abnormalities detected using 23Na MRI may be 
relevant to disability and disease progression. 
 
I applied 23Na MRI cross-sectionally at 15 years in the CIS cohort using a recently 
optimised protocol with smaller voxel size (3mm3 compared with 4mm3 in previous 
studies), and a 3D cones technique that has been shown to improve tissue contrast 
and signal-to-nose ratio with clinically acceptable scanning times (Riemer et al., 
2014). The aims of the study were (1) to investigate the relationship of tissue sodium 
concentrations in the brain with long-term disease course in a cohort of patients well-
matched for disease onset and (2) to investigate the relationship of tissue sodium 




Patients who attended the 15 year follow-up were invited to take part in the 23Na MRI 
study. I also recruited a group of healthy controls with no known neurological disorder 
who underwent the same MRI protocol.  
 
Clinical assessment 
MS was diagnosed using the McDonald 2010 criteria (Polman et al., 2011). Disability 
was assessed cross-sectionally at 15 years using the EDSS, TWT and 9HPT as 
described previously (Kurtzke, 1983; Cutter et al., 1999). The TWT raw scores were 
transformed into an inverse to determine walking speed (in seconds) and 9HPT times 
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were transformed into a z score using normative values from the MSFC taskforce 
database (Cutter et al., 1999).  
 
I assessed cognition using (1) tests of verbal and visual memory from the Adult 
Memory and Information Processing Battery (Coughlan and Hollows, 1985); (2) tests 
of information processing speed, the PASAT (Cutter et al., 1999) and the SDMT 
(Smith, 1982); and (3) tests of executive function, the Hayling and Brixton tests 
(Burgess and Shallice, 1997). Premorbid intellectual function was estimated using the 
National Adult Reading Test (NART) (Nelson, 1982). The raw test scores for each of 
the cognitive tests were transformed into a z score using published age-matched 
normative data from healthy controls. Patients were classified as being cognitively 
impaired if performance was abnormal (≥1.5 standard deviations from normative 
values) in one test in at least two of the cognitive domains assessed (memory, 
information processing speed, executive function).  
 
Self-reported fatigue was measured using the Fatigue Severity Scale (Krupp, 1989). 
Responses were converted into a mean value from 0-7, with higher values indicating 
greater fatigue.  
  
MRI acquisition  
Details of the full image acquisition protocol are summarised in Chapter 3. Briefly, all 
of the MRI scans were obtained on the same 3.0 T scanner (Achieva, Phillips 
Healthcare Systems). Using a 32-channel head coil the following 1H-MRI scans were 
obtained: (i) a PD/T2-weighted 2D fast spin multi echo scan for identification of T2-
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hyperintense lesions; (ii) a T1-weighted 2D spin echo scan for identification of T1-
hypointense lesions; and (iii) a T1-weighted 3D TFE scan for segmentation purposes. 
 
The 32-channel head coil was changed to 23Na coil (RAPID biomed) and the subject 
was returned to the scanner with two calibration phantoms containing a solution of 
NaCl with a sodium concentration of 33 mM and 66 mM respectively. The NaCl 
concentration in the calibration phantoms was chosen to encompass the range of 
physiological values expected in the brain. A sodium scan was obtained followed by 
a 1H PD/T2-weighted fast spin multi echo scan obtained using the body coil.  
 
Figure 9.1 shows examples of raw sodium images, sodium concentration maps and 




















T2-hyperintense and T1-hypointense white matter lesions were manually outlined on 
PD/T2-weighted and T1-weighted 2D spin echo scans using a semi-automated edge-
finding tool (JIM6.0, Xinapse Systems, Aldwincle, UK). The T2LV and T1LV was 
calculated by multiplying lesion area by slice thickness. The T2-hyperintense lesion 
masks were co-registered to the 3D T1-weighted TFE scan. White matter lesions 
were filled using a patch-based lesion filling technique (Prados et al., 2014). Brain 
extraction and probalistic tissue segmentation of the lesion-filled 3D T1-weighted TFE 
scans was done using Geodesic Information Flows (GIF) to create cortical grey 
matter, deep grey matter and NAWM masks (Cardoso et al., 2015). The brain 
parenchymal fraction (BPF), grey matter fraction (GMF) and white matter fraction 
(WMF) were calculated by dividing the tissue volumes by the total intracranial volume.  
 
A fully-automated image analysis pipeline was used to determine the total sodium 
concentration in tissues. The signal intensity in calibration phantoms was used to 
quantify the total sodium concentration on a voxel-by-voxel basis. A series of 
registration steps were then used to quantify total sodium concentration: (1) the 
sodium scan was registered to the PD/T2-weighted scan obtained using the body coil; 
(2) the PD/T2-weighted scan obtained using the body coil was registered to the 
PD/T2-weighted scan obtained using the 32-channel head coil; and (3) the PD/T2-
weighted scan obtained using the 32-channel head coil was registered to the 3D T1-
weighted TFE. Each of these registration steps were then reversed in order to 
transform the segmented tissue masks (cortical grey matter, deep grey matter, 
NAWM, T1-isointense lesions, T1-hypointense lesions) into sodium space and 




Partial volume correction was done to remove voxels with contamination of CSF 
containing unrealistically high sodium concentrations (Paling et al., 2013). 
 
Statistical analysis 
All clinical, 1H-MRI and 23Na-MRI data are presented as mean (SD) unless otherwise 
stated.  
 
Differences in clinical measures between groups were compared using univariable 
linear regression, except for EDSS which was compared using the non-parametric 
Wilcoxon rank-sum test. Differences in 1H-MRI findings between groups were 
compared using univariable linear regression, with age and sex included as 
covariates when comparing brain volumetric measures. Finally, differences in total 
sodium concentration in cortical grey matter, deep grey matter, NAWM and lesions 
between groups was compared using univariable linear regression using grey matter 
fraction (GMF) or white matter fraction (WMF) as a covariate depending on the tissue 
type being examined. 
 
Univariate correlations between tissue-specific total sodium concentrations and 
scores on tests of physical disability, cognition and fatigue were examined using 
Spearman’s rank correlation for EDSS and Pearson’s correlation coefficient for other 
measures. 
 
Multivariable linear regression was used to identify independent associations 
between tissue-specific total sodium concentrations and clinical measures. 
Significant univariate predictor variables were entered into the model and removed 
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by stepwise backward manual elimination of variables with p>0.08. Each of the 
omitted variables was then tested in the final models. Because EDSS is not normally 
distributed the final regression model was checked using non-parametric bias-
corrected and accelerated bootstrap with 1000 replicates to confirm associations. 
Tissue-specific brain atrophy (GMF, WMF or both) was included as covariates in all 
models. The estimated premorbid IQ measured using the NART was also included 
as a covariate in all models examining associations with cognitive measures. Age, 
sex and disease duration had no material effect on regression coefficients and were 
not included as covariates.  
 
9.3 Results 
A total of 130 subjects were included: 96 patients from the CIS cohort and 34 healthy 
controls. The patient group comprised 18 patients with CIS, 65 with RRMS and 13 
with SPMS after ~15 years. The demographic and clinical characteristics of the 
different patients groups and healthy controls is shown in Table 9.1.The healthy 
controls were younger than the patient group (mean age 35.5 vs 47.4 years, p<0.001) 
but the sex ratio was similar.  
 
A summary of the clinical assessments in the patient group is shown in Table 9.2. 
Compared with the patients who remained CIS at 15 years the MS patients had more 
physical disability, worse performance on cognitive tests (with the exception of visual 
memory) and greater self-reported fatigue (p<0.05 for all comparisons). The SPMS 
patients had worse performance on each of the clinical measures compared with the 
RRMS patients (p<0.05 for all comparisons), with the exception of verbal memory, 
which was similar in patients with SPMS and RRMS. 
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Age, years  35.5 (10.1) 49.0 (7.2) 46.8 (7.6) 47.8 (7.8) 
Female, n (%) 23 (66) 12 (67) 49 (77) 9 (69) 
Disease duration, years - 14.5 (2.1) 14.6 (2.4) 15.0 (2.8) 
DMT, n (%) - 0 (0) 18 (28) 4 (31) 
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Table 9.2 Physical disability and cognitive assessments in the patient groups. 
All data presented as mean (SD) unless otherwise indicated  
*p<0.05 compared with CIS, **p<0.01 compared with CIS, #p<0.05 compared with RRMS, ##p<0.05 compared with RRMS.  
  MS patients 








EDSS, median (range) 0 (0-1) 2 (0-7)** 2 (0-6.5) 6 (3.5-7)## 
1/TWT, seconds 0.24 (0.03) 0.18 (0.06)** 0.20 (0.04) 0.09 (0.05)## 
9HPT, z score 0.78 (0.70) 0.23 (0.91)* 0.50 (0.61) -1.16 (0.82)## 
Verbal memory, z score 0.21 (0.60) -0.32 (0.58)** -0.27 (0.54) -0.59 (0.74) 
Visual memory, z score 0.24 (0.49) -0.06 (0.65) -0.01 (0.63) -0.35 (0.76)## 
PASAT, z score 0.21 (0.68) -0.48 (1.09)* -0.32 (0.99) -1.32 (1.25)## 
SDMT, z score 0.31 (0.90) -0.65 (1.38)** -0.34 (1.18) -2.12 (1.38)## 
Brixton test, z score -0.19 (0.98) -1.06 (1.18)* -0.93 (1.09) -1.74 (1.44)## 
Hayling test, z score 0.20 (0.86) -0.63 (1.04)** -0.56 (1.01) -0.97 (1.15)# 




The structural 1H-MRI findings in patients and healthy controls are shown in Table 
9.3. The GMF (adjusted difference -0.003, p=0.281) and WMF (adjusted difference    
-0.001, p=0.788) were similar in patients who remained CIS at 15 years and healthy 
controls. The MS patients had a lower GMF (adjusted difference -0.011, p<0.001) and 
lower WMF (adjusted difference -0.011, p=0.002) compared with the healthy controls. 
The MS patients also had lower GMF (adjusted difference -0.009, p=0.002) and lower 
WMF (adjusted difference -0.011, p=0.004) compared with the patients who remained 
CIS. The SPMS had a lower GMF (adjusted difference -0.008, p=0.020) and lower 
WMF (adjusted difference -0.011, p=0.017) compared with the RRMS patients.  
 
The patients with SPMS had a higher T2LV (17.97 vs 9.81 ml, p=0.026) and higher 
T1LV (5.87 vs 1.90 ml, p<0.001) compared with the patients with RRMS. 
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Table 9.3 1H MRI findings in healthy controls and patients grouped by clinical status at 15 years. 
All data presented as mean (SD)  
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23Na-MRI findings: healthy controls 
Tissue sodium concentrations in healthy controls are shown in Table 9.4. In healthy 
control subjects the total sodium concentration was higher in cortical grey matter than 
deep grey matter. The TSC was also higher in cortical grey matter and deep grey 
matter compared with white matter.  
 
No correlation was found between total sodium concentration in cortical grey matter, 
deep grey matter or white matter with age or sex in the healthy controls.  
 
23Na-MRI findings: patients 
The total sodium concentrations in cortical grey matter, deep grey matter, NAWM 
and lesions are shown in Table 9.4.  
 
In the patients who remained CIS at 15 years, no significant differences were 
observed in the total sodium concentrations in cortical grey matter (adjusted 
difference 0.023 mM, p=0.971), deep grey matter (adjusted difference 1.28 mM, 
p=0.087) and NAWM (adjusted difference 1.16 mM, p=0.203) compared with healthy 
controls. 
 
In MS patients, the total sodium concentration in cortical grey matter (adjusted 
difference 2.12 mM, p=0.005), deep grey matter (adjusted difference 1.90 mM, 





Compared with the patients with RRMS, the SPMS patients had higher total sodium 
concentration in cortical grey matter (adjusted difference 1.88 mM, p=0.040) and 
deep grey matter (adjusted difference 2.10 mM, p=0.037). The total sodium 
concentration in NAWM was similar in patients with SPMS and RRMS (adjusted 
difference 1.58 mM, p=0.181). 
 
In the MS patients, the total sodium concentration in white matter lesions was 
significantly higher than in NAWM (adjusted difference 10.73 mM, p<0.001). The total 
sodium concentration was significantly higher in T1-hypointense compared with T1-
isointense white matter lesions (adjusted difference 8.14 mM, p<0.001). The overall 
total sodium concentration was higher in white matter lesions in SPMS patients 
compared with those with RRMS (adjusted difference 7.73 mM, p=0.002). The SPMS 
patients also showed higher total sodium concentration in T1-isointense lesions 
(adjusted difference 6.48 mM, p=0.003) and a trend towards higher total sodium 
concentration in T1-hypointense lesions (adjusted difference 6.55 mM, p=0.054) 


























  42.82 mM** 
(3.53) 
  42.30 mM 
(3.29) 
     45.45 mM# 
(3.69) 




  36.69 mM* 
(3.74) 
  36.14 mM 
(3.47) 
     39.47 mM# 
(3.98) 




  34.85 mM* 
(4.05) 
   34.43 mM 
(3.95) 
  36.95 mM 
(4.04) 
White matter lesions      




  51.99 mM## 
(6.92) 




  49.30 mM## 
(5.83) 




  57.45 mM ## 
(7.43) 
All data presented as mean (SD).  




Correlations between tissue sodium concentrations and disability 
Univariate correlations between tissue sodium concentrations and measures of 
physical disability, cognitive performance and fatigue in all subjects are shown in 
Table 9.5. 
 
The total sodium concentration in cortical grey matter, deep grey matter and NAWM 
total sodium concentration was positively correlated with EDSS and negatively 
correlated with walking speed, upper limb dexterity, speed of information processing, 
visual memory, executive function and fatigue. No correlation was seen between total 
sodium in any of the tissue compartments and verbal memory. 
 
The total sodium concentration in T1-hypointense lesions and T1-isointense lesions 
was positively correlated with EDSS and negatively correlated with walking speed, 
upper limb dexterity, SDMT and the Brixton test. No correlation was observed 
between the total sodium concentration in T1-hypointense lesions or T1-isointense 









Table 9.5. Univariate correlations between tissue sodium concentrations and clinical measures 
 




r p r p r p r p r p r p 
EDSS 0.453 <0.001 0.290 0.004 0.377 <0.001 0.349 0.002 0.371 0.001 0.274 0.017 
Walking speed -0.446 <0.001 -0.345 0.001 -0.399 <0.001 -0.285 0.011 -0.360 0.001 -0.319 0.005 
z 9HPT -0.462 <0.001 -0.409 <0.001 -0.385 <0.001 -0.478 <0.001 -0.418 <0.001 -0.390 <0.001 
z Verbal memory -0.195 0.062 -0.135 0.198 -0.164 0.199 -0.120 0.303 -0.108 0.355 -0.117 0.326 
z Visual memory -0.272 0.009 -0.320 0.002 -0.272 0.009 -0.153 0.190 -0.171 0.142 -0.211 0.073 
z PASAT -0.350 0.001 -0.307 0.003 -0.344 0.001 -0.185 0.112 -0.196 0.092 -0.201 0.089 
z SDMT -0.483 <0.001 -0.410 <0.001 -0.455 <0.001 -0.321 0.005 -0.232 0.046 -0.339 0.003 
z Brixton test -0.385 <0.001 -0.341 0.001 -0.346 0.001 -0.235 0.042 -0.277 0.050 -0.280 0.017 
z Hayling test -0.296 0.004 -0.277 0.001 -0.324 0.002 -0.130 0.268 -0.111 0.343 -0.194 0.100 
Fatigue severity score 0.240 0.024 0.271 0.010 0.239 0.024 0.019 0.880 0.120 0.310 0.038 0.752 
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Associations between tissue sodium concentrations and disability: All 
patients 
Results of the multivariable linear regression models investigating independent 
associations of tissue-specific total sodium concentration and clinical measures are 
shown in Table 9.6.  
 
Cortical grey matter sodium concentration was independently associated with 
measures of physical disability including EDSS (R2=0.26), walking speed (R2=0.23) 
and upper limb dexterity (R2=0.23), measured using the 9HPT.  Cortical grey matter 
sodium concentration was also independently associated with speed of information 
processing measured using the PASAT (R2=0.29) and SDMT (R2=0.31), and with 
performance on the Brixton test (R2=0.36), a measure of executive function. Deep 
grey matter sodium concentration was associated with visual memory with borderline 
significance (R2=0.13). No association was found between tissue sodium 
concentrations with verbal memory, the Hayling test or the Fatigue Severity Scale. 
 
All of the multivariable linear regression models were adjusted for brain atrophy. The 




Table 9.6.  Associations between tissue-specific total sodium concentrations and clinical measures in all patients (n=96)  
Clinical measure Tissue sodium concentration Coefficient 95% CI p R2 
EDSS Cortical grey matter 0.174 0.061, 0.287 0.003 0.26 
Walking speed Cortical grey matter -0.006 -0.010, -0.002 0.003 0.23 
z 9HPT Cortical grey matter -0.096 -0.148, -0.051 0.001 0.23 
z PASAT Cortical grey matter -0.105 -0.177, -0.032 0.005 0.29 
z SDMT Cortical grey matter -0.156 -0.246, -0.066 0.001 0.31 
z Visual memory Deep grey matter -0.054 -0.107, -0.000 0.052 0.13 





Associations between tissue sodium concentrations and disability: MS only  
The multivariable linear regression analysis was repeated after excluding patients 
who remained CIS (n=18), firstly to confirm findings in the MS-only group and 
secondly to examine associations between total sodium concentration in white matter 
lesions with disability measures  (none of the CIS patients at 15 years had typical 
demyelinating white matter lesions). The results are presented in Table 9.7. 
 
In the MS-only model (n=78), both cortical grey matter and T1-hypointense lesion 
sodium concentration were associated with EDSS (R2=0.25), walking speed 
(R2=0.24) and upper limb dexterity (R2=0.32). The associations with the cognitive 
tests was similar in the patients with MS to the whole cohort: cortical grey matter total 
sodium concentration was associated with PASAT (R2=0.29), SDMT (R2=0.31) and 
the Brixton test (R2=0.38), and deep grey matter total sodium concentration was 






Table 9.7. Associations between tissue-specific total sodium concentrations and clinical measures in the MS patients (n=78)  
Clinical measure Tissue sodium concentration Coefficient 95% CI p R2 





























z PASAT Cortical grey matter -0.101 -0.180, -0.023 0.012 0.29 
z SDMT Cortical grey matter -0.143 -0.240, -0.046 0.005 0.31 
z Visual memory Deep grey matter -0.060 -0.119, 0.000 0.051 0.12 
z Brixton test Cortical grey matter -0.066 -0.118, -0.015 0.013 0.38 




I investigated the relationship of total sodium concentration in grey matter, NAWM 
and lesions with long-term physical disability and cognitive impairment in a large 
cohort of patients, who were well-matched for disease onset and followed 
prospectively from presentation with CIS. The major findings of this work include: (1) 
higher total sodium concentration in normal-appearing tissues and white matter 
lesions in people with MS compared with healthy controls; (2) higher total sodium 
concentrations in cortical and deep grey matter, plus white matter lesions, in people 
with SPMS compared with those with RRMS; (3) a consistent association of cortical 
grey matter total sodium concentration with clinical measures of physical disability 
and cognitive performance. These findings suggest that 23Na-MRI detects metabolic 
abnormalities in the brain that are relevant to disease course and disability in relapse-
onset MS. 
 
In line with previous studies I found evidence of a widespread increase in total brain 
sodium in people with MS, not just confined to lesional tissue, but also normal-
appearing white matter and grey matter (Inglese et al., 2010; Zaaraoui et al., 2012; 
Paling et al., 2013; Maarouf et al., 2014; Maarouf et al., 2017). Higher total sodium 
concentration was observed in both cortical and deep grey matter in people with MS 
compared with healthy controls. In white matter, a gradient of total sodium 
concentration was seen with the highest values measured in T1-hypointense lesions, 
followed by T1-isointense lesions and then NAWM in people with MS. Total sodium 
concentrations in grey matter and white matter lesions were higher in people with 
SPMS compared with those with RRMS, suggesting a greater degree of neuroaxonal 
metabolic dysfunction and neuroaxonal loss in SPMS. These findings are consistent 
with a greater extent of tissue damage detected using 1H-MRI in patients with SPMS 
compared with patients with RRMS (Filippi et al., 1999; Fisniku et al., 2008b; Fisniku 
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et al., 2009). Microstructural tissue damage and tissue loss detectable using 1H-MRI 
may result in metabolic changes in tissues detectable using 23Na-MRI. 
 
No increase in total sodium concentration in grey or white matter was seen in the 
patients who remained CIS after 15 years. The structural 1H-MRI findings also 
showed no difference in brain volume measurements in the patients with CIS at 15 
years compared with healthy controls. These findings are supported by previous 1H-
MRI studies showing that patients who remain CIS in the longer term do not have 
detectable structural (Fisniku et al., 2008b; Fisniku et al., 2009) or metabolic (Kapeller 
et al., 2002) abnormalities of the sort seen in people with MS, and MRI findings are 
similar to healthy control subjects. 
 
Independent associations were observed between 23Na-MRI abnormalities and 
measures of clinical impairment. Total sodium concentration in cortical grey matter 
was independently associated with EDSS, walking speed and upper limb dexterity 
both in the whole cohort and in the subgroup of patients with MS after 15 years. 
Cortical grey matter total sodium concentration was also associated with performance 
on tests of information processing speed and executive function. Grey matter 
pathology is recognised as being a major substrate for clinical impairment in MS 
(Geurts and Barkhof, 2008). Cortical grey matter pathology detected using 1H-MRI, 
including grey matter lesions (Calabrese et al., 2012), atrophy (Fisniku et al., 2008b) 
and microstructural damage (Fisniku et al., 2009; Yaldizli et al., 2016a), is associated 
with both physical disability and cognitive impairment in MS. Established metabolic 
imaging methods such as 1H- MRS have also found an association between cortical 
grey matter abnormalities and physical disability in MS (Sastre-Garriga et al., 2005).  
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Previous 23Na-MRI studies have also reported an association of grey matter total 
sodium concentration with measures of clinical impairment. In a mixed cohort of 
patients with RRMS, SPMS and PPMS univariate correlations were found between 
both cortical and deep grey matter total sodium concentration and measures of 
physical disability (Paling et al., 2013). In multivariable models, deep grey matter total 
sodium concentration was independently associated with EDSS and walking speed. 
In a cohort of early RRMS patients with little physical disability (mean disease duration 
3.1 years, median EDSS 1), grey matter total sodium concentration was 
independently associated with cognitive impairment (Maarouf et al., 2017). Although 
the authors did not investigate cortical and deep grey matter separately, a voxel-wise 
analysis was done to investigate the topography of grey matter sodium accumulation. 
Widespread increases in total sodium concentration were seen in cognitively impaired 
patients, mainly in neocortical areas (Maarouf et al., 2017).  
 
In the group of patients with MS, total sodium concentration in T1-hypointense lesions 
was also independently associated with measures of physical disability including 
EDSS, TWT and 9HPT. These findings are in keeping with the extent of pathological 
changes observed in MS with the gradient of demyelination and neuroaxonal injury in 
white matter, being most severe in T1-hypointense lesions and least severe in NAWM 
(van Waesberghe et al., 1999; Schmierer et al., 2004).  
 
Some limitations should be noted, both to the work presented here and more 
generally to 23Na-MRI. Firstly, the healthy control group were significantly younger 
than the patients with CIS and MS. However, I found no relationship between age 
and total sodium concentrations in tissue-compartments, in keeping with previous 
studies (Paling et al., 2013). It is unlikely that the increase in total sodium 
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concentration found in people with MS is due to older age, particularly since there 
was no difference between healthy controls and patients who remained CIS. 
Secondly, although I studied a large number of patients (this study is largest 
application of 23Na-MRI in MS to date), the number of patients with SPMS who were 
scanned as part of the 15 year follow-up was small (n=13). Despite the small sample 
size clear differences were seen, particularly in cortical and deep grey matter, 
between the SPMS and RRMS group, findings that are consistent with a previous 
study with a larger sample of patients with SPMS (Paling et al., 2013). Thirdly, only a 
selective set of cognitive tests were administered rather than a comprehensive 
neuropsychological evaluation such as the Brief Repeatable Battery or MACFIMS. 
However, the tests chosen cover the three most commonly affected cognitive 
domains in MS, and included the SDMT plus tests of verbal and visual memory. An 
expert panel has recently highlighted that these tests should be the highest priority in 
brief cognitive assessments in people with MS (Langdon et al., 2012). Finally, this is 
an exploratory study and in the statistical analyses presented no correction was made 
for multiple comparisons.  
 
Although 23Na-MRI is a promising new imaging technique with the potential to provide 
tissue-specific metabolic information in vivo there are a number of technical 
challenges and limitations that need to be taken into consideration. The concentration 
of 23Na in tissues is significantly lower than 1H with a much lower signal-to-noise ratio. 
Consequently the voxel size required is significantly larger, typically 4x4x4 mm  in 
previous studies (Inglese et al., 2010; Zaaraoui et al., 2012; Paling et al., 2013; 
Maarouf et al., 2014; Maarouf et al., 2017). A larger voxel size increases the risk of 
partial volume effects, especially from CSF which contains a much higher sodium 
concentration than tissues (~150 mM). A number of steps were taken to reduce the 
effects of partial volume in this study. Firstly, the scans were acquired using an 
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optimised 23Na-MRI protocol that included a higher resolution (3x3x3 mm) and more 
efficient sampling of k-space using a 3D cones technique (Riemer et al., 2014). These 
changes have been shown to improve tissue contrast and increase signal-to-noise 
ratio (Riemer et al., 2014). Secondly, the image-analysis pipeline included a partial 
volume correction to identify voxels with CSF contamination (Soret et al., 2007). 
Thirdly, as an additional precaution all of the analyses were adjusted for tissue-
specific atrophy (GMF, WMF or both), which has not been done in previous studies.  
 
The total sodium concentration in tissues represents a composite of intracellular and 
extracellular sodium. The increased total sodium concentration observed in grey 
matter, NAWM and lesions in people with MS could be due to an increase in 
intracellular sodium due to axonal metabolic dysfunction, an increase in extracellular 
sodium due to expansion of the extracellular space from neuroaxonal loss, or both. A 
number of approaches have been described for measuring intracellular sodium 
concentration in vivo (Petracca et al., 2016a). A recent study at 7 T used triple 
quantum filtering to exploit the differences in the relaxation properties between 
intracellular and extracellular sodium (Fleysher et al., 2013; Petracca et al., 2016b). 
This technique allows quantification of total sodium concentration, intracellular 
sodium concentration and the intracellular sodium volume fraction (a surrogate 
measure of the extracellular sodium). This approach has been applied in a study of 
19 patients with RRMS. Compared with healthy controls, the RRMS patients showed 
a significant increase in intracellular sodium concentration and decrease in 
intracellular sodium volume fraction (Petracca et al., 2016b). These findings suggest 
that both an increase in intracellular sodium concentration and expansion of the 




Sodium channel blockade has been proposed as a neuroprotective strategy in MS 
(Raftopoulos and Kapoor, 2013) based on results of animal studies showing that 
sodium channel blocking agents ameliorate axonal loss in EAE models (Bechtold et 
al., 2004). These observations are supported by a recent phase II that demonstrated 
a neuroprotective effect of phenytoin on retinal nerve fibre layer thinning in patients 
with acute optic neuritis (Raftopoulos et al., 2016). Phase II studies of putative 
neuroprotective agents in MS typically use brain atrophy as the primary outcome 
measure. 23Na-MRI is potentially a novel MRI endpoint for future neuroprotection 
studies, particularly of agents targeting ion homeostasis or mitochondrial function that 
might influence intracellular sodium concentration. Longitudinal studies are required 
to determine whether 23Na-MRI is sensitive to changes in total sodium concentration 
over time and to undertake sample size calculations for future clinical trials. 
 
9.5 Conclusions 
23Na-MRI detects pathological abnormalities that are relevant to long-term disease 
progression, physical disability and cognitive dysfunction in relapse-onset MS. These 
associations remain even after adjusting for brain atrophy suggesting that 23Na-MRI 
may detect neuroaxonal metabolic abnormalities. Metabolic as well as structural 
abnormalities in cortical grey matter may be an important mechanism contributing to 









Conclusions and future directions 
 
10.1 Introduction 
I completed a 15 year follow-up study of people with CIS with three major objectives: 
(1) to improve the diagnosis MS in people with CIS using MRI; (2) to investigate the 
prognostic value of early MRI abnormalities in people with CIS and early MS; and (3) 
to investigate the pathological mechanisms that underpin the development of 
secondary progression and long-term disability in relapse-onset MS. The major 
findings presented in this thesis relating to each of these objectives is summarised 
here along with future directions. 
 
10.2 Improving the diagnosis of multiple sclerosis in people with CIS 
The McDonald criteria allow the use of MRI to provide evidence of dissemination in 
time and space, rather than waiting for a second clinical attack. I applied the 
McDonald 2001, 2005 and 2010 criteria retrospectively in the CIS cohort and found 
that each revision of the criteria has allowed for an earlier diagnosis of MS. Using the 
current McDonald 2010 criteria the mean time to diagnosis of MS was 6.2 months 
compared with 23.1 months using the Poser criteria, and almost half of the CIS 
patients could be diagnosed with MS using a single contrast-enhanced MRI scan. In 
clinical settings the application of the McDonald 2010 criteria in patients with typical 
CIS presentations should allow for earlier diagnosis and treatment of MS. 
 
I found that when applying the McDonald criteria, MS is diagnosed sooner but also 
more often in CIS patients. With each revision of the McDonald 2010 the number of 
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CIS patients with MRI-only conversion to MS has increased. Patients with milder 
forms of MS may be identified when the diagnosis is made using MRI criteria, rather 
than on the basis of clinical features alone. Changing diagnostic criteria for MS may 
influence the natural history of MS, independent of the effects of disease-modifying 
treatments. Clinicians should be mindful of this when counselling patients with CIS 
and early MS about how their condition might progress in the future. 
 
The MAGNIMS group has recently proposed changes to the DIS criteria. I 
investigated two of these recommendations to provide evidence to support future 
revisions to the diagnostic criteria for MS. I found that inclusion of lesions in the 
symptomatic region improved performance of MRI criteria for a diagnosis of MS with 
higher sensitivity/accuracy and the same specificity as the McDonald 2010 criteria. 
There was a trend towards earlier diagnosis with DIS criteria that included 
symptomatic lesions, but this was not significant in the relatively small cohort studied. 
I also investigated the influence of periventricular lesion number on the performance 
of MRI criteria. The MAGNIMS group has proposed increasing the number of 
periventricular lesions required for DIS from 1 to 3. This recommendation was based 
on expert consensus that a single periventricular lesion may be insufficient to say 
there is DIS. I found that increasing periventricular lesion number from 1 to 3 resulted 
in a reduction in sensitivity and accuracy with no overall improvement in specificity.  
 
Misdiagnosis of MS is an important contemporary clinical issue. Misapplication of the 
McDonald criteria in patients with presentations not typical of demyelination or those 
without objective neurological signs is a major contributor to misdiagnosis. My 
findings confirm previous studies that when the McDonald criteria are applied in 
young adults with symptoms typical of MS (e.g. unilateral optic neuritis) the criteria 
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have a very high sensitivity, specificity and accuracy. An important finding is that DIT 
significantly enhances the specificity of MRI criteria for diagnosis of MS. 
Demonstration of both DIS and DIT remains essential in making a diagnosis of MS 
and should be retained in future diagnostic criteria for MS.  
 
10.3 Prognostic value of early MRI abnormalities in people with CIS and 
 early multiple sclerosis 
I investigated early MRI abnormalities seen at the time of presentation with CIS and 
over the first 3 years of follow-up in order to identify the most robust predictors of 
disease course at 15 years. The presence of asymptomatic spinal cord lesions at the 
time of CIS was independently associated with secondary progressive disease 
course and physical disability at 15 years. Spinal cord MRI is not done routinely as 
part of the diagnostic process in people with suspected MS. Although spinal cord 
imaging may be helpful diagnostically, my findings suggest that it might also provide 
important prognostic information in people with CIS and early MS. The number of new 
spinal cord lesions after 1 year and 3 years was also associated with SPMS and 
disability at 15 years suggesting that spinal cord MRI may also have a role in 
monitoring the course of MS.  
 
A higher number of asymptomatic gadolinium-enhancing lesions at the time of 
presentation with CIS was also associated with secondary progressive disease 
course and physical disability after 15 years. This association remained significant 
even when changes in MRI measures over the first 3 years of follow-up were included 
in models. As well as providing evidence of DIT, gadolinium-enhancing lesions at the 




Established MRI techniques already in clinical use might provide useful prognostic 
information in patients with CIS and early MS. Obtaining spinal cord and post-contrast 
T1-weighted scans in addition to standard PD/T2-weighted or FLAIR scans of the 
brain may not only assist in the diagnosis and differential diagnosis of suspected MS, 
but also provide information helpful in counselling patients about prognosis and 
personalising treatment plans. It will be important to confirm these findings in larger 
CIS cohorts, particularly cohorts with a more representative number of patients with 
brainstem/cerebellar and spinal cord syndromes.  
 
10.4 New insights into the mechanisms of disease progression in relapse-
 onset multiple sclerosis 
The mechanisms responsible for disease course heterogeneity in MS, particularly 
those underlying the development of secondary progression, remain poorly 
understood. My findings identify a number of mechanisms that may potentially 
influence the onset of secondary progression and irreversible disability in relapse-
onset MS: (1) early inflammatory disease activity, particularly the accrual of lesions in 
clinically-eloquent sites; (2) the HLA-DRB1*1501 allele which was associated with a 
greater extent of inflammatory disease activity, neurodegeneration and disability 
progression; and (3) energy failure detectable in vivo as an increase in total sodium 
concentration in brain tissues, particularly cortical grey matter. 
 
I found that gadolinium-enhancing lesion load at the time of presentation with CIS 
was independently associated with disability and the development of SPMS at 15 
years. This is consistent with previous observations in natural history studies that the 
extent of early inflammatory activity (measured clinically in the form of relapses) is 
associated with shorter latency to the onset of SPMS. Focal lesions in clinically-
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eloquent sites may be of particular importance in disease progression in relapse-
onset MS. Asymptomatic spinal cord lesions seen at the time of CIS and new spinal 
cord lesions over time was associated with disability at 5 years and with both disability 
and secondary progressive disease course at 15 years. Similarly, accrual of new 
spinal and infratentorial lesions over the first 3 years after presentation with CIS was 
also associated with disability and secondary progression at 15 years. Collectively, 
these observations point to a link between early inflammatory disease, particularly at 
clinically-eloquent sites, and later disease progression in relapse-onset MS. My 
findings also support the concept that early initiation of disease-modifying treatment 
may prevent or delay the onset of SPMS.  
 
The course of relapse-onset MS is highly variable. At 15 years there was a wide range 
of outcomes in the CIS cohort with all levels of disability observed. It has been 
suggested that genetic factors may be one of the mechanisms responsible for disease 
course heterogeneity in MS. However, studies to date have produced conflicting 
results. I investigated whether the effect of the HLA-DRB1*1501 haplotype on MRI 
measures of inflammation and neurodegeneration plus disability progression over the 
first 15 years after CIS. I found that HLA-DRB1*1501-positive patients had a greater 
extent of inflammatory disease activity (higher number of gadolinium-enhancing 
lesions and faster rate of change in T2LV) and also neurodegeneration (faster rate of 
brain atrophy, spinal cord atrophy and change in T1LV) compared with the HLA-
DRB1*1501-negative patients. The HLA-DRB1*1501-positive patients also displayed 
a faster rate of disability progression measured using the EDSS and had worse 
performance on cognitive testing at 15 years. My findings suggest that HLA-




Energy failure within demyelinated axons is thought to be a major factor contributing 
to chronic neuroaxonal loss and disease progression in MS. I applied the novel 
metabolic imaging technique 23Na-MRI in the CIS cohort at 15 years to investigate 
energy failure in vivo. I found evidence of widespread increases in total sodium 
concentration in white matter lesions, NAWM and grey matter in people with MS. The 
total sodium concentration in cortical grey matter was consistently associated with 
measures of physical disability and cognitive impairment. Metabolic abnormalities in 
cortical grey matter may be an important contributor to disease progression and 
disability in relapse-onset MS and 23Na-MRI might be a future outcome measure in 
clinical trials of neuroprotective agents that target energy failure.  
 
10.5 Future directions 
Further revisions to the diagnostic criteria for MS are anticipated following a meeting 
of an international panel in 2016. The findings presented in this thesis highlight both 
the importance of symptomatic lesions in DIS and the high sensitivity/specificity of a 
single periventricular lesion in MRI criteria. I was not able to test other recently 
recommended changes to dissemination in space criteria such as inclusion of optic 
nerve or cortical grey matter lesions because this data was not collected in the CIS 
cohort. These and other possible changes to the diagnostic criteria for MS should 
ideally be confirmed in a larger, multicentre study. Data collected as part of this thesis 
has been included in a multicentre study involving seven other European centres 
organised by the MAGNIMS group. The findings from this thesis and other studies 
will inform revisions to the diagnostic criteria for MS. 
 
I found that conventional MRI abnormalities including spinal cord lesions and 
gadolinium-enhancing lesions may be helpful in predicting long-term disease course 
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in patients with CIS and early MS. The cohort studied is predominantly untreated and 
the extent to which disease-modifying treatments attenuate these associations is 
uncertain. Prospective studies in treated cohorts of patients with CIS and early MS 
will be required to determine the prognostic significance for long-term disability and 
whether they predict a differential response to disease-modifying therapies. 
 
My analyses focussed on secondary progressive disease course and EDSS at 15 
years, two outcome measures heavily weighted towards ambulatory disability. I also 
assessed cognition, fatigue and mood in the CIS cohort at the 15 year follow-up. 
Analyses are ongoing to determine whether the MRI variables associated with long-
term physical disability are the same as those associated with cognitive impairment, 
fatigue and affective disorders. 
 
Much of the variability in the early course of MS, including relapse rates, accrual of 
new focal inflammatory lesions, and ultimately neurodegeneration measured in the 
form of brain and spinal cord atrophy, is poorly understood. My findings suggest a 
possible role for HLA-DRB1*1501 in disease heterogeneity in MS. The effect of HLA-
DRB1*1501 may be influenced by interactions with other HLA and non-HLA genes, 
and this warrants further investigation. Future genotype-phenotype studies in MS 
should focus on patient cohorts that have been deeply phenotyped both clinically and 
with MRI or other biomarkers. 
 
Neuroprotection to slow or prevent progressive neuroaxonal loss in MS is an area of 
unmet need. Novel imaging methods are required to facilitate the discovery of 
neuroprotective agents. 23Na-MRI is a promising new metabolic imaging technique to 
provide information about energy failure in vivo. Longitudinal studies of 23Na-MRI are 
237 
 
required to assess the sensitivity of this technique to change over time and to provide 
sample size calculations for future phase II trials. A limitation of currently available 
23Na-MRI techniques at 3T is the inability to separately quantify intracellular sodium 
(reflecting neuroaxonal metabolic dysfunction) and extracellular sodium 
concentration (reflecting expansion of the extracellular space and neuroaxonal loss). 
This is an area of active interest and a number of approaches are being explored.  
 
10.6 Conclusions 
In this 15 year follow-up study of people with CIS I found that use of MRI allows for 
an earlier diagnosis, and potentially earlier treatment, of RRMS. Evidence is 
presented to help refine the diagnostic criteria for MS further. Early MRI abnormalities 
in CIS patients may provide important prognostic as well as diagnostic information. 
Asymptomatic spinal cord and gadolinium-enhancing lesions at presentation with CIS 
are associated with disability and SPMS course 15 years later. Early inflammatory 
disease activity (potentially modified by carriage of the HLA-DRB1*1501 allele), 
especially accrual of focal lesions at clinically-eloquent sites, in early relapse-onset 
MS may be important mechanisms underlying later disease progression. Metabolic 
abnormalities, particularly in cortical grey matter, may contribute to physical disability 
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